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This dissertation focuses on the implications of social position and life course on
the experience of Amyotrophic Lateral Sclerosis (ALS). Using a sociology in medicine
frame, I test three theoretical perspectives (fundamental cause theory, social determinants
of health, and life course theory) to determine the influence of social conditions on the
development and progression of, and medical care for, people with ALS (pALS). Further,
I use ALS as an exemplar of the need for a sociology of disease.
Using the Amyotrophic Lateral Sclerosis National Registry, I first assess the
association of social position with the reported onset location at the time of diagnosis of
ALS. Second, I assess the influence of social position on the time between reported date
of symptom development and diagnosis. The final study evaluates the odds of reporting
several types of medical care dependent on the position in the life course.
Results indicate that social position (race/ethnicity, gender, and education)
influence the experience of the onset of ALS. Further, position in the life course is
associated with the reporting of onset location, with those at older ages being more likely

to report bulbar or global onset in contrast to limb onset. Position in the life course is also
associated with symptoms of ALS, with older persons with ALS (pALS) experiencing
symptoms earlier, often prior to diagnosis. Social position and position in the life course
also influenced the adoption of life-extending medical care for pALS, with younger
pALS adopting more of these interventions.
Overall, the results indicate that even in a rare disease with an unknown cause,
fundamental cause theory, the social determinants of health, and life course theory
provide a valuable framework for understanding the experience of ALS. These theories,
however, need refinement when used in the sociology of disease. Additionally, the results
are evidence of a need for a sociology of disease. Finally, the results highlight the need
for more inclusive research designs, as well as additional qualitative and quantitative
work in understanding how social position shapes the lived experience of ALS.

ii
DEDICATION
“It's not going to be easy, but it's going to be awesome. Awesome Ain't Easy.”
-Steve Gleason
I dedicate this dissertation in memory of my father, Timothy J. Milliman, Sr., and to all
pALS and their caregivers.
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CHAPTER ONE: INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a progressive disease characterized by the
degeneration of the motor neurons and resulting atrophy and paralysis of the muscles,
leading to respiratory distress and eventually death two to five years after diagnosis. ALS
is a rare diagnosis, affecting approximately five per 100,000 people in the United States
(Mehta et al., 2016). Furthermore, the number of people diagnosed with ALS is expected
to increase globally as the population ages, from 222,801 people with ALS in 2015 to a
projected number of 376,674 in 2040 (Arthur et al., 2016).
A diagnosis of ALS is a process of elimination, and the cost of simply obtaining a
diagnosis can be in the tens of thousands of dollars prior to insurance coverage, which
may factor into the perception of a short survival time after diagnosis (Kiernan et al.,
2011; Obermann & Lyon, 2015). Further complicating the detection of ALS is the
presentation of the disease. The onset location of ALS symptoms, as well as the
symptoms themselves, vary by case. Limb onset ALS often begins with weakness in the
hand or foot, with the first symptoms presenting as drop foot or trouble grasping objects,
bulbar onset begins as difficulty in speaking or swallowing, and global onset can be a
combination of limb and bulbar and/or weakness in the chest and trunk muscles (Kiernan
et al., 2011; Andersen, 2018). Further, atypical presentations can include weight loss,
fasciculations, and frontal-temporal dementia, among others (Kiernan et al., 2011;
Andersen, 2018).
The variability in onset location has been implicated in the failure of clinical trials
for promising treatments for ALS, as well as the inconsistency in the effectiveness of
currently approved treatments (Belsh and Schiffman, 1996; Srinivasan et al., 2006).
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Additionally, the variability of the earliest symptoms can lead to incorrect diagnoses and
unnecessary medical procedures, culminating in a substantially delayed diagnosis which
prevents access to medications and enrollment in clinical trials before the disease has
progressed into later stages (Mitchell et al., 2010; Rothstein, 2017; Jaiswal, 2019).
In the absence of a cure, understanding how social position might shape the
experience of ALS is an important part of understanding the differences in onset location,
symptoms, and medical care among pALS. A considerable amount of ALS research is
biomedical. In the biomedical research, the emphasis is on how suspected risk factors1
are associated with the development and progression of ALS (Del Agulia et al., 2003;
Paillisse et al., 2005; Watanabe et al., 2014; Pupillo et al., 2014). Yet a sociological
perspective highlights the potential importance of social position in the experience of
ALS and may demonstrate that social position is more than just a control variable, but a
signal of larger social processes which can lead to disparities in access to medical care,
support, and altering the experience of ALS. The ability to understand ALS from a
sociological perspective may provide insight on how social factors shape the experience
of the disease and the health of the population effected by the disease (Link, 2008).
Whether the biological aspects of ALS are so powerful as to supersede the effects of the
social position remains unknown at this time, but as with other diseases (e.g. diabetes,
cancer, Alzheimer’s), there is the potential for a greater understanding of the biological
disease process by incorporating attention to social position, as well as the how the social
world shapes the experience of the disease by pALS (Cassileth et al., 1985; Lyman, 1989;
Luftey & Freese, 2005; Timmermans and Haas, 2008).

1

A risk factor is any attribute, characteristic or exposure of an individual that increases the likelihood of
developing a disease or injury (WHO, 2017).
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Overall, the goal of this dissertation is threefold. First, the work presented here
contributes to the understanding of the both biological disease process of ALS and the
illness experience of pALS by using a sociological lens to understand how social position
shapes the experience of ALS. Additionally, the research presented here tests three of the
prominent theories in medical sociology on a rare disease with unknown causes, a
category of conditions often overlooked by social scientists. Finally, using ALS as an
exemplar, I turn the attention of broader theories to a specific disease, in order to
illustrate the need for a sociology of disease, a more targeted form of medical sociology.
Moreover, this dissertation provides an opportunity to engage not only sociologists, but
epidemiologists, biomedical researchers, and medical providers in a conversation across
disciplines, opening doors to a new perspective in understanding ALS as a disease
process and as a lived experience.
The Status of Current Research on the Onset of ALS
The onset of ALS is heterogeneous, and without a clear understanding of the
underlying reasons for the differences. The unknown factors in ALS onset makes
prevention efforts and diagnosis difficult. In addition, risk factors for the development of
ALS are largely unknown, however, researchers have identified several potential
candidates. Several genetic mutations, such as the mutation of the SOD1 gene, have been
suspected in the development of familial ALS and may be a risk factor for sporadic ALS
as well (Wang et al., 2016). Exposures to heavy metals (e.g. lead), organic chemicals
(e.g. pesticides used in farming), and occupational exposures (e.g. electrical shock), are
considered potential risk factors that have been studied extensively, although not in
connection to each other (Sutedja et al., 2007; Fang et al., 2009; Yu et al., 2014; Wang et
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al., 2017). Research on ALS in Guam, where rates historically have been high, has linked
exposure to Beta-N-methylamino-L-alanin (BMAA) to a potential gene-by-environment
trigger. Exposure to BMAA is high in Guam due to its presence in water sources and
marine animals, and prior research links BMAA exposure to pockets of high ALS rates in
areas of the Atlantic seaboard due to participation in the fishing industry (Caller et al.,
2011; Stommel et al., 2013; Wang et al., 2017).
Military service has been linked to ALS development, as veterans are twice as
likely as civilians to develop the disease, but the link is currently unclear (Weisskopf et
al., 2015; Wang et al., 2017). For example, previous research has indicated physical
trauma or injury, lower BMI, lower educational attainment, and the higher levels of
physical activity found in higher rates among service members may be particular risk
factors for the development of ALS (Weisskopf et al., 2015; Wang et al., 2017). Findings
on the link between ALS and physical activity, however, are unclear (Longstreth et al.,
1998; Wang et al., 2017). Previous research, for example, has suggested that professional
sports players are more likely to develop ALS as a result of their occupation (e.g.
American football, soccer) which includes both a high level of physical activity, but also
the potential for head injuries both of which are linked to ALS development (Chiò et al.,
2005; Wang et al., 2017).
Research suggests health conditions and health behaviors are potential risk factors
for ALS development. For example, viral infections, through a mechanism of the immune
response, may initiate the cascade of symptoms associated with ALS (Wang et al, 2017).
In addition, researchers have posited that ALS may be an issue of energy consumption in
the body, and metabolic conditions as a potential risk factor may be linked to the lower
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BMI and high levels of physical activity seen in people with ALS (Ingre et al., 2015). In
addition, individuals who smoke are at higher risk of developing ALS, however, this
correlation has been debated as the association appears in some studies and not in others
when other risk factors are included in the measures (Sutedija et al., 2007; Yu et al.,
2014; Wang et al., 2017).
The Status of Current Research on the Symptoms and Progression of ALS
ALS progression is measured using the Amyotrophic Lateral Sclerosis Functional
Rating Scale revised scale (Cedarbaum et al., 1999) which monitors the progression of
impairment in people with ALS from the date of their diagnosis, including both limb and
bulbar function as well as difficulty breathing and ventilator support. Understanding the
variability in progression, however, is difficult given that many symptoms often develop
long before a diagnosis is reached.
Much of the work in ALS progression has been biomedical, focusing on
nutritional status (e.g. weight loss, vitamin D deficiencies), comorbidities (e.g.
hyperlipidemia, diabetes), and genetics as factors in symptom development and the rate
of progression (Dupuis et al., 2011; Wang et al., 2017). Social position, when included in
research on the diagnosis and progression of ALS, is considered through a biomedical
lens and are often limited to age and gender (Del Agulia et al., 2003; Paillisse et al.,
2005; Watanabe et al., 2014; Pupillo et al., 2014). Socioeconomic status does, however,
influence both health and the ability to access to care (Adler et al., 1994), leading to the
potential for SES to be linked through these factors to a delayed diagnosis and a
perception of a more rapid progression of ALS.
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The Status of Current Research on Medical Care in the Treatment of ALS
Treatment of ALS is complex for all involved, including health professionals
(Radunovic et al, 2007). Multidisciplinary ALS clinics (MDCs) and palliative home care
are the most recommended options, with MDCs being the option of choice of ALS
experts (Radunovic et al, 2007; Obermann & Lyon, 2015). Not all patients, however,
choose to use or have access to multidisciplinary ALS clinics without a long journey
(Stephens et al., 2015; Horton et al., 2018) and palliative care services and in-home
respite care can be limited by financial constraints and availability (Radunovic et al,
2007; Obermann & Lyon, 2015). For those who are not referred by a medical provider to
an MDC or Telemedicine program, other barriers including the lack of knowledge or lack
of time to research and consider such treatment options may prevent access (Stephens et
al., 2015). In addition, it can take approximately five months to receive Medicare
coverage after a diagnosis of ALS. Without these resources, people with ALS may find
that they have needs that they are not prepared for (e.g. mobility, nutrition, speech
assistance) and/or have limited time to research and access assistance due to disease
progression.
Additionally, there are concerns and confusion over what types of care are
considered supportive (e.g. improving quality of life) versus life-sustaining (Shneerson,
2011). People with ALS may avoid care seen as life-extending due to fears of being a
burden to family members, the cost of life-sustaining care, and the potential of being
locked-in and unable to express wishes to end such care (Oliver and Turner, 2010).
Moreover, life-sustaining care can be complex and highly technical, which may deter
older and less technologically savvy patients from accessing such care.

7
Theoretical Perspectives
Sociology in Medicine and Social Position
Robert Straus outlined two distinct divisions in medical sociology—sociology of
medicine and sociology in medicine. Sociology of medicine is interested in the structure,
role relationships, rituals, and functions of medicine as a system of behavior, while
sociology in medicine is primarily concerned with the disease process or factors
influencing the response to illness (Strauss, 1957; Gevitz, 1986). The dissertation is
framed within the ideas of sociology in medicine, with its primary goal to gain a better
understanding of the disease process of ALS as well as pALS responses to the disease in
the form of medical care.
In using sociology in medicine as a frame, one must carefully consider how to
present the topic of social hierarchies and how they influence the disease process, as well
as the response to illness. Doing so is important, as using the biomedical terminology
(e.g. race, sex) can inadvertently give the impression that biology, rather than social
experiences, are being described as variables of interest when discussing disease
development and outcomes.
Social location is more commonly used to describe how people are situated in
history and society, specifically positioning within the matrix of domination (Crenshaw,
1990; Collins, 1990). Social location encompasses race/ethnicity, gender, social class,
age, ability, and other factors that can be used to describe people’s location within social
hierarchies. Social location often suggests intersectionality; someone who identifies as
Black, queer, and a woman will have a vastly different social location within the matrix
of domination than a White, cisgender, heterosexual man (Crenshaw, 1990).
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Rather than risking the implication of an intersectional approach, I have opted to
use social position to represent dichotomous distinctions (e.g. man/woman, White/Nonwhite) in the analysis presented in the dissertation. The decision to use social position is
threefold: (1) ALS has long been described and represented as a disease predominantly
affecting White, middle-aged men (e.g., Lou Gehrig disease) (2) the known population of
people diagnosed with ALS is very small and often has a short time of survival after
diagnosis, which limits data collection and restricts the ability to complete intersectional
analysis within the confines of the dissertation, and (3) the limitations of the data used in
the dissertation, including the admitted underrepresentation of racial/ethnic minority
populations. The use of social position to describe a dichotomous distinction recognizes
these limitations, while acknowledging that the ALS community represented here is more
than a dichotomy of several different statuses.
Sociology of Disease
More recently, Timmermans and Haas (2008) noted the need for a ‘sociology of
disease’, in which sociologists explore the connection between the social world and
disease. Few sociologists make one disease, such as ALS, the focus of their work.
Further, few have used clinical endpoints in their analysis, which is one way to determine
how social processes affect disease outcomes (Timmermans and Haas, 2008). Overall,
the goal of a sociology of disease is to take the themes and theories from the sociology of
health and illness and focus attention on specific health outcomes. Although social
epidemiology may seem like a more natural fit for this type of work, the goal is not to
point out collective risk factors but to account for the multiple pathways in which the
experience of the social world may influence disease directly (Pescosolido, 2006;
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Timmermans and Haas, 2008). In fact, the success of epidemiology and biomedicine
highlights the need to understand how the social affects the development and experience
of disease (Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008). In this
dissertation, I use ALS as an exemplar to illustrate the need for a sociology of disease, as
well as testing the use of more general sociological theories—including fundamental
cause theory, social determinants of health, and life course theory—in a specific disease
which has already been diagnosed.
Fundamental Cause Theory and Social Determinants of Health
Many medical sociologists have posited that social position, such as
socioeconomic status, race/ethnicity, and education, are fundamental causes of health
disparities that can influence overall health, leading to differential outcomes in
interventions and potentially altering outcomes of clinical trials (Link & Phelan, 1995;
Williams & Collins, 2001; Phelan et al., 2004; Braveman et al., 2005; Pampel, 2009;
Phelan et al., 2010; Freese & Luftey, 2011; Phelan & Link, 2013; Phelan & Link, 2015;
Masters et al., 2015). Social factors, such as social position, are useful in understanding
what factors differentially places people at ‘risk of risks’ of exposure to proximal risk
factors (Link & Phelan, 1995).
Fundamental cause theory posits that decreased risk reflects metamechanisms,
which include flexible resources (e.g. education, income). Flexible resources allow
individuals, when they have access, to take purposive action to prevent disease or
improve prognosis after an disease is diagnosed, the ability to avoid proximal risks (e.g.
avoiding polluted neighborhoods, avoiding smoking), and unintentional exposure to
health enhancing norms (Link & Phelan, 1995; Williams & Collins, 2001; Mirowsky and
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Ross, 2010; Freese & Luftey, 2011; Diez Roux, 2012; Phelan & Link, 2013). Moreover,
the unequal distribution of flexible resources affects multiple disease outcomes through
multiple pathways that can change over time as people with more access to the resources
develop strategies to avoid risk (Link & Phelan, 1995; Williams & Collins, 2001; Freese
& Luftey, 2011; Diez Roux, 2012; Phelan & Link, 2013).
The influence of fundamental causes on the outcomes of disease are expected in
medical sociology, however, they are too often disregarded or taken for granted in
traditional epidemiological research (Link, 2008). Modern epidemiology, though
beginning to consider social position as a potential contributor to health disparities, still
largely focuses on proximal risk factors (e.g. diet, chemical exposure) (Link & Phelan,
1995). Additionally, social factors—over and above their contributory nature to health
outcomes—can influence how scientific progress is communicated and how treatment
and recommendations are understood and utilized by the larger population (Link, 2008).
The fundamental causes of health disparities, in particular socioeconomic status,
are tied to the social determinants of health (Braveman, Egerter, and Williams, 2011). For
example, people in a lower socioeconomic position may be exposed to higher levels of
environmental toxins in their neighborhood, may have constrained choices and therefore
be led to a career that increases the risk of injury or exposure to dangerous chemicals,
and/or may have less access to healthcare resources, all of which have been implicated in
the increased risk of developing ALS and the potential for a delayed diagnosis of the
disease. The use of fundamental cause theory and the social determinants of health
framework allows for a better grasp of both the upstream and downstream effects on
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health (Link & Phelan, 1995; Glass & McAtee, 2006; Braveman, Egerter, and Williams,
2011).
Fundamental cause theory and the social determinants of health are often used to
describe how inequities increase the risk of developing medical conditions in specific
populations. I, however, have opted to use these theories in another way. In an attempt to
understand how inequity might shape the biological disease course and the illness
experience of a disease with an unknown cause, I use fundamental cause theory and the
social determinants of health on a population already diagnosed with ALS. In other
words, the fundamental causes of health disparities may not only make a difference
between experiencing good health or disease, but also how the experience of disease is
shaped by social position.
Given that those in more privileged positions are able to access more flexible
resources, they could be more apt to notice ALS symptoms and pursue diagnosis earlier
in the disease course, with the results being illustrated by differences in onset type.
Further, those with more flexible resources may be more likely to opt into more time
consuming and higher cost options for care, improving the quality of life for the pALS in
these positions. Overall, the ability to understand a disease from fundamental cause/social
determinants perspective prior to the discovery of an eventual cause could provide insight
on how social factors shape the experience of the disease itself, the health and wellbeing
of the population affected, and the ability to access future treatments or cures (Link,
2008).
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Life Course Theory
Timing of life transitions within the life course can also affect health outcomes
(Elder, 1998). For example, care decisions by and for those diagnosed with ALS can be
different based on the when the diagnosis is given in the life course. The diagnosis of
ALS and the likelihood of a fatal outcome within a few years would be considered an offtime transition—ALS often strikes in the years where people are in the prime of their
careers, raising children, and caring for elderly parents (Elder & Rockwell, 1979).
Research illustrates that people who are over the age of 70 when diagnosed with ALS
tend to be more accepting of the disease course than those in early-to-mid adulthood
(Foley et al., 2014). Further, it suggests the difference may be that people diagnosed with
ALS in late adulthood are more likely to anticipate the end of their lives, and the
diagnosis comes after important milestones such as raising children into adulthood and
reaching other important life transitions (Foley et al., 2014). People with ALS who have a
partner and adult children, more common in late adulthood, are likely less reliant on inhome nursing care or respite care and potentially make different decisions regarding
mechanical ventilation and other invasive treatments, especially if the pALS feels as
though these options puts undue burden on others (Foley et al., 2014). Further, the timing
of ALS development in the life course potentially influences resources available to those
diagnosed. For example, already qualifying for Medicare coverage could allow for
shorter time to diagnosis, allowing more intervention to take place earlier in the disease
course, thereby influencing the rate of progression. In addition, life course theory
includes human agency, allowing for people diagnosed with ALS to construct their life
course in a way best suited to their needs (Elder, 1994).
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Using life course theory, in conjunction with fundamental cause theory and the
social determinants framework, informs the considerations of how disadvantage and
misfortune can accumulate over the life course, increasing the potential for ALS
development in those who are susceptible (Ferraro et al., 2009; Ferraro et al., 2016). Life
course theory illustrates that timing of diagnosis in the life course, the lives the pALS are
linked to, and the experience of life transitions, should matter in the decisions to pursue
medical treatments for ALS.
Summary
Amyotrophic Lateral Sclerosis (ALS) is a relatively rare disease, approximately
5,000 people in the US are diagnosed per year. At any given time, it is estimated that
16,000 people in the US are living with ALS. Ninety to ninety-five percent of cases of
ALS are sporadic with no known cause, and the remaining 5-10% are familial (genetic).
Moreover, the majority of people with ALS die within 2-to-5 years. Consequently,
longitudinal studies with sufficient baseline data that allow for comprehensive research
on determining who will develop ALS and who will not do not currently exist. Further,
using matched cases (e.g. American Community Survey) is difficult, as ALS may strike
anyone at any point in the life course and there is no known test to show otherwise.
Among those who have been diagnosed, however, there are many questions about
patterns of onset type, the patterns of symptom development and progression, and
medical care utilization. Therefore, this dissertation focuses on a population of people
who have already diagnosed with ALS.
Using fundamental cause theory, the social determinants of health, and life course
theory as a theoretical guide (Figure 1.1 and 1.2), I look at if, and how, social position
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shapes the experience of ALS. Currently, ALS is not well understood by either the
biological or the social sciences. While the biological research is underway, a next step
for medical sociologists is to understand how these theories may apply in a little
understood, relatively rare, and deadly disease in those who are already diagnosed in
ALS. ALS is often thought of as solely a biological disease; however, a sociological
perspective allows for the expansion of ideas to social position in order to develop a
better understanding of the experience of the disease (Ingre et al., 2015; Brown and AlChalabi, 2017). Previous work in diseases such as diabetes (Lutfey & Freese, 2005),
arthritis (Reisine et al., 1995), and cancer (Rubin et al., 2014) have highlighted how the
social affects the biological, and the dissertation expands this line of research into
understanding the experience of ALS. Further, using these theories, I turn the attention of
theories used in the broader study of the sociology of health and illness to ALS, to
illustrate the need for a sociology of disease.
To accomplish the goals of the dissertation, the second chapter explores how
social position shapes the reported onset location at the time of an ALS diagnosis. The
third chapter investigates how social position shapes the time between reported symptom
development and diagnosis of ALS. Chapter four examines how position in the life
course and social position shape medical care decisions reported by people with ALS.
Understanding the way social position and life course position shape these experiences
will potentially inform the fruitfulness of fundamental cause, social determinants,
sociology of disease, and life course theory for better understanding the experience of a
rare and incurable disease plus inform clinical trial formation, access to and the
effectiveness of ALS treatments, and advances efforts to prevent health disparities, thus
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hopefully improving the quality of life for people with ALS. The concluding chapter of
the dissertation discusses the contribution of the research presented in the preceding
chapters, the limitations of the National ALS Registry, and directions for future research.
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Figure 1.1 Using Sociological Theories to understand the Social Context of ALS2

2

Bolded text indicates available variables in the National ALS Registry Dataset.
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Figure 1.2 Outline of Variables connected to theories used in understanding the
Social Context of ALS

3

*

Veteran status may be considered a life transition, a social determinant of health, or as a potential
indicator of flexible resources.
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CHAPTER TWO: HOW DOES SOCIAL POSITION SHAPE ALS ONSET
LOCATION?
Introduction
Amyotrophic Lateral Sclerosis (ALS) researchers often study social position in
isolation as individual risk factors (e.g. race/ethnicity, gender, socioeconomic class)
(Ingre et al., 2015). For example, previous epidemiological and biomedical studies have
implicated exposures to toxic chemicals, smoking behavior, and physical activity levels
as potential risk factors for the development of amyotrophic lateral sclerosis (ALS),
including where symptoms first appear on the body (Swinnen and Robberecht, 2014;
Wang et al., 2016). Without understanding these exposures and behaviors within their
social context, however, Ingre et al. (2015) suggests that scientists are unable to
determine if they are risk factors in and of themselves, or proxies for larger social
processes interacting with biological factors (Ingre et al., 2015). I posit, based upon
fundamental cause theory and the social determinants of health that social position shapes
the onset location of ALS, and therefore shaping the earliest experiences of ALS (Link &
Phelan, 1995; Glass & McAtee, 2006; Braveman, Egerter, and Williams, 2011). Further I
evaluate how fundamental cause theory, social determinants of health, and life course
theory (Elder & Rockwell, 1979; Elder, 1998) define the social dimensions of ALS,
further indicating a need for a sociology of disease (Timmermans and Haas, 2008).
Diagnosis of ALS and Onset Location
A diagnosis of ALS is a process of elimination, and the cost of simply obtaining a
diagnosis can be in the tens of thousands of dollars prior to insurance coverage (Kiernan
et al., 2011; Obermann & Lyon, 2015). Common tests in the diagnostic pathway for ALS
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include an electromyogram (EMG), MRIs of the brain, neck, and cervical spine, lumbar
puncture (also known as a spinal tap), and biopsies of the muscle tissues in affected areas
(Iwasaki, and Kinoshita, 2001). The EMG is essential for the confirmation of a diagnosis
of ALS, and muscle biopsy is often the last step in the confirmation process (Iwasaki, and
Kinoshita, 2001).
The diagnostic pathway is how a physician, most of a neurologist, determines
diagnosis of ALS and the suspected onset location of ALS symptoms. The onset location
of ALS is heterogeneous, however, and there is not a clear understanding of the
underlying reasons for the differences in onset location. ALS onset is classified by the
motor neurons affected, with the resulting damage being expressed by the different
regions of the body (Kiernan et al., 2011; Andersen, 2018). Limb onset, the most
common onset location, begins with asymmetric, painless weakness in a limb. The person
with ALS often presents with atrophy and weakness of the muscles, fasciculations
(twitching), and abnormal reflexes. Bulbar onset, which affects about 20% of patients,
affects the bulbar (neck and jaw) muscles, leading to slurred speech and difficulty
swallowing. Trunk or global onset affects 3-5% of people with ALS (pALS), and
symptoms are first reported in the trunk, including the back or abdominal areas, breathing
muscles, or total body weakness. All forms of ALS, limb, bulbar, and trunk/global,
eventually progress, leaving the person who is affected unable to speak, move, or breathe
on their own. ALS is universally fatal with an average life expectancy of 2-5 years,
however, with medical intervention (e.g. tracheostomy, PEG tube) people with ALS may
potentially live for much longer (Georgoulopoulou et al., 2013).
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The heterogeneity of ALS onset and the relative rarity of the disease may lead to
incorrect diagnoses or a delayed diagnosis of ALS (Belsh and Schiffman, 1996;
Srinivasan et al., 2006; Kraemer, Buerger, and Berlit, 2010; Nzwalo et al, 2014).
Moreover, the diagnosis of ALS may be delayed until further into its progression if
symptoms are not recognized as significant by the patient, their family members, or their
family physicians (O’Brien et al., 2011). A delayed diagnosis of ALS may mean that the
disease has progressed further than the original onset site, leading to a distorted clinical
picture of where onset truly began. Further, a delay in diagnosis may give the appearance
of shorter survival times for the patient, which may be a source of distress (Househam
and Swash, 2000; O’Brien et al., 2011).
Proximate Risk Factors in ALS
Risk factors for the development of ALS are largely unclear; however, researchers
have identified several potential candidates. These risk factors are often considered
largely from a biomedical lens. Several genetic mutations, such as the mutation of the
SOD1 gene, have been suspected in the development of familial ALS and may be a risk
factor for sporadic ALS as well (Wang et al., 2016). Exposures to heavy metals (e.g.
lead), organic chemicals (e.g. pesticides used in farming), and occupational exposures
(e.g. electrical shock, chemical exposure), are considered potential risk factors that have
been studied extensively, although not in connection to each other (Sutedija et al., 2007;
Fang et al., 2009; Yu et al., 2014; Wang et al., 2016). Additionally, research suggests
health behaviors are potential risk factors for ALS development. Individuals who smoke
are at higher risk of developing ALS, however, this correlation has been debated as the
association appears in some studies and not in others when other proximal risk factors are
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included in the measures (Sutedija et al., 2007; Yu et al., 2014; Wang et al., 2016).
Alcohol consumption has been reported as having a potential protective effect (de Jong et
al, 2012) or no association with the development of ALS (Nelson et al., 2000).
Social Position and ALS Onset Location
Social position (e.g. indicated by gender, race/ethnicity, or social class), when it is
included in ALS research, is often considered largely through a biomedical lens. The
wide variation of potential proximate risk factors, however, indicates there may be more
at work than simple environmental exposures. As Ingre et al. (2015) noted, different risk
factors have been studied independently of each other, but little work has been done to
study how they may interact and what factors may predispose a person to those
circumstances. Further, the onset location of ALS may be, in part, due to the differences
in the vulnerability of nerves to exposure to proximal risk factors linked to ALS
development (Brown, Lockwood, and Sonawane, 2005; Aschbacher et al., 2013;
D’Amico et al., 2013; Bozzo et al., 2017).
Exposures to risks, however, is often a function of experiences in the social world.
Extant research has considered that social position—race/ethnicity, education, and
socioeconomic status—operate as fundamental causes of health disparities (Link and
Phelan, 1995; Williams and Collins, 2001; Lutfey and Freese; 2005; Mirowsky and Ross,
2010). Fundamental cause theory is useful in understanding what social factors may
differentially place people at ‘risk of risks,’ including the proximate risk factors related to
the development of ALS (Link & Phelan, 1995). Fewer studies explore how fundamental
social structures shape the experience of those with a disease (Timmermans and
Buchbinder, 2010; Umberson et al., 2016). Moreover, understanding the patterns of
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social position in an illness may help to understand how ALS symptoms are expressed
and experienced through differing exposures (Link & Phelan, 1995; Glass & McAtee,
2006; Braveman, Egerter, and Williams, 2011). For example, women and people of color
are often at higher risk of poorer health due to exposure to socio-environmental stressors
(e.g. discrimination and harassment). Social and environmental stressors may increase
the level of cortisol, as well as increase oxidative stress within the cells (Fidler et al.,
2011; Goosby and Heidbrink, 2013; Aschbacher et al., 2013). In the case of ALS, the
weathering of the body from these constant insults may leave the central nervous system
more vulnerable to damage, leading to differences in the expression of individual
symptoms (Geronimus et al., 2001). Differences in stressors due to social position is one
potential explanation for variations in the experience of ALS; yet there are other potential
connections that I detail below.
Race and Ethnicity. ALS is often depicted as a disease that effects White men,
however, this may be due to White men being overrepresented in many clinical and
registry studies (Chiò et al., 2011; Mitsumoto et al., 2014; Kaye et al., 2018). Further,
White men may be overrepresented in cases of ALS because they have fewer competing
risks of death compared to Black men (Ferraro and Farmer, 1996; Howard et al; 2000).
Currently, development of ALS is thought to be less frequent in minorities and is often
hypothesized as perhaps a result of genetic differences (e.g., protective genes) (Gundogdu
et al., 2014). Considering fundamental cause theory and the social determinants of health,
it is more likely that racial/ethnic minority populations have differing access to resources,
leading to this population remaining undiagnosed until the disease has advanced to later
stages. Further, people of color have reported believing ALS is a ‘White disease’ leading
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to the potential dismissal of symptoms or a delay of diagnostic tests, especially if the
provider is under the same impression, due to the majority of ALS coverage in popular
media portraying the disease as affecting only White men (Carter, 2019). In addition,
later diagnosis of ALS may limit the ability of racial/ethnic minority populations to
access specialty clinics and clinical trials, limiting information on this population. Based
upon prior data and fundamental cause theory and the social determinants of health, I
hypothesize that:
H1: Given that racial/ethnic minorities face greater social and environmental
risk factors which may cause widespread damage to the nervous system, as
well as may face later diagnosis due to the perception of ALS as disease of
White men, racial/ethnic minorities will have different patterns of onset, with
minorities having higher odds of reporting global onset of ALS symptoms.
Gender. Although ALS has been presented as overwhelmingly affecting males,
European studies have indicated the differences in rates of ALS diagnosis between men
and women diminish in the fifth and sixth decade of life (Mehta et al., 2014; Manjaly et
al., 2010). In addition, the onset location for women tends to be different than for men.
For example, studies report women are much more likely to report bulbar onset of ALS
symptoms, but posit the differences is potentially due to gonadal hormones or biological
differences in the nervous system (McCombe and Henderson, 2010; Swinnen and
Robberecht, 2014). Other potential behavioral and environmental factors, such as
cigarette smoking and occupational risk exposure, have previously been shown to explain
the increased rate of bulbar onset in women (McCombe and Henderson, 2010; Sutedja,
2010). The differences in ALS prevalence rates between men and women, as well as the
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differences in onset location between the genders is not well understood. Previous
studies, however, have not accounted for race/ethnicity or socioeconomic status, as well
as proximate risk factors, when attempting to explain the differences in onset location
between men and women. Therefore, I posit that:
H2: Women will have different patterns of onset than men, with women
having higher odds of reporting bulbar onset of ALS symptoms, which will
not be explained by proximate risk factors when including social positions of
race/ethnicity or socioeconomic status.
Socioeconomic Status and Education. Socioeconomic status and education are
linked (Krieger, Williams, and Moss; 1996; Mirowsky and Ross, 2010). Further,
education is both thought of as a fundamental cause of health disparities and as a proxy
for socioeconomic status (Krieger, Williams, and Moss; 1996; Mirowsky and Ross,
2010). Exposure to hazards such as pesticides or environmental toxins are influenced by
socioeconomic status and education—people of lower socioeconomic status and
minorities may live in areas with a greater level of environmental pollution—and lower
educational attainment may prohibit leaving an occupation or a home where proximate
risks occur. In addition, those with lower education levels may have constrained choices
and therefore be led to a career that increases the risk of injury, and/or may have less
access to healthcare resources (Link & Phelan, 1995; Williams & Collins, 2001;
Mirowsky and Ross, 2010; Freese & Luftey, 2011; Diez Roux, 2012; Phelan & Link,
2013). All these risks have been individually implicated in the increased risk of
developing ALS; however, research has not connected these factors back to
socioeconomic status or education level. Moreover, lower education may lead to a
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difference in the type of work one engages in, as well as in how symptoms of ALS
become salient (Krieger, Williams, and Moss; 1996; Mirowsky and Ross, 2010). For
example, a job that requires more physical labor (e.g., mechanic) may lead to the belief
that limb onset symptoms are due to overuse or injury rather than signs of ALS, whereas
trouble with speech or swallowing may be more unusual and require attention.
Considering these factors, I hypothesize:
H3: pALS with different levels of education will have different patterns of
onset, with those with a college degree or more having lower odds of
reporting global or bulbar onset of ALS symptoms than those with an
education of high school or less.
Military service has been linked to ALS development, as veterans are twice as
likely as civilians to develop the disease, but the link is currently unclear (Weisskopf et
al., 2015; Wang et al., 2016). For example, previous research has indicated physical
trauma or injury, lower BMI, lower educational attainment, and the higher levels of
physical activity found among service members may be particular risk factors for the
development of ALS (Weisskopf et al., 2015; Wang et al., 2016). Although military
service is often described as a proximate risk factor, it may also operate as an indicator of
social position. For example, military enlistment is particularly attractive to young people
with lower socioeconomic statuses, larger family sizes, and less-educated parents
(Kleykamp, 2006). The development of ALS is twice as common among military
veterans, which may be in part due to the exposures during military service but may also
be influenced by the experiences of the veteran both pre- and post-enlistment. Given the
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potential similarities between veterans and those with lower levels of education, I
hypothesis that:
H4: Civilians will be more likely to report bulbar and trunk/global onset of
ALS symptoms than Veterans.
Life course and social resources. Position in the life course, including age and
marital status, may influence when symptoms become salient for an individual. Having a
partner or spouse in the home may act as another set of eyes, allowing for earlier
detection of ALS symptoms and a clearer picture of where the symptoms started (Waite
and Gallagher, 2001). Furthermore, younger adults who are more physically active may
recognize limb onset symptoms as unusual for their daily activities (e.g. difficulty
running), whereas an older adult may dismiss troubles with daily activities (e.g. dressing)
as a sign of aging, consequently delaying diagnosis until there is greater involvement of
the nerves. Therefore, it is reasonable to suspect that these social factors may influence
the reported onset location of ALS via how the person affected by ALS may come to
realize that something has changed within their body in the time leading up to diagnosis. I
posit that:
H5: Those who are not married (e.g. never married, divorced, or widowed)
will have higher odds of reporting global onset of ALS symptoms, compared
to their married counterparts.
and
H6: Those younger than 50 will be less likely to report bulbar or global onset,
whereas those older than 59 will more likely to reporting bulbar or global
onset, compared to those aged 50-59.
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Data and Methods
Data
The National ALS Registry, created in October 2010, is a voluntary web-based
registry for people who have been diagnosed with ALS. The registry collects data on
demographic characteristics, risk factors, current and lifetime occupational and military
history, family history of ALS, clinical data such as phenotype, and outcome data. In
addition, the registry collects information from the Department of Veterans Affairs and
Medicare for people diagnosed with ALS. The risk factor survey in the ALS Registry was
created and validated by the Stanford University School of Medicine’s ALS Consortium
of Epidemiologic Studies and is constructed to eliminate the need for healthcare provider
involvement in answering the survey questions (Bryan et al., 2016; Raymond et al.,
2019). Due to the potential physical, mental, and emotional limitations of pALS, the risk
factor survey utilizes smaller modules to facilitate completion (Bryan et al., 2016). The
National ALS Registry collects data through a secure web portal from those who have
self-identified as having ALS. In addition, each participant completes a separate
questionnaire developed by the U.S. Department of Veterans Affairs ALS registry to
confirm an accurate ALS diagnosis (Bryan et al., 2016). One potential drawback to the
online survey is the potential for self-selection bias, with the data slanted toward an urban
dwelling, younger, better educated patient.
The clinical symptoms survey module was created in partnership with the ALS
Research Group to examine physical symptoms participants developed before and after a
diagnosis of ALS (Raymond et al, 2019). The survey contains fifty-four questions on
topics such as site of onset, time of initial symptom onset to diagnosis, and time of
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diagnosis to hospice referral. The module launched in December 2013 to new enrollees
and previous enrollees were prompted to return to the web portal to complete this survey.
Therefore, this analysis covers from 19 October 2010 to 31 December 2016. In total,
9,789 respondents are included in this study with no exclusions.
Measures
Onset Location. The dependent variable is the part of the body where the patient
first reported ALS-related weakness or symptoms. In order to create a categorical
variable for analysis, the body was subdivided into 3 areas: 1) limb—symptoms first
reported in the extremities, including the hand, arm, foot or leg, 2) bulbar— symptoms
first reported in the oral and facial muscles, including issues with speech and/or
swallowing, and 3) trunk/global—symptoms first reported in the trunk, including the
neck, back or abdominal areas, breathing muscles, or total body weakness. Onset location
was missing for .54% of the registry respondents.
Social Position. Potential factors in the development of ALS include the social
position of the patient at the time they entered the registry. Race/ethnicity was
constructed as a dichotomous variable due to the small number of racial/ethnic minority
patients in the registry, with White (=0) and Minority (=1) as populations of interest. The
gender of the patient is a dichotomous variable of men (=0) and women (=1). Education
is a categorical variable of high school or less (=0), tech or trade school or some college
education (=1) and a bachelor’s degree or more (=2). Race/ethnicity, sex, and education
did not have missing data.
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Veteran’s Status. I include veteran status as a dichotomous variable in the model,
with veteran (=0) and civilian (=1). Military enlistment data was missing for .07% of the
registry respondents.
Proximal Risk Factors. The National ALS Registry asks for respondent’ longest
occupation. In order to create categories which would include enough respondents, this
variable is categorized as low risk (= 0) and high risk (= 1). Occupations were
categorized using previous research as a guide; if exposure to risks would be considered
low (e.g. secretarial work) or high (e.g. automotive technician) the occupation was
included in the corresponding category. Occupational data was missing for 38.18% of the
respondents. A dichotomous question of personal history of ever smoking (yes = 1) or
ever drinking (yes = 1) was asked of the respondents. Smoking history was missing for
.72% of the respondents, and drinking history was missing for .23% of the respondents.
Life Course and resources. In order to account for a potential social relationship
which may influence recall of diagnosis or an earlier diagnosis, I include marital status.
Marital status is a dichotomous variable of married or cohabitating (= 0) or never
married, separated/divorced, or widowed (= 1), with missing data for .12% of the
respondents. As age may play a role in what symptoms are noticed first, I included age as
a categorical variable: 18-39 (= 0), 40-49, 50-59, 60-69, 70-79, and 80+ (= 5). Age was
missing for .02% of the respondents.
Analysis
Multiple Imputation using Chained Equations was used to impute missing data
with ten imputations completed (Bodner, 2008). Table 1.1 reports the pre- and postimputation proportions in each category. The similar estimates for each variable, as well
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as between the pre-and-post imputation bivariate analyses, demonstrate reliably imputed
data. Bivariate tests of the association between onset location and each of the dependent
variables were then performed. I use multinomial logistic regression to examine the
relative risk ratio of reporting bulbar onset or global onset compared to limb onset. Model
1 includes the distal factors of social position (race/ethnicity, gender, education). Model 2
includes social position and veteran status. Model 3 includes social position, veteran
status, and proximal risk factors, including occupational risk and smoking/drinking
history. Finally, Model 4 includes the addition of marital status and age at diagnosis.
Results for Model 4 are reported in this chapter; tables for Models 1-3 can be found in
appendix A. All analyses were completed using STATA version 15.
Results
Demographics
As indicated by Table 1.1, just over 73% of the respondents reported limb onset,
just over 20% reported bulbar onset, and nearly 6% reported trunk/global onset. The
sample is almost exclusively White (97.18%), and nearly 60% of the sample is male.
Over 60% of the respondents reported having at least a bachelor’s degree. Veterans make
up nearly 24% of the sample. Over 60% of the individuals in the registry records report
working in a low risk occupation, while just over 45% report a history of smoking and
81% report a history of drinking alcohol. The majority of the sample is married or
cohabitating (82%). Most of the respondents are between the ages of 50-59 and 60-69
(29.79% and 35.99 % respectively).
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Bivariate Associations
Table 1.2 displays the F tests results used to determine if there were relationships
between the dependent variable of onset location and the independent variables. Tests of
the bivariate associations do not show associations between onset type and race/ethnicity,
occupational risk category, marital status, or a history of smoking. The results show there
is an association between onset location and (1) gender, with women being more likely to
report bulbar onset than men, (2) education, with higher levels of education less likely to
report global onset than lower levels of education, (3) alcohol consumption, with pALS
who consume alcohol more likely to report limb onset than pALS who do not consume
alcohol, (4) veteran status, with veterans more likely to report limb onset than civilians
and, (5) age at diagnosis, with younger pALS more likely to report limb onset than older
pALS (p < .001).
Multinomial Logistic Regression of Reporting of Onset Location
Table 1.3 presents the results of the multinomial logistic regression. In contrast to
Hypothesis 1, racial/ethnic minorities are no more likely to report bulbar onset (RR =
1.29, 95% CI [.96, 1.73]) versus limb onset, or global onset (RR = .93, 95% CI [.54,
1.60]) versus limb onset, compared to whites. This finding is surprising, given the
existing literature on racial/ethnic minority health disparities we would expect to see a
potentially greater level of nerve involvement at diagnosis. Due to the small number of
nonwhite participants in the registry, however, the lack of association may be an issue of
power. Therefore, Hypothesis 1 is not supported.
The results show women, in comparison to men, are more likely to report bulbar
onset compared to limb onset of ALS symptoms, supporting Hypothesis 2 and consistent
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with existing research in onset location. The higher risk of bulbar onset among women is
interesting, given that many clinical studies are populated by pALS with limb onset, and
thus there are gaps in knowledge relevant to the disease for women. Compared to men,
women are more likely to report bulbar onset compared to limb onset (RR = 1.43, 95%
CI [1.28, 1.61]), and less likely to report global onset compared to limb onset (RR = .93,
95% CI [.33, .51]).
The results of education and onset location partially support Hypothesis 3, as
results do show that those with the highest level of educational attainment are 28% less
likely to report global onset (RR = .72, 95% CI [.57, .90]) compared to limb onset in
contrast to pALS with a technical or trade degree or at least some college education. With
the addition of age at diagnosis and marital status, pALS with a high school education or
less compared to those with pALS with a technical or trade degree or at least some
college education do not significantly differ in their risk of bulbar onset versus limb onset
(RR = 1.09, 95% CI [.92, 1.30]). Education level may make a difference in the perception
of onset, as those with higher levels of education (e.g. bachelor’s degree of greater) could
have fewer work-related explanations for symptoms in the limbs than those with less
education.
In comparison to veterans, civilians are 25% more likely to report bulbar onset
versus limb onset (RR = 1.25, 95% CI [1.09, 1.44]) and 119% more likely to report
global onset versus limb onset (RR = 2.19, 95% CI [1.73, 2.79]). These results support
Hypothesis 4, as civilian pALS have higher odds of reporting bulbar and trunk/global
onset of ALS symptoms than those pALS who served in the military.
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Concerning marital status, those pALS who are not married are no more likely to
report bulbar onset versus limb onset (RR = 1.01, 95% CI [.89, 1.16), however, they are
47% more likely to report global onset versus limb onset (RR = 1.47, 95% CI [1.18,
1.84]) when compared to those who are married. These results support Hypothesis 5. For
married pALS, it may be that a spouse notices symptom earlier in the disease course and
wives may be more insistent on their spouse obtaining medical care. Further, in support
of Hypothesis 5, the results show that pALS under the age of 50 are less likely to report
bulbar or global onset of symptoms compared to limb onset, and those pALS over the age
of 59 are more likely to report bulbar onset or global onset compared to limb onset, when
compared to those between the ages of 50 and 59. One exception to this is pALS who are
ages 40-49 are no more or less likely to report bulbar onset over limb onset than those
ages 50-to-59. Overall, the results indicate a pattern of younger pALS being less likely to
report bulbar or global onset compared to limb onset (see Table 1.3 for full results),
which may be due to the perception of the initial onset of ALS being confused with the
normal process of aging in older adults.
Discussion
In an attempt to better understand how social position may shape the reported
onset location of ALS symptoms, I use fundamental cause theory, social determinants of
health, and life course theory in analyzing the National ALS Registry data. The use of
these theories in analyzing the registry data provides new insights into how social
position may shape the onset location of ALS. Further, I use sociological theories to
understand the social dimensions of a disease that is often conceptualized and studied as
purely biological (Ingre et al., 2015; Brown and Al-Chalabi, 2017).
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Social position and position in the life course does seem to shape onset location,
which is a new finding in research on ALS. There are several potential explanations for
these findings. Social position and position in the life course could influence the
perception of symptoms of ALS and where they begin. Moreover, social position could
be an influence on the exposures that trigger a gene by environment interaction which
influences the biological development of symptoms are where they begin. Finally, social
position has been shown in previous work to influence access to healthcare resources,
allowing the symptoms to spread prior to diagnosis and changing the reported onset
location.
Women and people of color are often at higher risk of poorer health due to
exposure to socio-environmental stressors (e.g. discrimination, harassment) (Schultz et
al., 2001; Williams and Jackson, 2005). In the case of ALS, the weathering of the body
from socio-environmental stressors leave the central nervous system more vulnerable to
damage, leading to differences in the expression of individual symptoms. pALS of color
in the National ALS Registry, however, were no more likely to report bulbar or global
onset versus limb onset in comparison to white pALS. Biomedical research has posited
this is due to a potential difference in genetics, as it appears that minorities are less likely
overall to develop ALS. Alternatively, there is a small sample of racial/ethnic minority
pALS in the registry and issues overall with collecting data on ALS, potentially masking
differences. Previous work has compared the registry to other sources of data and has
noted that the registry underreports cases of ALS among non-whites (Kaye et al., 2018).
In addition, health disparities research has illustrated the issues with access to and the
quality of care/diagnosis for minorities in the US healthcare system (Phillips, Meyer, and
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Adiar, 2000; Shi, Lebrun, and Tsai, 2010; Shi et al., 2014). Cases of ALS are difficult to
diagnosis, taking a good deal of time and resources, which may limit the number of
accurate diagnoses in racial/ethnic minority populations. Finally, the differences in life
expectancy between Whites and minorities could affect the reported numbers of ALS
diagnosis in racial/ethnic minority patients. For example, it may be that Black-Americans
develop other serious health conditions and have other social exposures (e.g. violence)
that increase the potential they do not live long enough to develop ALS, as the average
age of diagnosis is in the late fifties and early sixties (Geronimus et al., 2001).
Women were more likely to report bulbar onset in comparison to limb onset when
compared to men, consistent with previous research in this area. Previous work in gender
differences in ALS onset have posited biomedical explanations for the increase in bulbar
onset in women. For example, higher levels of bulbar onset reports in women may be due
to differences in gonadal hormones (e.g. estrogen, progesterone, testosterone) or
biological differences in the central nervous system (McCombe and Henderson, 2010;
Swinnen and Robberecht, 2014). Other potential behavioral and environmental factors,
such as cigarette smoking and occupational risk exposure, have previously been shown to
explain the increased rate of bulbar onset in women (McCombe and Henderson, 2010;
Sutedja, 2010), however, the inclusion of these proximal risk factors in these models does
not explain away the higher likelihood of women reporting bulbar onset.
Women, given their position in the social hierarchy, face potential differences in
the amount and type of chronic stressors in comparison to men. Higher levels of chronic
stress for women leads to higher levels of oxidative stress via the repeated activation of
the HPA axis, causing damage to the cells in the body, including the nervous system
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(Aschbacher et al., 2013). Oxidative stress has been implicated as one potential trigger
for ALS, and may influence the onset location (Bozzo et al., 2017). Gender, however,
does not seem to affect survival rates between women and men, meaning the oxidative
stress may only trigger ALS, but not influence mortality (McCombe and Henderson,
2010). Therefore, it is important to not disregard the potential of social position to shape
ALS experience when including women in biomedical research of ALS, including the
potential of exploring stress-related biomarkers in the development of ALS.
Education and socioeconomic status are often thought of as the fundamental
causes of health disparities (Link & Phelan, 1995; Williams & Collins, 2001; Mirowsky
and Ross, 2010; Freese & Luftey, 2011; Diez Roux, 2012; Phelan & Link, 2013). For the
population of people with ALS in the National Registry, pALS with the highest-level of
education were less likely to report global onset than limb onset, however, there was no
difference in the likelihood of reporting bulbar onset compared to limb onset. pALS with
higher levels of education (and by proxy potentially higher socioeconomic status) are
more aware of the potential for symptoms to mean that something is going on with their
body and are likely to seek medical care for symptoms earlier in the disease course,
preventing the appearance of global symptoms (e.g. total body weakness). In addition,
individuals with higher education levels may be less likely to be exposed to
environmental and occupational hazards and have occupations that allow for less of the
symptoms to be explained as related to activities on the job.
Civilians are more likely to report onset of ALS symptoms in the bulbar region or
in the trunk/global region than limb onset, in comparison to their veteran peers. Prior
research has hypothesized that differences in both the rate of development and onset
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location may be due to differences between those who enlist in the military and those
who do not, including higher rates of physical trauma or injury, lower BMI, lower
educational attainment, and the higher levels of physical activity (Weisskopf et al., 2015;
Wang et al., 2016). Considering prior research has shown that military enlistment is
particularly attractive to young people with lower socioeconomic statuses, larger family
sizes, and less-educated parents (Kleykamp, 2006), it is likely that onset location is
influenced by the experiences of the veteran both pre-and-post enlistment, including
higher rates of occupational and environmental exposures. It is important to future
research to include early life experience and related exposures, in addition to military
service, to begin to understand the differences in reported onset location between
veterans and civilians. Additionally, veterans often have access to different healthcare
systems (e.g. VA system) which are aware of the greater risk of ALS among veterans,
allowing for the testing of suspicious symptoms earlier in disease development.
pALS who are not married are more likely to report global onset compared to
limb onset, with no differences between bulbar and limb onset, compared to their married
peers. Given that ALS eventually affects all areas of the body, having a partner in the
home may help to catch the gradual onset of limb or bulbar symptoms before they begin
to affect other areas of the body. Further, extant research has shown that marriage is
beneficial to one’s health, by lowering the impact of stress on both physical and
psychological health (Slatcher, 2010; Carr et al., 2014). Therefore, it might be that
marriage and its potential for reducing stress protects the central nervous system from
damage, leading to ALS symptoms developing in one region of the body (e.g. bulbar or
limb) rather than in a widespread manner.
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It becomes apparent when considering age at diagnosis that position in the life
course may influence the reported onset location of ALS. pALS diagnosed with ALS who
are younger are less likely to report bulbar or global onset than limb onset compared to
those who are diagnosed between the ages of 50-59, the average age at diagnosis. pALS
older than 50-59 are more likely to report bulbar or global onset than limb onset. There
are several potential reasons for these results. Previous research has postulated aging
itself may cause damage to neurons, leading to an increase in global onset (Atsuta et al.,
2009; Yokoi et al., 2016). People diagnosed with Familial ALS (FALS), which is due to
genetic causes, tend to be younger with limb onset being most common among these
patients (Gaudette et al., 2000). FALS only makes up 5-10% of ALS cases, however,
which does not fully explain the differences in onset location. It may be that symptoms of
ALS that develop in the limbs are more salient to those who are younger and are more
physically active. Older adults may dismiss troubles with daily activities as a sign of
aging, which may delay diagnosis until there is further involvement of the nerves.
Finally, in line with many of the other patterns found in the data, it may be that the effects
of stress accumulate over the life course, causing damage to the nervous system and
affecting onset location (Geronimus. 1992; Geronimus et al., 2001; Ferraro et al., 2009;
Ferraro et al., 2016).
Limitations
There are a number of limitations to consider with this study. The first is the
nature of the National ALS Registry. The National ALS Registry has been designed for
biomedical and epidemiological research, and therefore limits the work of the social
scientist. The ALS Registry is reliant on patient self-reporting data and may be subject to
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recall bias and bias due to self-identification. Further, the registry is a large non-random
sample that is opt-in and is therefore not generalizable to the ALS population.
The registry is available in an online format only, which may limit access and
cause the registry to reflect a younger, White, and educated patient sample. The registry
sample provided by the CDC is less racially diverse than the overall registry which
includes Medicare and Veteran’s Association claims data. There are several potential
reasons for this, including access to computers that are required for self-registration;
reduced awareness of the registry; and reduced participation in areas with substantial
nonwhite populations (Kaye et al., 2018). In addition, while the sample size overall is
robust, smaller numbers of specific populations, such as non-white patients, makes it
difficult to detect single axis disparities and limits the ability to do intersectional analysis
to better understand the relationship of social position and ALS. Finally, the limited
access to data due to reidentification risks limit the analysis to a small number of survey
modules, which prevents a fuller picture of the experience of ALS. Even with these
limitations, the National ALS Registry is the most comprehensive, geographically diverse
sample of people diagnosed with ALS.
Conclusion and Implications
Fundamental cause theory, social determinants of health, and life course theory
are valuable sociological theories in understanding health disparities and differences in
disease development. These theories have helped to highlight differences in social
position and reported onset location of ALS in patients who have registered with the
National ALS Registry. Although fundamental cause theory, as well as the social
determinants of health, do not fully and consistently explain the differences in onset
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location among pALS, they do highlight areas where these theories may help clarify
where differences are occurring in the disease course. Further, the use of these theories
shows where potential refinements in the theories are needed to allow for their use at the
micro-level in a rare disease with unknown causes. Additionally, the findings reinforce
the need for a sociology of disease, in order to understand the disparities in trajectories
and health outcomes in specific diseases rather than understanding disparities from a
general overview (Timmermans and Haas, 2008). The goal of a sociology of disease in
the case of ALS is to take the themes and theories from the sociology of health and
illness and focus attention on specific health outcomes such as onset location. Although
social epidemiology may seem like a more natural fit for this type of work, the goal here
is not to point out collective risk factors but to account for the multiple pathways in
which the experience of the social world may influence ALS onset directly (Pescosolido,
2006; Timmermans and Haas, 2008). In fact, the previous successes of epidemiology and
biomedicine in understanding ALS highlights the need to understand how the social
affects the development and experience of ALS (Pescosolido, 2006; Link, 2008;
Timmermans and Haas, 2008).
Future research in ALS should consider the implications of social position and the
position in the life course on the experience of ALS. These considerations are especially
important as it relates to risk exposures, to not only suspected proximate risk factors, but
to the experience of stress. Stress is known to affect health in a myriad of ways, both
physically and psychologically. Previous research has examined the effects of stress in
ALS through pathways related to hormones (e.g. cortisol) and damage to the nervous
system (e.g. oxidative stress) (Fidler et al, 2011; Bozzo et al., 2017). The addition of a
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module to the registry asking about life events and chronic stressors, in combination with
biomarker data, could begin to clarify the connection between stress and ALS.
An additional implication of the work presented here is the need to rethink the
way clinical trials are designed. The results presented illustrate concerns—reported onset
location varies by social position—which is often not accounted for in clinical trials for
ALS treatments. Prior research evaluating clinical trials implicated a lack of
consideration of variations in the disease (e.g. onset location, speed of progression) in the
widespread failure of promising trials, as the majority of trial participants are young,
white and male, the majority of those with limb onset (Chiò et al., 2011; Mitsumoto et al.,
2014). I argue that addition to ensuring variation in onset location in clinical trials, it is
important to take into consideration the social position of the participant, as variations in
onset location do appear to have connections to social forces. By beginning to understand
how social position and position in the life course are related to the reported onset
location of ALS, researchers and health professionals can begin to incorporate the social
factors into research on the diagnosis, treatment, and biomedical research of ALS.
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Table 2.1. Descriptive Statistics for Pre and Post Imputation Data (N = 9789)
Pre-Imputation
Variable
Onset Location

Post-Imputation
Percentage

Frequency Percent
Limb (0)
Speech/Swallowing (1)
Trunk/Global (2)
Missing

7169
2003
564
53

73.24
20.46
5.76
.54

73.61
20.59
5.80
0

White (0)
Non-White (1)
Missing

9513
276
0

97.18
2.82
0

97.18
2.82
0

Men (0)
Women (1)
Missing

5861
3928
0

59.87
40.13
0

59.87
40.13
0

High School or Less (0)
Tech/Trade/Some College (1)
College Degree (2)
Missing

1392
2034
6363
0

14.22
20.78
62.00
0

14.22
20.78
62.00
0

Civilian or Other (0)
Veteran (1)
Missing
Occupational Risk Category
Low Risk (0)
High Risk (1)
Missing
Ever Smoked Cigarettes
No (0)
Yes (1)
Missing
Ever Drank Alcohol
No (0)
Yes (0)
Missing
Marital Status
Married or Cohabitating (0)
Never Married, Separated, Divorced, Widowed (1)
Missing
Age at Diagnosis
18-39 (0)
40-49 (1)
50-59 (2)
60-69 (3)
70-79 (4)
80+ (5)
Missing

7473
2309
7

76.34
23.59
.07

76.41
23.59
0

3810
2242
3737

38.92
22.90
38.18

62.22
37.78
0

5288
4431
70

54.02
45.27
.72

54.40
45.60
0

1815
7951
23

18.54
81.22
.23

18.61
81.39
0

7998
1779
12

81.70
18.17
.12

81.80
18.20
0

427
1382
2916
3522
1406
134
2

4.36
14.12
29.79
35.99
14.37
1.37
.02

4.36
14.12
29.79
35.99
14.36
1.37
0

Race/Ethnicity

Gender

Education

Veteran Status
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Table 2.2. Bivariate Associations by Reported Onset Location (N = 9789)
Limb
Onset

Bulbar
Onset

Trunk/Global
Onset

White
Non-White

.74
.71

.20
.23

.06
.05

Men
Women

.75
.71

.18
.25

.07
.04

.71
.74
.74

.22
.19
.21

.07
.07
.05

.73
.77

.21
.18

.06
.05

Race/Ethnicity

Chi-Square Test
Pre-Imputation
P Value
p = .51

Gender
Education
High School or Less
Tech/Trade/Some College
College Degree or More
Veteran Status
Civilian or Other
Veteran
Occupational Risk
Category
Low Risk
High Risk
Ever Smoked Cigarettes
No
Yes
Ever Drank Alcohol
No
Yes
Marital Status
Married or Cohabitating
Never Married, Separated,
Divorced, Widowed
Age at Diagnosis
18-39
40-49
50-59
60-69
70-79
80+
*p < .05, **p < .01, ***p < .001

.73
.74

.20
.21

.06
.05

.74
.73

.20
.21

.06
.05

.72
.74

.23
.20

.05
.06

.74
.72

.20
.22

.06
.07

.95
.79
.78
.69
.66
.60

.03
.17
.17
.25
.24
.34

.01
.04
.05
.06
.10
.06

F-Test PostImputation
P Value
p = .51

p < .001 ***

p < .001 ***

p = .01 **

p = .01 **

p < .001 ***

p < .001 ***

p = .05 *

p = .06

p = .20

p = .20

p = .03 *

p = .04 *

p = .07

p = .08

p < .001 ***

p < .001 ***
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Table 2.3. Model 4: Multinomial Logistic Regression Predicting Reporting of Onset Location, Risk
Factors, Social Position, Marital Status, and Age at Diagnosis, Relative Risk Ratios (N=9789)
Base Category: Limb

Racial/Ethnic Minority
Women
Education (ref= Tech, Trade, or Some
College)
High School or Less
College or More
Civilian
Low Occupational Risk
Ever Smoked Cigarettes (ref=Never)
Ever Drank Alcohol (ref=Never)
Single/Separated/Divorced
Age at Diagnosis (ref=50-59)
18-39
40-49
60-69
70-79
80+
Constant
*p < .05, **p < .01, ***p < .001

Bulbar
Global
Relative Confidence Relative Confidence Interval
Risk Ratio
Interval
Risk Ratio
1.29
(.96, 1.73)
.93
(.54, 1.60)
1.43*** (1.28, 1.61)
.41***
(.33, .51)
1.09
1.14
1.25***
.93
1.02
.94
1.01

(.92, 1.30)
(1.00, 1.30)
(1.09, 1.44)
(.79, 1.08)
(.91, 1.13)
(.82, 1.08)
(.89, 1.16)

1.02
.72**
2.19***
1.46**
.78*
1.14
1.47***

(.77, 1.37)
(.57, .90)
(1.73, 2.79)
(1.10, 1.93)
(.65, .95)
(.89, 1.50)
(1.18, 1.84)

.15***
.98
1.67***
1.77***
2.72***
.15***

(.09, .25)
(.83, 1.18)
(1.48, 1.91)
(1.50, 2.09)
(1.84, 4.00)
(.11, .20)

.22***
.71*
1.34**
2.79***
1.87
.03***

(.10, .50)
(.52, .97)
(1.07, 1.67)
(2.17, 3.59)
(.88, 4.00)
(.02, .05)
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CHAPTER THREE: DO SOCIAL FACTORS SHAPE THE TIME FROM ALS
SYMPTOMS TO DIAGNOSIS?
Introduction
Sociologists are uniquely positioned to translate how social factors influence
symptoms of disease progression and to inform biomedical researchers of the potential
perils of taking social factors for granted in biomedical research. Further, there is a need
for sociologists to understand how well existing theories, including fundamental cause
theory, social determinants of health, and life course theory, describe the social factors
involved in the experience of ALS. Finally, in response to Timmermans and Haas’ (2008)
call for a sociology of disease, sociologists need to understand how well existing theories
in the sociology of health and illness fit the experience of disease, especially one as rare
as ALS.
Therefore, this paper addresses the question: How does social position shape the
time between early symptoms of ALS and diagnosis? I posit that differences in the time
between symptoms and diagnosis for people with ALS may in part be due to differences
in social position and position in the life course. Developing a better understanding of
how social position can potentially reveal patterns in the time between reported symptom
development and diagnosis may help to understand how social forces shape the
variability of ALS symptoms among people with ALS.
Guided by fundamental cause theory, I expect that those in less advantaged social
positions (e.g. minorities, women, lower levels of education) will report more time
between the development of ALS symptoms than their more advantaged peers. Guided
by life course theory, I expect that older adults will report less time between the
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development of symptoms and diagnosis than younger adults. Overall, I expect that the
development of most of the early symptoms of ALS will be reported as happening before
diagnosis by participants in the ALS registry, indicating the disease must progress to later
stages in order to be noticed and diagnosed.
Social Position and the Time Between ALS Symptoms and Diagnosis
The order of appearance of ALS symptoms and the rate of progression are highly
variable (Havercamp et al., 1995; Voustianiouk et al., 2008). Given that many symptoms
of ALS develop prior to diagnosis, a delay in diagnosis may give the appearance of
shorter survival times, as well as limit access to medications during the time when they
would be most beneficial (Househam and Swash, 2000).
In order to assess disease progression, ALS progression is typically measured
using the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised Scale (ALSFRR) (Cedarbaum et al., 1999) or the Appel Rating Scale (Appel et al., 1987). Both scales
monitor the progression of impairment in people with ALS from the time of diagnosis,
including strength and function of the muscles, speech and swallowing function, as well
as respiratory function and ventilator support. The ALSFR-R and Appel Rating Scale are
used as predictors of progression to the terminal stage of ALS (Appel et al., 1987;
Cedarbaum et al., 1999).
Given that many of the early symptoms of ALS develop long before diagnosis,
progression estimates may be influenced by the mechanisms which drive variability in
symptom development. The potential for ALSFR-R scores to be influenced by these
unknown mechanisms is concerning—ALSFR-R scores are used extensively in as part of
the qualification requirements for clinical trials testing new ALS treatments—and a poor
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initial ALSFR-R score may preventing enrollment in clinical trials (Mitchell et al., 2010;
Rothstein, 2017; Jaiswal, 2019).
The variability of the earliest symptoms can lead to incorrect diagnoses and
unnecessary medical procedures, culminating in a delayed diagnosis and preventing
access to medications when they are most effective (Belsh and Schiffman, 1996;
Srinivasan et al., 2006). For example, two pharmaceutical drugs are thought to slow ALS
progression - Riluzole and Edaravone; however, these medications slow progression only
in certain subgroups of people in the initial stages of ALS (Rothstein, 2017; Jaiswal,
2019). Without a better understanding of symptom development and progression of ALS,
many people with ALS (pALS) may miss the window where these medications are most
effective.
Fundamental cause theory may be useful in understanding why there is variability
in ALS symptom development and the timing of diagnosis. Fundamental cause theory
posits that social factors, such as the stratification of people by social position, are
underlying causes of health disparities leading to worse health outcomes in the form of
disease development (Link & Phelan, 1995). ALS itself may be due in large part to
biological factors interacting with the social, however, the discovery and treatment of the
disease itself may be influenced by fundamental causes (e.g. the ability to react to the
disease).
For example, race/ethnicity, as well as socioeconomic status (SES), have been
shown to influence both health care access and utilization for those in less advantaged
positions (Adler et al., 1994). pALS in lower SES positions may disregard symptoms as a
consequence of their work and of getting older. Additionally, there are many potential
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penalties for lower SES groups needing to attend to health needs (e.g. lost wages,
employment termination) which may delay seeing a physician until the symptoms can no
longer be ignored, leading to longer times between symptom development and diagnosis.
Similarly, veterans seem to have symptoms develop more quickly than civilians,
yet this association may be spurious and simply reflect socioeconomic status or education
levels related to military enlistment (Muddasir Qureshi et al., 2006; Kleykamp, 2006).
Therefore, fundamental cause theory and the social determinants of health may help to
explain the variability of time between symptom development and diagnosis.
Life Course Theory and the Time Between ALS Symptoms and Diagnosis
Position in the life course, including age and marital status, may influence when
symptoms become salient for an individual as an indicator of a potential disease process.
Having a partner or spouse in the home may act as another set of eyes, allowing for
earlier detection of ALS symptoms (Waite and Gallagher, 2001). Furthermore, younger
adults who are more physically active may react to some symptoms as unusual (e.g.
difficulty running), whereas an older adult may dismiss these symptoms as a sign of
aging. Therefore, it is reasonable to suspect that these social factors may influence the
time between symptom onset and diagnosis via how the person perceives symptoms as
they develop.
The Current Study
The role of fundamental causes (e.g. social stratification) in the progression of
ALS symptoms is an area in need of further exploration. Existing research tests potential
social factors such as gender and age with a biomedical lens, while disregarding the
potential effects of racial and class (i.e. education) stratification (Del Agulia et al., 2003;
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Paillisse et al., 2005; Watanabe et al., 2014; Pupillo et al., 2014). The emphasis on social
inequality in fundamental cause theory and the lack of prior emphasis on social status in
prior research on ALS leads me to ask: How does social position shape the length of time
between awareness of ALS symptoms an ALS diagnosis? Using the framework provided
by fundamental cause theory, I posit that social position will shape the time between
symptom development and diagnosis. In addition, I ask: Do fundamental cause theory,
social determinants, and life course theory fit in the case of a rare disease? These
sociological theories suggest the importance of examining if social stratification (e.g.
fundamental cause theory) and age (e.g. life course theory) are associated with the time
between the development of the symptoms of ALS and diagnosis of ALS. At this time, it
is unclear if people with more or less privilege will have a shorter period of time between
the development of ALS symptoms and a diagnosis of ALS. Potentially, people with
more privilege could have more knowledge of symptoms as an issue that can be
addressed, as well as more resources to access medical care that can lead to diagnosis.
The access to resources for people with more privilege suggests that the time between
symptoms and diagnosis may be shorter. People with fewer resources, however, tend to
have more physical jobs and the physical impairments that often signal ALS (e.g.
weakness and cramping) may be more salient when the symptoms begin to affect their
job performance. The result of a reduction in productivity may lead to people with less
privilege to seek medical care more quickly after recognizing symptoms. Thus,
fundamental cause theory highlights the importance of examining how social positions
are likely to matter for time between symptom appearance and diagnosis. Finally, I posit
that these broader theories will be useful in a sociology of disease framework to
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understand how social position and life course position shape the experience ALS. To
explore the potential connection between social position, position in the life course, and
the development of symptoms, I use data from the National ALS Registry.
Data and Methods
Data
The National ALS Registry, created in October 2010, is a voluntary web-based
registry for people who have been diagnosed with ALS. The registry collects data on
demographic characteristics, risk factors, current and lifetime occupational and military
history, family history of ALS, clinical data such as phenotype, and outcome data. Due to
the potential physical, mental, and emotional limitations of pALS, the risk factor survey
utilizes smaller modules to facilitate completion (Bryan et al., 2016). The clinical
symptoms survey module was created in partnership with the ALS Research Group to
examine physical symptoms participants developed before and after a diagnosis of ALS
(Raymond et al., 2019). The survey contains fifty-four questions on topics including the
time between symptom onset and diagnosis. The clinical symptom module launched in
December 2013 to new enrollees and previous enrollees were prompted to return to the
web portal to complete this survey. Therefore, this analysis covers from 19 October 2010
to 31 December 2016. The number of respondents who reported a symptom varies by
category and are reported in Table 3.1.
Measures
Dependent variable: Time between symptom development and diagnosis.
Five symptoms, weakness, cramping, trouble swallowing, twitching (fasciculations), and
trouble with bowels, were available in the dataset provided from the National ALS
Registry. To calculate the time between symptom and diagnosis, only those who reported
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developing the symptom were included in the analysis. Because the data is crosssectional it is not possible to do time-to-event analysis. I measure the time between
symptom development and diagnosis in years by subtracting the reported date of
symptom development from the date the respondent was diagnosed with ALS. Negative
values represent symptom development before diagnosis and positive values represent
symptom development after diagnosis.
Independent variables. The independent variables include: (1) social position
(race/ethnicity, gender, education), (2) age at diagnosis, (3) onset location, (4) veteran
status, (5) proximal risk factors, and (6) social resource of marriage, which are detailed in
chapter 2. In addition, the analysis includes insurance coverage and multidisciplinary
clinic usage. Insurance coverage provides a measure for access to medical care, which
may influence the ability to receive a diagnosis in a timely manner. In the case of the
National ALS Registry, all participants reported some form of insurance, which is not
unusual as ALS qualifies pALS for Medicare, Veterans Administration coverage, and/or
Medicaid. Insurance is a count variable of one (reference), two (=1), or three (=2) types
of insurance policies. Multidisciplinary ALS clinic (MDC) attendance is a resource for
people with ALS in recognizing symptoms. I categorize MDC use as never attended
(reference), attended but discontinued (=1), and currently attending (=2).
Analysis
Multiple Imputation using Chained Equations was used to impute missing data
(Enders, 2003). Table 3.1 reports the post imputation means and proportions in each
category. I then perform bivariate tests of association to explore potential bivariate
patterns of the time between the development of a symptom and diagnosis and each of
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the dependent variables. I use multivariable ordinary least squares regression to examine
the time between the development of each symptom and diagnosis. Each regression is
created in steps; (1) social position, (2) social position and age at diagnosis, (3) social
position, age at diagnosis, onset location (to control for disease variability), veteran
status, and proximate risk factors (to control for exposures and the potential relationship
with social position), and (4) social position, age at diagnosis, onset location, veteran
status, proximate risk factors, and social resources. Reference categories were chosen in
order for the constant to represent the characteristics of those most commonly diagnosed
with ALS; White males in between the ages of 50-59 with at least some college
education, who are veterans and married, have healthy health behaviors, and report limb
onset of ALS symptoms. The discussion of the results focuses primarily on the final
models.
Results
Demographics
Table 3.1 reports the proportion of people with different characteristics overall,
the proportion in each category with a symptom, and the mean time between each
symptom and ALS diagnosis for each category of each variable. All 9,787 members of
the registry reported weakness, with a mean time between symptom development and
diagnosis of 1.29 years before diagnosis. Fewer (N = 5,675) respondents reported
cramping, with a mean time between symptom development and diagnosis of 2.07 years
after diagnosis. Trouble swallowing was reported 2,170 respondents, with a mean time
between symptom development and diagnosis of .62 years before diagnosis. Twitching,
also known as fasciculations, was reported by 5,410 members of the sample with a mean
time between symptom and diagnosis of 1.32 years before diagnosis. The final symptom,

53
trouble with bowels, was reported by 1138 respondents, with a mean time between
symptom and diagnosis of 2.11 years before diagnosis. Four symptoms, weakness,
trouble swallowing, twitching, and trouble with bowels are, on average, reported as
developing before diagnosis and cramping as developing after diagnosis. The results
potentially indicate that ALS must progress further than the earliest symptom in order to
be noticed and diagnosed.
The registry sample is mostly White (97%) and nearly 60% male. The sample is
also more educated than the US population as a whole with over 60% of the respondents
having at least a bachelor’s degree. Veterans make up nearly 24% of the sample. Over
60% of the sample report working in a low risk occupation, while just over 45% report a
history of smoking and 81% report a history of drinking alcohol. The majority of the
sample is married or cohabitating (82%). Most of the respondents are between the ages of
50-59 and 60-69 (29.79% and 35.99 % respectively). The individual demographics for
each symptom sample are described in Table 3.1 as not all pALS reported each symptom
and the sample sizes vary.
Bivariate Analysis
In addition to the descriptive statistics described above, Table 3.1 also displays
the F tests results used to determine if there were associations between the dependent
variable of time between symptoms and diagnosis and the independent variables (Cohen
et al., 2014). Results are reported for each symptom. Overall, there is evidence that the
time between symptom development and diagnosis is shaped by social position and
position in the life course, although the same patterns do not exist in the case of every
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symptom, suggesting that a combination of fundamental cause and life course theory are
fruitful for understanding social position patterns of the experience of ALS.
Weakness. The only social position indicator associated with the time between
weakness and diagnosis is education. pALS with a high school or less education reported
less time between weakness and diagnosis than those with at least a tech degree or some.
pALS who were older at diagnosis report more time between weakness and diagnosis.
pALS with bulbar onset report less time between recognizing weakness and diagnosis, as
do civilians. pALS who are single report less time between developing weakness and
their diagnosis date.
Cramping. Women report less time between cramping and the date of diagnosis.
Civilians also report less time between the development of cramping and diagnosis.
pALS who have a history of smoking report more time between the development of
cramping and diagnosis, as do those who are single.
Trouble Swallowing. Differences in reporting trouble swallowing do seem to be
related to more proximal risks and resources. pALS who are in the higher occupational
risk category reported more time between trouble swallowing and diagnosis than those in
the low occupational risk category, and those with a history of drinking reported less time
between the development of swallowing issues and diagnosis. pALS with three types of
insurance reported less time between trouble swallowing and diagnosis, and those who no
longer attend an MDC reported trouble with swallowing, on average, after diagnosis,
compared to reported developing trouble swallowing prior to diagnosis.
Twitching. pALS with higher education and those who are older have longer
times between the development of twitching and diagnosis. pALS with bulbar onset
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reported less time between twitching and diagnosis. Veterans, those in low risk
occupations, as well as those who have a history of smoking or drinking reported
developing twitching longer before diagnosis.
Trouble with Bowels. The time between reporting developing trouble with
bowels and diagnosis is associated with the social position variables race/ethnicity,
gender, and education. Racial/ethnic minority pALS report trouble with bowels longer
before diagnosis, as do women. pALS with the highest levels of education report more
time between trouble with bowels and diagnosis. In addition to social position indicators,
several other characteristics and resources are associated with the difference between
trouble with bowels and diagnosis. Those who are older, have limb onset, are civilians,
have high occupational risk, and no history of smoking nor alcohol use have longer times
between trouble with bowels and diagnosis. pALS who are currently attending an MDC
also had more time between developing bowel trouble and diagnosis.
Multivariate OLS Regression of Time between Symptoms and the Date of Diagnosis
Time between weakness and diagnosis. Table 3.2 reports the results of the
regression analysis for time between weakness and diagnosis. The constant for the
regression models represent the characteristics of those with the value “zero” on all of the
variables – coded so that the reference categories represent those most commonly
diagnosed with ALS (i.e. exemplar pALS); White males in between the ages of 50-59
with at least some college education, who are veterans and married, have healthy health
behaviors, and report limb onset of ALS symptoms. Measured by the constant, the
average time between developing weakness and diagnosis is just over a year (b = -1.13, p
< .001) for exemplar pALS. In what might appear to be contrary to fundamental cause
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theory and the social determinants of health, those with a high school education or less
report less time between the development of weakness and the diagnosis of ALS than
those with at least a tech or trade degree or some college, meaning they may be more
likely to think of weakness as related to a disease, rather than as a sign of aging or workrelated (b = .31, p < .001; therefore for this group the time is -1.13 + .31 = -.82). It is also
possible that due to limited resources, those with less education may be concerned about
the costs of seeing a doctor (e.g. losing a physical job or taking time off of work) and
therefore they may wait until the symptoms of ALS have advanced to a point they can no
longer be ignored, thus resulting in a quicker time to diagnosis. There were no differences
between pALS with a college education or more and those with a tech or trade degree or
some college. Age at diagnosis further shapes when weakness is experienced, with pALS
who are 60-69 (b = -.46, p < .001), 70-79 (b = -.32, p < .001), and 80+ (b = -.96, p <
.001), report more time between developing weakness and diagnosis than those at
younger ages, with results consistent with life course theory. pALS with bulbar onset
report less time between the onset of weakness and diagnosis than other onset types,
perhaps due to the nature of bulbar onset having more involvement of the muscles in the
tongue, mouth, and neck (b = .53, p < .001). In contrast to the idea that resources should
shorten the time between symptoms and diagnosis, those pALS who report having two
types of insurance report more time between weakness and diagnosis than those with one
type of insurance (b = -.14, p = .05), and consistent with the work of family sociologists
(Waite and Gallagher, 2001) pALS who are unmarried also report more time between the
onset of weakness and diagnosis than those who are married (b = -.30, p < .001). Both
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marriage and insurance could be signs of social resources, allowing for another person or
healthcare provider to notice weakness earlier than the pALS themselves.
Time between cramping and diagnosis. Gender shapes the experience of
cramping as an ALS symptom. The constant value shows that the exemplar pALS report
developing cramping about two years prior to diagnosis on average (b = -2.29, p < .001).
Women report less time between developing cramping and diagnosis (b = .33 p < .05 or 2.29+.33 or -1.96), compared to men. The time between experiencing cramping and
diagnosis may be due to the differences in onset type, as bulbar onset develops more
often in women (Table 3.3). In addition, those with the lowest level of education report
less time between the development of cramping and diagnosis than those with at least a
tech or trade degree or some college, similar to the pattern for weakness (b = .43, p <
.05). Further, there is less time between the development of cramping and diagnosis for
pALS who are younger (the ages of 18 and 39 (b = 1.19, p < .001), and more time
between cramping and diagnosis among those who are older (60-69 (b = -.35, p < .01))
and over 80 years old (b = -6.32, p < .001) compared to pALS who are between the ages
of 50 and 59. pALS who report bulbar onset also report less time between the
development of cramping and diagnosis. The findings for bulbar onset reflect the
findings for women, the group who are most often diagnosed with bulbar onset (b = .90,
p < .001). pALS who previously attended a multidisciplinary ALS clinic (MDC) but have
discontinued attendance report more time between the onset of cramping symptoms and
diagnosis (b = -1.29, p < .001). Finally, pALS who are unmarried have, on average, more
time between the onset of cramping and diagnosis (b = -.37, p < .01).
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Time between trouble swallowing and diagnosis. Table 3.4 reports the results
of the regression analysis of the time between trouble swallowing and diagnosis.
Exemplar pALS report developing trouble swallowing one year before diagnosis on
average (b = -1,00 p < .01). In the final model, none of the social position variables are
associated with the time between the trouble swallowing symptom onset and diagnosis,
however, prior to the addition of onset location and proximate risk factors into the model
(Model 2), women reported less time between developing trouble swallowing and
diagnosis than men (b = .27, p < .05). Women are more likely to have bulbar onset of
ALS, and those with bulbar onset report less time between the development of trouble
swallowing and diagnosis (b = .37, p < .05), thus adding the indicator for bulbar onset
may have explained the association between the onset of trouble swallowing and the
diagnosis of ALS. Age shapes the time between the experience of trouble swallowing
symptoms and diagnosis, with those who are between the ages of 40-49 (b = -.64, p <
.01), 60-69 (b = -1.23, p < .001), 70-79 (b = -1.09, p < .001), and over 80 (b = -1.61, p <
.01) reporting more time between swallowing symptoms and diagnosis than those who
are ages 50-59. Civilians report less time between the development of trouble swallowing
and diagnosis than veterans (b = .37, p < .05), consistent with the findings in chapter 2
that civilians are more likely to develop bulbar onset ALS.
Proximate risk factors are related to symptoms of trouble swallowing as well,
with those who report lower occupational risk experiencing less time between
swallowing symptoms and diagnosis than those with high occupational risk (b = .67, p <
.01), and those with a history of alcohol use (b = -56, p < .01) reporting more time
between developing swallowing symptoms and diagnosis. pALS with two forms of health
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insurance (b = .51, p < .01) and three forms of health insurance (b = 1.22, p < .001)
report less time between developing trouble swallowing and diagnosis, and those with
three forms of insurance reporting swallowing symptoms after diagnosis. Finally,
resources in the form of MDC attendance, also shape the time when pALS notice trouble
swallowing. pALS who do not attend an MDC clinic (b = .62, p < .001) and have
attended but since discontinued MDC use (b = .96, p < .01) report less time between the
development of trouble swallowing and diagnosis.
Time between twitching and diagnosis. Table 3.5 reports the results of the
regression models for the time between twitching symptoms and diagnosis. The constant
for this model shows the exemplar pALS report developing twitching at the same time as
diagnosis (b = .31, p >.05). The only social position variable that is associated with the
time between twitching and diagnosis is education, with those with a high school
education or less reporting less time between developing twitching and diagnosis,
following the patterns of weakness and cramping (b = .53, p < .01). pALS with bulbar
onset of ALS report less time between twitching and diagnosis, following the patterns of
other symptoms as well (b = .69, p < .001). For both woman and pALS with bulbar onset,
twitching is reported as developing after diagnosis. Civilians report developing twitching
earlier than veterans (b = -.28, p < .05). pALS who have a history of smoking report more
time between developing twitching and diagnosis (b = -.26, p < .01). Resources, such as
insurance coverage, MDC attendance, and marriage are also associated with the time
between cramping and diagnosis. pALS with two forms of insurance (b = -.70 p < .001)
and three types of insurance (b = -1.40, p < .001) report recognizing twitching longer
before diagnosis than those with one form of insurance. pALS who do not attend an
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MDC clinic (b = -.30, p < .01) and who are not married (b = -.25, p < .05) report more
time between the development of twitching and diagnosis than those who do attend an
MDC and who are married.
Time between trouble with bowels and diagnosis. For the constant value
representing the exemplar pALS, trouble with bowels is reported as developing at the
same time as diagnosis (b = .44, p >.05) on average. Similar to the time between
swallowing and diagnosis, of the social position indicators, only gender (not
race/ethnicity nor education) is associated with the time between trouble with bowels
and diagnosis (Table 3.6). Women report more time between having trouble with bowels
and diagnosis than men (b = -1.50, p < .001). This association could reflect that women
are more willing to seek medical help, or the association could be spurious because
women are also more likely to have bulbar onset, and bulbar onset has a strong
association with trouble with bowels. Age does shape the experience of trouble with
bowels, with those who are in between the ages of 40 and 49 reporting less time between
developing trouble with bowels and diagnosis (b = 2.16, p < .001) with bowel symptoms
reported as developed post diagnosis by 1.7 years. pALS who are 60-69 (b = -1.22, p <
.01), 70-79 (b = -1.61, p < .01), and over the age of 80 (b = -3.18, p < .05) report more
time between bowel issues and diagnosis, with bowel issues developing prior to
diagnosis. Age may play a role here due to the salience of these symptoms for older
adults but may often be disregarded as a potential consequence of aging.
Proximate risk factors also influence time to trouble with bowels. pALS who
report low occupational risk (b = 1.39, p < .01) and who report a history of smoking (b =
1.95, p < .01) experience more time between bowel trouble and diagnosis, with bowl
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trouble developing post diagnosis, while those who report alcohol use report more time
between the development of bowel issues and diagnosis (b = -2.23, p < .001). Social
resources also shape the experience of bowel issues. pALS who do not use an MDC
report more time between bowel issues and diagnosis than those who do (b = -1.22, p <
.001). Unmarried pALS report more time between the development of bowel trouble and
diagnosis than married pALS, with trouble with being noticed post diagnosis (b = 1.01, p
< .01; solving the equation indicates -.44 + 1.01 = .59), or about half a year after
diagnosis.
Discussion
Four of the symptoms included in the analysis presented here—weakness, trouble
swallowing, twitching, and trouble with bowels—are on average reported by pALS in the
National ALS Registry as appearing prior to diagnosis. The appearance of faster
progression for some pALS may be, in part, due to the length of time between when
pALS notice and/or experience symptoms and the diagnosis of ALS. Therefore,
understanding how social position shapes when symptoms first occur and are noticed is
important to understanding the experience of progression of ALS. Time is of the essence
when it comes to a diagnosis of ALS, as the median survival time from diagnosis is
between 20 and 48 months (Chiò et al., 2009)
Whilst the analysis presented here includes proximate risk factors which are often
the focus of ALS progression research, proximate risks are not the sole factor in the
timing of the development of symptoms. Education, gender, and age all have a role over
and above the proximate risks included in the models, either through their relationship
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with the biological processes underlying ALS or through the perception and reporting of
symptoms.
Education level shapes when symptoms occur, with pALS who have a high
school or less education reporting the development of weakness, cramping, and twitching
as developing closer to the date of diagnosis than those with higher levels of education.
Weakness and twitching are often the very earliest signs of ALS, therefore the reporting
by people with higher levels of education of these symptoms earlier than their peers with
lower education is potentially a concern as pALS with lower levels of education may be
missing earlier signs of weakness. Reporting of these symptoms closer to the date of
diagnosis for those pALS with lower levels of education may be due to the speed of the
biological development of the disease, however, it may be due to the type of work people
with lower levels of education engage in, as well as access and utilization of healthcare
services. As one example, people who work in highly physical jobs may think early
weakness is due to aging, a higher than normal workload, or being overly tired. Earliest
experiences of twitching may be disregarded as a consequence of overtired and
overworked muscles. Therefore, these symptoms may be dismissed as normal
consequences of daily activities, and the date reported to the registry may be when the
symptoms became salient as something outside of the norm. In addition, fundamental
cause theory often posits education (as well as its connection to socioeconomic status) as
a cause of health disparities, with access to and utilization of health care being a part of
these inequalities. pALS with lower education levels are more likely to not have been
able to access medical care due to cost (e.g. copays, lost time at work) to ask questions
about these symptoms until they become too hard to ignore, therefore delaying diagnosis.
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Women report cramping and trouble swallowing later in the disease course and
trouble with bowels earlier in the disease course, perhaps due to the higher prevalence of
bulbar onset in this population. pALS often do not recognize bulbar dysfunction if the
rate of progression is slow, therefore pALS unknowingly adapt to swallowing issues until
the symptoms become hard to ignore (Onesti et al., 2017). The delay in recognizing
swallowing difficulties may lead to a delay in diagnosis (Onesti et al., 2017). Moreover,
the gradual adaptation to difficulty swallowing may result in changes in the diet, leading
to constipation and other difficulties with the bowels. Therefore, as noted in chapter two,
it is important to better understand why women disproportionately develop bulbar
symptoms.
Age at diagnosis also has some bearing on when pALS report symptoms
occurring. Older pALS report symptoms occurring earlier in the disease course than
younger pALS. As noted in chapter two, one reason for this difference might be that ALS
onset is influenced by the aging of the central nervous system, and extant research also
implicates aging of the central nervous system in symptom development and the rate of
disease progression. The timing of diagnosis in the life course, however, would also be
related to the perception of symptoms as outside the norm. For pALS who are older, as
well as their spouses, caregivers, and physicians, early symptoms of ALS may be
considered as signs of aging and not as potential signs of a fatal disease.
Social and material resources, including marriage, insurance coverage, and MDC
use, also shape the experience of symptoms of ALS. Compared to those who are married,
unmarried pALS report earlier development of twitching and later development of
weakness. Changes in strength or ability are something that is potentially noticed by a
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partner or spouse as unusual, therefore may be recognized by married pALS earlier.
Twitching, on the other hand, is often visible throughout the muscles, and for unmarried
pALS may be one of the first signs that something is amiss that cannot be reasonably
explained away. Moreover, pALS who are single may attempt to solve issues on their
own for a longer period of time before realizing that symptoms are not due to a lack of
self-care, whereas the inability to solve a health issue with self-care may be pointed out
earlier by a partner or spouse leading to earlier help-seeking behavior.
Insurance and MDC use are difficult to parse out, however, as these may change
after diagnosis. It may be that an increase in the number of insurances policies may mean
that the pALS is further into disease progression, as Medicare coverage is not available
until five months post diagnosis and the determination of permanent disability. Insurance
coverage may also be an indicator of socioeconomic status. Reporting discontinuation of
using an MDC may be due to progression of the disease, as many pALS find it is difficult
to travel the distance to these providers once they are no longer able to move (Radunovic
et al, 2007; Hodgen et al., 2012; Obermann & Lyon, 2015; Stephens et al., 2016; Horton
et al., 2018). In addition, never using or discontinuing MDCs may be an indicator of
socioeconomic status or geographical location, as many MDCs are located in highly
populated cities rather than rural areas (Radunovic et al, 2007; Hodgen et al., 2012;
Obermann & Lyon, 2015; Stephens et al., 2016; Horton et al., 2018).
There are several limitations to the research presented here. Designed for
biomedical and epidemiological research, the National ALS Registry has limited
measures of social status and social experiences. In addition, the registry limits access to
survey data due to reidentification risks, therefore limiting the analysis. For example, it
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would be ideal to have measures of parental status to assess if the demands of parenting
make some symptoms more salient earlier in disease progression. Further, not all of the
registry participants reported symptom development, either due to slowly progressing
ALS, or perhaps due to not recognizing the symptom as described in the module. In
addition, while the sample size overall is robust, smaller numbers of specific populations
such as non-white patients, impedes intersectional analysis. Being able to assess the
combined effects of gender, race/ethnicity and education is often important for
understanding health (Warner and Brown, 2011) to better understand the relationship of
social position and ALS. Doing intersectional analysis could help to parse out if social
location (e.g. the intersection of several social positions) explains the association between
social position and ALS symptoms.
The ALS Registry is reliant on patient self-reporting data and may be subject to
recall bias and bias due to self-identification. In addition, patients can complete the
registry survey only online, which may limit access and cause the registry to reflect a
younger, mostly white, and more educated patient sample. The registry sample provided
by the CDC is less racially diverse than the overall registry which includes Medicare and
Veteran’s Association claims data. There are several potential reasons for this, including
access to computers that are required for self-registration; reduced awareness of the
registry; and reduced participation in areas with substantial nonwhite populations (Kaye
et al., 2018). Further, the registry is a large non-random sample that is opt-in and
therefore results are not generalizable to the ALS population as a whole. Even with these
limitations, the National ALS Registry is the most comprehensive, geographically diverse
sample of people diagnosed with ALS.
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Fundamental cause theory provides important guidance for exploring the social
structural dimensions of ALS symptom development and diagnosis, yet the findings
suggest limited support for the theory, as those with limited resources often have less
time between symptom onset and diagnosis. In the case of ALS, however, it may be that
a shorter time between symptoms and diagnosis is not evidence of greater resources, but
of less opportunity to acknowledge symptoms as something out of the ordinary and less
opportunity to seek medical care for what might seem to be a minor complaint. In
addition, using fundamental cause theory in the design of the research presented here
further suggests the need for a sociology of disease, as well as an adjustment in
sociologists’ conceptualization of existing sociological theories to use them within this
framework. Future research on ALS should consider the implications of social position in
the development of symptoms, especially in the early in the diagnostic process. For
example, including education level in the design of future research projects would help to
distinguish if education level is causally related to symptom development and
progression, or if it influences the perception of symptoms.
Many of the earliest symptoms of ALS develop, on average, more than a year
prior to diagnosis. Therefore, social position may influence ALSFR-R progression
estimates. This is of particular concern, as ALSFR-R scores are used extensively as part
of the evaluation process for participation in clinical trials. If trial administrators assume
that time from symptom development to diagnosis reflects only the disease and not social
position factors, then inclusion criteria will be inconsistently applied. There is the
potential for symptoms to progress to a point prior to diagnosis that pALS are excluded
from participating in these trials. As noted in chapter 2, trial participants are often young,
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white, male, and mostly with limb onset (Chiò et al., 2011; Mitsumoto et al., 2014).
Ensuring the inclusion of those who occupy different social positions, even with lower
ALSFR-R scores, may help to bring more effective treatments that work for a broader
spectrum of those experiencing ALS.
Symptom development and progression can influence the effectiveness of
approved treatments. The medications Riluzole and Edaravone slow progression only in
certain subgroups of people with initial stages of ALS (Rothstein, 2017; Jaiswal, 2019).
Social position shapes when symptoms develop and are reported, which may delay
diagnosis and prevent access to these medications when they are most effective. In
addition, the results presented in chapter two and here indicate that social position should
be included in future analysis of ALS subgroups in order to better understand who
benefits from new treatments and technologies.
Similarly, it is important to understand how social position interacts with
biological processes, as noted in the previous chapter. For example, women are more
likely to develop bulbar onset ALS, which changes the nature of symptoms and the order
in which they develop, as well as when symptoms become salient to the pALS. Being
able to understand why women are more likely to develop bulbar onset ALS and the
behaviors they engage in when symptoms begin to develop, may improve diagnosis and
treatment for women with bulbar onset ALS. Moreover, these connections may help to
clarify if there is a biological (e.g. hormones), a social exposure (e.g. stress), or a
combination of the two implicated in the onset location and development of symptoms
for women.
Conclusion
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The analyses of the timing of symptoms relative to diagnosis contributes to the
knowledge of both sociology of disease and research, specifically on ALS. First, for
several symptoms, the timing of symptoms relative to diagnosis is shaped by social
position, as suggested by fundamental cause theory and the social determinants of health.
These theories guided the exploration of social position and disease experience, but the
patterns for ALS are not all consistent with predictions by the theories. In the case of a
specific disease, it may be that the ways in which sociologists understand fundamental
cause theory and the social determinants of health need to be adjusted in order to be used
in a sociology of disease (Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008).
In the case of ALS, people with limited resources often have less time between symptom
onset and diagnosis. Rather than an indicator of greater access to resources, a diagnosis
closer to the reported appearance of symptoms may be a sign of having less opportunity
to acknowledge the signs of a disease that may at first seem to be a minor complaint
related to people’s circumstances. The results from this work reaffirms the need for a
sociology of disease, as dealing with a disease just prior to and after diagnosis is different
from understanding how disease can be prevented altogether. Additionally, age, as an
indicator of life course theory, shapes the experience of ALS symptoms. Future research
should address if these differences are due to the perception and salience of symptom
development, or if the differences may be due to the interaction of the biological and
social aspects of ALS.

69
Table 3.1 Descriptive Statistics and Bivariate Association Results for Time between the development of Symptoms and Diagnosis
Weakness n = 9787
Cramping n = 5675
Swallowing n = 2170 Twitching n = 5140
Bowels n = 1138
Sample
P Value Proportion Yes P Value Proportion P Value Proportion Yes P Value Proportion Yes P Value
Proportion
Mean
Mean
Yes
Mean
Mean
Mean (SD)
(SD)
(SD)
(SD)
(SD)
Race/Ethnicity
*
White (0)
.97
-1.29 (.03)
.58
-2.07 (.06)
.22
-.62 (.25)
.76
-1.33 (.05)
.12
-.63 (.50)
Racial/Ethnic Minority (1)
.03
-1.39 (.12)
.76
-1.99 (.23)
.28
-.62 (.07)
.55
-1.13 (.19)
.21
-2.19 (.14)
Gender
**
***
Male (0)
.60
1.27 (.04)
.60
-2.20 (.08)
.20
-.73 (.07)
.59
-1.36 (.07)
.09
-1.22 (.17)
Female (1)
.40
1.32 (.04)
.55
-1.85 (.07)
.26
-.50 (.11)
.50
-1.25 (.05)
.16
-2.82 (.22)
Education
***
***
***
High School or Less (0)
.14
-1.04 (.11)
.64
-1.95 (.21)
.29
-.73 (.16)
.61
-.72 (.19)
.16
-1.57 (.30)
Tech/Trade/Some College (1)
.21
-1.31 (.04)
.62
-2.13 (.11)
.21
-.64 (.10)
.53
-1.30 (.09)
.14
-1.13 (.25)
College Degree or More (2)
.65
-1.34 (.03)
.56
-2.08 (.06)
.21
-.59 (.09)
.55
-1.47 (.05)
.10
-2.73 (.21)
Age at Diagnosis
***
***
***
18-39 (0)
.04
-1.18 (.07)
.66
-.92 (.15)
.11
.85 (.35)
.67
-1.05 (.14)
.06
.38 (.48)
40-49 (1)
.14
-1.19 (.07)
.62
-1.65 (.13)
.20
-.73 (.23)
.62
-1.27 (.11)
.07
.26 (.33)
50-59 (2)
.30
-1.04 (.07)
.62
-1.92 (.11)
.20
-.07 (.18)
.59
-1.14 (.11)
.19
-2.14 (.28)
60-69 (3)
.36
-1.50 (.04)
.57
-2.30 (.09)
.25
-.96 (.06)
.50
-1.50 (.07)
.12
-2.58 (.26)
70-79 (4)
.14
-1.37 (.06)
.50
-2.37 (.16)
.24
-.73 (.14)
.52
-1.48 (.13)
.17
-2.22 (.31)
80+ (5)
-4.02
.01
-1.93 (.22)
.36
-8.29 (.96)
.44
-1.15 (.39)
.26
-1.30 (.64)
.18
(1.37)
Onset Location
**
**
*
Limb
.74
-1.38 (.03)
.62
-2.17 (.06)
.13
-.74 (.09)
.58
-1.42 (.06)
.13
-2.24 (.18)
Bulbar
.21
-.92 (.07)
.40
-1.42 (.21)
.53
-.58 (.10)
.44
-.77 (.10)
.09
-1.85 (.30)
Trunk/Global
.05
-1.53 (.11)
.69
-2.35 (.21)
.32
-.26 (.20)
.62
-1.49 (.18
.06
.20 (.93)
Veteran Status
**
***
**
*
Civilian or Other (0)
.76
-1.25 (.03)
.57
-1.93 (.07)
.22
-.56 (.08)
.54
-1.25 (.05)
.11
-2.32 (.19)
Veteran (1)
.24
-1.43 (.04)
.61
-2.51 (.12)
.25
-.79 (.08)
.59
-1.53 (.10)
.14
-1.58 (.20)
Occupational Risk Category
***
**
**
Low Risk (0)
.62
-1.31 (.03)
.57
-2.16 (.09)
.22
-.34 (.09)
.53
-1.45 (.05)
.11
-1.45 (.21)
High Risk (1)
.38
-1.26 (.06)
.60
-1.93 (.15)
.23
-1.08 (.13)
.60
-1.13 (.10)
.13
-3.05 (.38)
Ever Smoked Cigarettes
***
**
***
No
.54
-1.27 (.04)
.56
-1.88 (.08)
.22
-.54 (.11)
.54
-1.21 (.07)
.10
-3.04 (.25)
Yes
.46
1.32 (.03)
.60
-2.28 (.08)
.23
-.71 (.07)
.57
-1.44 (.06)
.14
-1.30 (.15)
Ever Drank Alcohol
***
*
*
No
.19
-1.23 (.07)
.55
-2.14 (.14)
.28
-.57 (.17)
.52
-1.07 (.10)
.13
-1.40 (.32)
Yes
.81
-1.31 (.03)
.59
-2.06 (.06)
.21
-.18 (.15)
.56
-1.37 (.05)
.12
-2.29 (.16)
Insurance
***
***
***
One
.49
-1.16 (.04)
.59
-1.79 (.10)
.21
-.75 (.08)
.54
-.92 (.08)
.12
-2.62 (.34)
Two
.44
-1.42 (.04)
.57
-2.32 (.09)
.23
-.54 (.12)
.56
-1.62 (.06)
.12
-1.59 (.40)
Three
.07
-1.43 (.11)
.62
-2.49 (.25)
.25
-.35 (.20)
.61
-2.15
.11
-1.51 (.65)
Marital Status
***
*
***
Married or Cohabitating (0)
.82
-1.24 (.03)
.58
-2.00 (.07)
.21
-.62 (.08)
.55
-1.29 (.06)
.10
-2.28 (.18)
Divorced, Single, Widowed
.18
-1.52 (.05)
.60
-2.39 (.13)
.28
-.62 (.09)
.57
-1.46 (.08)
.19
-1.71 (.22)
Attend Multidisciplinary
*
***
***
Clinic
Yes
.25
-1.20 (.06)
.60
-2.03 (.10)
.26
-.34 (.16)
.57
-1.43 (.09)
.13
-3.34 (.27)
Yes, but no longer attend
.05
-1.18 (.14)
.67
-3.49 (.37)
.28
.19 (.24)
.52
-.97 (.18)
.13
-.62 (.64)
No
.70
-1.33 (.03)
.57
-1.98 (.08)
.20
-.83 (.07)
.55
-1.30 (.06)
.11
-1.73 (.18)
Table 3.1 reports the proportion of people with different characteristics overall, the proportion in each category with a symptom, and the mean time
between each symptom and ALS diagnosis for each category of each variable

70

Table 3.2 Multivariate Regression of Time between the development of Weakness and Diagnosis by Social
Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 9787)
Model 1:
Model 2: Distal
Model 3: Distal
Model 4: Distal Factors,
Distal Factors Factors, Age, and Factors, Age, Onset
Age, Onset Location,
Onset Location Location, and Proximal Proximal Risk Factors,
Risk Factors
and Resources
Dependent Variable
β
SE β
Racial/Ethnic Minority
-.14
.16
Female
-.06
.05
Education (ref =
Tech/Trade/Some College)
High School or Less
.27 ** .09
College or More
-.03
.07
Age at Diagnosis (ref=50-59)
18-39
40-49
60-69
70-79
80+
Onset Location (ref = Limb)
Bulbar
Trunk/Global
Civilian
Low Occupational Risk
History of Smoking
History of Drinking
Insurance (ref = 1 type)
Two Types
Three Types
Multidisciplinary Clinic Use (ref
= Currently Attend)
Do not Attend
Previously Attended but
Discontinued
Never Married, Separated,
Divorced, Widowed
Constant
-1.28 *** .06
+ p < .10, *p < .05, **p < .01, ***p < .001

β
-.21
-.09

SE β
.16
.05

β
-.22
-.14

.31 *** .09
-.04
.07

.30
-.05

-.03
.14
-.14
.09
-.50 *** .07
-.38 *** .08
-1.06 *** .26

-.06
-.15
-.49
-.35
-1.02
.53
-.15
.12
.01
-.02
-.06

*
***

***
***
***
***

SE β
.16
.06

β
-.20
-.10

SE β
.16
.06

.09
.07

.31
-.04

.14
.09
.07
.09
.26

-.04
-.14
-.46
-.32
-.96

.07
.12
.06
.07
.06
.08

.53
-.13
.10
.01
-.01
-.04

***

.07
.12
.08
.08
.06
.08

-.14
-.03

*

.07
.16

***

***
***
***

.12
.19

-1.10 *** .08

-1.12

***

.12

.09
.07
.14
.09
.07
.09
.27

.07
.15

-.30

***

.07

-1.13

***

.13
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Table 3.3 Multivariate Regression of Time between the development Cramping and Diagnosis by Social
Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 5675)
Model 1: Distal
Factors

Dependent Variable
β
SE β
Racial/Ethnic Minority
.11
.29
Female
.36 ** .13
Education (ref =
Tech/Trade/Some College)
High School or Less
.16
.18
College or More
.08
.14
Age at Diagnosis (ref=50-59)
18-39
40-49
60-69
70-79
80+
Onset Location (ref = Limb)
Bulbar
Trunk/Global
Civilian
Low Occupational Risk
History of Smoking
History of Drinking
Insurance (ref = 1 type)
Two Types
Three Types
Multidisciplinary Clinic Use
(ref = Currently Attend)
Do not Attend
Previously Attended but
Discontinued
Never Married, Separated,
Divorced, Widowed
Constant
-2.28 *** .14
+ p < .10, *p < .05, **p < .01, ***p < .001

Model 2: Distal Factors, Model 3: Distal Factors, Model 4: Distal Factors,
Age, and Onset Location Age, Onset Location,
Age, Onset Location,
and Proximal Risk
Proximal Risk Factors, and
Factors
Resources
β
-.04
.34

**

SE β
.29
.12

β
-.04
.31

*

SE β
.29
.13

β
.005
.33

*

SE β
.29
.14

.41
.01

*

.18
.14

.42
-.01

*

.18
.15

.43
.03

*

.18
.15

1.09
.25
-.47
-.48
-6.84

***

.27
.17
.13
.19
.87

1.16
.23
-.38
.29
-6.66

***

.27
.18
.13
.20
.89

1.19
.23
-.35
-.27
-6.32

***

.27
.18
.13
.21
.91

.87
-.08

***

.22
.24

.85
-.16
.28
-.20
-.29
.38

***

.22
.24
.17
.21
.12
.17

.90
-.15
.25
-.17
-.21
.31

***

***
**
***

**
***

*
*

**
***

-.19
-.03

-2.20

***

.15

-2.49

***

.27

.22
.24
.20
.20
.12
.18
.18
.35

-.06
-1.29

***

.15
.29

-.37

**

.17

-2.29

***

.31
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Table 3.4 Multivariate Regression of Time between the development of Trouble Swallowing and Diagnosis by
Social Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 2170)
Model 1:
Distal Factors

Dependent Variable

β

SE
β
.36
.13

Racial/Ethnic Minority
-.02
Female
.26 *
Education (ref = Tech/Trade/Some
College)
High School or Less
-.09
.22
College or More
.10
.18
Age at Diagnosis (ref=50-59)
18-39
40-49
60-69
70-79
80+
Onset Location (ref = Limb)
Bulbar
Trunk/Global
Civilian
Low Occupational Risk
History of Smoking
History of Drinking
Insurance (ref = 1 type)
Two Types
Three Types
Multidisciplinary Clinic Use (ref =
Currently Attend)
Do not Attend
Previously Attended but Discontinued
Never Married, Separated,
Divorced, Widowed
Constant
-.79 *** .17
+ p < .10, *p < .05, **p < .01, ***p < .001

Model 2: Distal
Factors, Age, and
Onset Location
β
.06
.27

*

-.03
.20

Model 3: Distal Factors,
Model 4: Distal Factors,
Age, Onset Location, and
Age, Onset Location,
Proximal Risk Factors Proximal Risk Factors, and
Resources

SE β

β

SE β

β

SE β

.36
.13

-.05
.15

.36
.14

-.49
.23

.38
.15

.23
.17

-.14
.07

.23
.18

-.15
.08

.23
.18

.48
.24
.16
.21
.49

.61
-.64
-1.23
-1.09
-1.61

.15
.25
.17
.17
.14
.18

.37
.68
.23
.67
.06
-.56

1.00
-.63
-.95
-.65
-1.09

*
**
***
***
*

.48
.24
.16
.20
.50

.73
-.49
-1.00
-.82
-1.14

.29
.62

*

.15
.25

.30
.67
-.06
.74
.15
-.60

-.49

*

.21

-.32

*
***
***
*
*
**
***
***

.32

**
***
***
**
*
**

.47
.24
.16
.22
.53

**

.15
.25
.18
.18
.14
.18

.51
1.22

**
***

.17
.33

.62
.96
.15

***
**

.15
.32
.17

-1.00

**

.32

***
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Table 3.5 Multivariate Regression of Time between the development of Twitching and Diagnosis by Social
Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 5410)
Model 1: Distal
Factors

Dependent Variable

β

SE
β
.24
.10

Racial/Ethnic Minority
.08
Female
.06
Education (ref = Tech/Trade/Some
College)
High School or Less
.58 *** .17
College or More
-.17
.12
Age at Diagnosis (ref=50-59)
18-39
40-49
60-69
70-79
80+
Onset Location (ref = Limb)
Bulbar
Trunk/Global
Civilian
Low Occupational Risk
History of Smoking
History of Drinking
Insurance (ref = 1 type)
Two Types
Three Types
Multidisciplinary Clinic Use (ref =
Currently Attend)
Do not Attend
Previously Attended but
Discontinued
Never Married, Separated,
Divorced, Widowed
Constant
-1.33 *** .12
+ p < .10, *p < .05, **p < .01, ***p < .001

Model 2: Distal
Factors, Age, and
Onset Location
β
.06
.03
.61
-.17
.23
-.14
-.45
-.43
-.67
.70
-.07

-1.22

***

***
**
***

***

Model 3: Distal Factors,
Model 4: Distal Factors,
Age, Onset Location, and
Age, Onset Location,
Proximal Risk Factors Proximal Risk Factors, and
Resources

SE β

β

SE β

β

SE β

.24
.10

.07
.006

.24
.11

.16
.02

.24
.11

.17
.12

.54
-.20

.17
.12

.53
-.19

.21
.14
.12
.17
.71

.16
-.19
-.43
-.38
-.59

.22
.14
.12
.17
.72

.22
-.17
-.23
.03
.07

.13
.19

.70
-.05
.07
-.24
-.26
-.17

.13
.19
.12
.12
.10
.15

.69
.01
-.28
-.19
-.26
-.06

***

-.70
-1.40

***
***

.12
.23

-.30
.48

**

.12
.27

-.25

*

.13

.14

-.82

**

***
*
***
*
**

***

.23

-.31

**

.17
.13
.22
.14
.12
.19
.71

*
**

.13
.19
.13
.12
.10
.15

.24
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Table 3.6 Multivariate Regression of Time between the development of Trouble with Bowels and Diagnosis by
Social Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 1138)
Model 1:
Model 2: Distal
Model 3: Distal
Model 4: Distal Factors,
Distal Factors Factors, Age, and Factors, Age, Onset
Age, Onset Location,
Onset Location Location, and Proximal Proximal Risk Factors,
Risk Factors
and Resources
Dependent Variable

β

SE
β
SE β
β
.78
.73 .43
.73
-1.54 *** .30 -1.86 *** .30

Racial/Ethnic Minority
Female
Education (ref =
Tech/Trade/Some College)
High School or Less
-.32
.48 .13
College or More
-1.49 *** .37 -1.32 ***
Age at Diagnosis (ref=50-59)
18-39
3.09 ***
40-49
2.18 ***
60-69
-.70
70-79
-.74
80+
-2.31
Onset Location (ref = Limb)
Bulbar
.63
Trunk/Global
1.83
Civilian
Low Occupational Risk
History of Smoking
History of Drinking
Insurance (ref = 1 type)
Two Types
Three Types
Multidisciplinary Clinic Use
(ref = Currently Attend)
Do not Attend
Previously Attended but
Discontinued
Never Married, Separated,
Divorced, Widowed
Constant
-.39
.31 -.31
+ p < .10, *p < .05, **p < .01, ***p < .001

β
.49
-.78

.48
.34

-.05
-.67

.91
.55
.40
.41
1.23

1.45
2.24
-1.05
-1.38
-2.98

.38
1.08

.38
1.89
-.55
1.53
2.13
-2.16

SE β

β

.71
.30

.12
-1.50

.49
.34

.01
-.66

***
**
***
*

.87
.53
.39
.40
1.14

1.16
2.16
-1.22
-1.61
-3.18

**
***
***

.38
1.03
.35
.35
.31
.44

.38
1.65
-.30
1.39
1.95
-2.23

***

SE β
***

.47
.35
***
**
**
*

.86
.51
.46
.57
1.31

**
***
***

.39
1.00
.50
.48
.35
.44

.93
.52

.43

-.26

.73

.38
.30

.84
1.32

-1.22
.10

***

.28
.80

1.01

**

.32

-.44

.72
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CHAPTER FOUR: DOES POSITION IN THE LIFE COURSE SHAPE MEDICAL
CARE FOR PEOPLE WITH ALS?
Introduction
Research has made clear the need to address gaps and shortcomings in treatment
and care provision for ALS (Goutman & Simmons, 2018). Although calls for additional
research are more general in nature, sociologists are well positioned to understand the
disparities in care for people diagnosed with ALS. Therefore, this paper asks the
question: Does position in the life course and social position shape medical and
supportive care reported by people with ALS? Guided by life course theory and
fundamental cause theory, I posit the timing in the life course of an ALS diagnosis and
social position (e.g. race/ethnicity, gender, education level) shapes medical and
supportive care accessed by people who are diagnosed with ALS.
Medical Care and ALS
Treatment of ALS is complex for all involved (Radunovic et al, 2007).
Multidisciplinary ALS clinics (MDCs) are the option of choice of ALS experts
(Radunovic et al, 2007; Obermann and Lyon, 2015). MDCs have teams of ALS
specialists, allowing for care and needed devices and supplies to be coordinated from one
center (Mitsumoto and Del Bene, 2000). Not all patients, however, choose to use or have
access to multidisciplinary ALS clinics without facing a long journey or needing to
overcome the financial constraints of travel (Radunovic et al, 2007; Hodgen et al., 2012;
Obermann & Lyon, 2015; Stephens et al., 2016; Horton et al., 2018).
For pALS who are not referred by a medical provider or are otherwise unable to
attend an MDC (e.g. cost, distance), other barriers to adequate care include a lack of pre-
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existing knowledge of ALS (Stephens et al., 2015). Moreover, pALS often face lack of
time to research ALS and to consider potential treatment options (Stephens et al., 2015).
Each stage of ALS comes with new levels of care, which require difficult conversations
and decisions. Medications, such as Riluzole, are often prescribed at diagnosis even
before attending an MDC (if one is available) (Dorst et al., 2018). As patients lose the
ability to walk, wheelchairs and scooters become necessary. As difficulties with speaking
and swallowing become more frequent, people with ALS may need an assistive
communication device in order to communicate with caregivers, a percutaneous
gastrostomy (PEG) tube for nutrition, and may need to decide on non-invasive ventilation
support (e.g. C-PAP or Bi-PAP) (Dorst et al., 2018). As the disease progresses and
breathing becomes more difficult, people with ALS need to make the decision to accept
or decline invasive mechanical ventilation (e.g. tracheotomy), which is accompanied by
the need to complete advanced directives (Dorst et al., 2018). When ALS enters into the
final stages, people are faced with making decisions about entering in-home or facilitybased hospice care and ending treatments. Many care decisions have to be made quickly,
depending on the rate of progression, in order to ensure the timing of care meets the
needs of the person with ALS (Radunovic et al, 2007; Obermann and Lyon, 2015;
Stephens et al., 2016; Horton et al., 2018; Dorst et al., 2018; Andersen, 2018).
Timing in the Life Course and Medical Care Decision Making
pALS make care decisions within the context of their lives. The diagnosis of ALS
and the likelihood of death within a few years is an off-time transition, given ALS often
strikes in the years where people are in the prime of their careers, raising children, and
caring for elderly parents (Elder & Rockwell, 1979). Research illustrates that people who
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are over the age of 70 when diagnosed with ALS tend to be more accepting of the natural
course of the disease than those in early-to-mid adulthood (Foley et al., 2014). Older
adults with a diagnosis of ALS have completed many important milestones (e.g. raising
children into adulthood) (Foley et al., 2014). Further, pALS who perceive that the end of
life is near often adjust their choices regarding interventions, placing more value on the
social relationships and the remaining time they have left, rather than the potential
extension of a life with limited means of communication and more burdensome care
(Kotter-Grühn et al., 2010; Foley et al., 2014). In addition, those people with ALS who
have a partner and adult children, more common in late adulthood, may be less reliant on
hiring in-home nursing or respite care, and in that context make different decisions
regarding mechanical ventilation and other invasive treatments (Foley et al., 2014). Given
these factors, I hypothesize:
H1: People who are diagnosed later in the life course will be less likely to
report accessing each type of care due to their acceptance of the natural
disease course, with the exception of advanced directives and hospice care
which reflect preparing for the end of life.
H2: Marital status will shape the medical and supportive care received, with
those who are married being more likely to report accessing each type of care
because they have caregivers and a support system in place prior to decisionmaking.
Fundamental Cause Theory and Disparities in Medical Care for ALS
Although many argue that healthcare is a right, the reality is that in the United
States, healthcare is a commodity favoring those who can afford it (Pereira, 2003). Social
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position, including race/ethnicity, gender, and socioeconomic status/education, have been
considered social determinants of health and potentially fundamental causes of health
disparities (Link & Phelan, 1995). Fundamental cause theory may be useful in
understanding why there are variations in the medical and supportive care people with
ALS access.
Race/ethnicity, gender and socioeconomic status, are indicators of structural
inequalities, and are associated with both health care access and utilization. Lower
socioeconomic status can prevent access to healthcare in multiple ways, including by
limiting affordable options, limiting the time available to explore and gain knowledge of
potential treatment options, and the decision to postpone needed care due to cost
(Pereiria, 2004). Structures of inequality, as indicated by gender and race/ethnicity, may
also play a role in access due to bias in the healthcare system, as demonstrated in the case
of cardiac care (McMurray et al., 1991; Menezes et al., 2014; Gay, 2018). Further,
education is important to overall health; Mirowsky and Ross (2010) find that education
affects the evaluation and use of health information plus the ability to enact health
knowledge.
Barriers due to social position may limit medical and supportive care used to
improve quality of life for pALS. Therefore, fundamental cause theories suggests the
following hypothesis:
H3: Compared to those in more privileged positions, people who are
racial/ethnic Minorities, women, and those with lower education will have
lower odds of higher cost medical and supportive care for ALS (e.g.
wheelchair or scooter use, invasive ventilation, assisted communication

79
devices, Riluzole, and MDC usage), due to potential bias in the medical
system, cost, and level of knowledge and information provided.
Fundamental cause theory also suggests that race/ethnicity and gender are likely
to play a role in the level of trust placed in genetic testing or in research studies.
Historical evidence of research mistreatment and omissions of racial minorities and
women shapes trust in research and providers. Clinical trials have illustrated that a lack of
information on and access to clinical trials may influence the rate of racial/ethnic
minority groups and women participating in clinical trials (Roberson, 1994; Shavers et
al., 2001; Murthy et al., 2004; Suther and Kiros, 2012; Coakley et al., 2012). Results of
clinical trials that have not included women have led to consequences for women and
their children (e.g. thalidomide disaster, tetracycline in pregnancy), which may dissuade
women from participating in clinical trials (Ridings, 2013; Vennila et al., 2014). Further,
a history of abuse of Black-Americans in the name of research (e.g. Tuskegee Syphilis
Study, the case of Henrietta Lacks) has created fear and distrust of the medical
community in this population (Harris et al., 1996; Murthy et al., 2004). Therefore, I
hypothesize:
H3a: Women and minorities will be less likely to report genetic testing and
participating in clinical trials.
Although prior research has not studied the use of hospice by racial and ethnic
minorities diagnosed with ALS, studies regarding cancer mortality have shown
race/ethnicity shapes the use of hospice care in the United States with minorities entering
hospice less often than Whites (Virnig et al., 2002; Connor et al., 2008; Turkman et al.,
2019). Several factors seem to contribute to the underuse of hospice services by members
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of the Black-American community in particular. For Black-Americans, personal or
cultural values often conflict with hospice philosophy, which requires giving up
lifesaving or life-extending measures for comfort care alone (Washington et al., 2008). In
addition, Black-Americans often cite a lack of awareness of hospice services, as well as
concerns of burdening family in terms of emotional burden and time/economic burden
(Washington et al., 2008). Similar to research on clinical trials, there is a mistrust of the
health care system which may limit the acceptance of hospice care (Washington et al.,
2008). Finally, for racial and ethnic minorities, there is a fear that there will be little
diversity among hospice workers, which may limit understanding of cultural and personal
preferences (Washington et al., 2008).
Therefore, I postulate:
H3b: Minorities will be less likely to report being enrolled in hospice.

Data and Methods
Data
The National ALS Registry, created in October 2010, is a voluntary web-based
registry for people who have been diagnosed with ALS. The registry collects data on
demographic characteristics, clinical data such as phenotype, and outcome data. Due to
the potential physical, mental, and emotional limitations of pALS, the risk factor survey
utilizes smaller modules to facilitate completion (Bryan et al., 2016). The analysis covers
from 19 October 2010 to 31 December 2016 and includes 9789 people diagnosed with
ALS.
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Measures
Dependent Variable: Medical Services and Supportive Care. The National
ALS Registry gathers data on ten medical or supportive care options, including (1)
wheelchair or scooter use, (2) non-invasive ventilation, (3) invasive ventilation
(tracheostomy), (4) assisted communicative device, (5) research study participation, (6)
genetic testing, (7) advanced directives, (8) hospice care, (9) Riluzole use, and (10)
multidisciplinary clinic use (MDC). Riluzole and MDC usage are each a categorical
variable with values of currently use (ref), used but discontinued (=1), and never used
(=2). All other variables are dichotomous, with the categories of have not used (=0) and
have used (=1).
Independent Variables. The independent variables include: (1) age at diagnosis,
(2) onset location as an indicator of the disease process, (3) social position, with
education as a dichotomous variable of less than or more than a bachelor’s degree (4)
veteran status, and (5) social resources, including insurance coverage and marital status.
The independent variables, with the exception of the recoding of education, have been
detailed in chapter 2 and chapter 3. I was unable to include proximal risk factors into the
analysis due to the inability of the imputation model to converge. The large amount of
missing data for some variables (e.g. health insurance), as well as the small number of
pALS who reported accessing some types of medical and supportive care (e.g. invasive
ventilation), required the omission of these variables used in chapters 2 and 3.
Analysis
Multiple Imputation using Chained Equations was used to impute missing data
(Enders, 2006). I use logistic regression with odds ratios to examine odds of reporting
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each dependent variable, with the exception of Riluzole and MDC use, which use
multinomial logistic regression with relative risk ratios. Each model is created in steps;
(1) age at diagnosis, (2) age at diagnosis and onset location, (3) age at diagnosis, onset
location, and social position (4) age at diagnosis, onset location, social position, and
social resources. Models are built to reflect the timing of the ALS diagnosis in the life
course as the variable of interest, include the control for the disease process (e.g. global
onset indicates a quicker timeline to deciding on invasive ventilation), social position,
and finally the addition of social resources to determine if these factors change the
relationship between life course and medical and supportive care decisions. Results are
reported for the full models, and statistical significance was determined at the p < .05
level.
Results
Demographics
As indicated by Table 4.1, the sample is a majority White (97.18%), and nearly
60% male. Over 60% of the respondents reported having at least a bachelor’s degree.
Veterans make up nearly 24% of the sample. The majority of the sample is married or
cohabitating (82%). Most of the respondents are between the ages of 50-59 and 60-69
(29.79% and 35.99 % respectively). Although all of the respondents reported health
insurance coverage, the majority of the respondents reported either one type of insurance
coverage (50.17%) or two types of insurance coverage (43.72%).
Most pALS use some kind of medical and/or supportive care. The most common
kind is wheelchair or scooter use (72%), followed by non-invasive ventilation (29%).
Fewer pALS use invasive ventilation (tracheotomy) (2%). Nearly 13% of respondents
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reported assistive communication device use. About a fifth of respondents reported
participating in a research study or having genetic testing done (22% and 20%
respectively). Over two-thirds (68.89%) of respondents report having advanced directives
in place, however, only 4% have reported enrolling in hospice care. Fifty percent report
using Riluzole currently, and nearly 70% report currently attending an MDC.
Regression Models of Medical and Supportive Care
Life course and medical or supportive care. Age at diagnosis is associated with
reported medical and/or supportive care for pALS, with many categories of care less
likely to be reported by older pALS. There is, however, an exception with the reporting
of non-invasive ventilation, with groups who have less privileged having higher odds of
accessing non-invasive ventilation. In addition, end of life care, including advanced
directives and hospice enrollment, were more likely to be reported by pALS diagnosed at
younger ages. Therefore, Hypothesis 1 is partially supported.
In Table 4.2, the results show that pALS who are diagnosed between the ages of
60-69 (OR = .74, CI [.65, .83]), 70-79 (OR = .45, CI [.38, .53]), and who are diagnosed at
80+ (OR = .56, CI [.36, .86]) are less likely to report using a wheelchair or scooter than
pALS who are between the ages of 50-59. The predicted probability of wheelchair or
scooter use decreases as pALS age (Figure 4.1).
The association of age with non-invasive ventilation, reported in Table 4.3, was
contrary to hypothesis one. pALS who are diagnosed between the age of 18 and 49 are
42% less likely to use non-invasive ventilation (OR = .58, CI [.44, .78]), whereas those
who are diagnosed between the ages of 60 and 69 are 18% more likely to use noninvasive ventilation (OR = 1.18, CI [1.00, 1.38]) than those who are between the ages of
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50 and 59. Age at diagnosis does not appear to shape the use of non-invasive ventilation,
however, non-invasive ventilation is a standard of care for pALS who are having
shortness of breath or other difficulties breathing which may mean all pALS are more
likely to be accepting of this type of care.
Age is associated with invasive ventilator use (Table 4.4). pALS who are
diagnosed between the ages of 40 and 49 are 114% more likely to report the use of
invasive ventilator use compared to those who are diagnosed between the ages of 50-59
(OR = 2.14, CI [1.44, 3.16]). pALS who were diagnosed between the ages of 60 and 69
were 48% less likely (OR = .52, CI [.33, .82]) and 70 and 79 were 92% less likely (OR =
.08, [.02, .27]) to report invasive ventilator use. For invasive ventilation, 4% of pALS
between 40-49, 2% of pALS between 18-39 and between 50-59, and 1% of pALS
between 60-69 are predicted to opt into invasive ventilation (Figure 4.2).
Age is also associated with the use of assistive communication devices among
pALS (see Table 4.5). pALS who are diagnosed between the ages of 60 and 69 (OR =
.52, CI [.43, .62]), 70 and 79 (OR = .39, CI [.31, .50]), or 80 and older (OR = .57, CI [.33,
.98]) they are less likely to report the use of an assistive communication device than those
who are diagnosed between the ages of 50 and 59. There is no statistically significant
difference for assistive communication device use for pALS who are diagnosed between
the ages of 18-49 and 40-49 when compared to pALS who are diagnosed between the
ages of 50-59. The predicted probability of opting into assistive communication device
use decreases for those who are diagnosed after age 50 (Figure 4.3).
Age at diagnosis also shapes participation in research studies, as well as genetic
testing (Table 4.6 and 4.7). pALS who are younger at the time of an ALS diagnosis are
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more likely to report participating in a research study, and pALS who are older at
diagnosis are less likely to have participated (see Table 4.6 for full results). The
probability of reporting participation in a research study decreases with older age, from
40% of pALS diagnosed between ages 18-19, to 2% diagnosed at ages 80 and older
(Figure 4.4). For genetic testing, pALS who are diagnosed between the ages of 18-39 are
117% more likely (OR = 2.17, CI [1.71, 2.74]) and those diagnosed between 40 and 49
are 49% more likely (OR = 1.49, CI [1.26, 1.76]) to report using genetic testing
performed than those who are between the ages of 50-59. pALS who were diagnosed
between the ages of 70-79 were 47% less likely to report having genetic testing done than
pALS between diagnosed between 50-59 (OR = .53, CI [.43, 1.19]). The predicted
probability of reporting having genetic testing done were lowest (12%) for pALS
diagnosed between ages 70-79, and highest (36%) between the ages for pALS diagnosed
between 18-39 (Figure 4.5). For genetic testing, some of the differences in age may be
due to familial (genetically linked) ALS developing earlier in the life course, leading to a
higher likelihood of testing, although it is offered to all patients. The lower levels of
reporting genetic testing in older pALS does support hypothesis one.
Table 4.10 reports the results of the multinomial logistic regression for Riluzole
use. Riluzole is one of two medication options for pALS and is thought to extend survival
by two to three months (Dorst et al., 2018). pALS who are over the age of 80 are 141%
more likely to report never having used Riluzole (RR = 2.41, CI [1.62, 3.58] than pALS
who are between the ages of 50 and 59. pALS between the ages of 60 and 69 are 40%
less likely to report having discontinued the use of Riluzole (RR = .60, CI [.51, .86]), and
pALS between the ages of 70 and 79 are 32% less likely to report discontinued the use of
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Riluzole (RR = .68, CI [.54, .86]) than pALS between the ages of 50 and 59. The fact that
older adults are less likely to report discontinuing Riluzole use may be due to these pALS
never starting Riluzole, supporting hypothesis one.
Finally, age at the time of diagnosis also shapes who has never used a
Multidisciplinary ALS clinic. When compared to attending an MDC, pALS who are in
the older age groups (between the ages of 60 and 69 (RR = 1.15, CI [1.02, 1.32]), 70 and
79 (RR = 1.51, CI [1.28, 1.78]), and who are over 80 years of age (RR = 2.12, CI [1.38,
3.25]) are more likely to report never attending an MDC compared to pALS between the
ages of 50 and 59. Age is not associated with discontinued MDC use compared to
currently attending an MDC (Table 4.11). Again, this may be because older adults do not
access MDCs in the first place.
Planning for end of life care, as well as accepting that the end of life is near, is
also shaped by the pALS age at diagnosis in expected ways. Consistent with the idea that
a diagnosis of ALS and the likelihood that death will happen in the future, which may be
an on-time or off-time transition depending on the position in the life course, pALS who
are between the ages of 18 and 39 at diagnosis are 57% less likely (OR = .43, CI [.34,
.54]) and those who are diagnosed between the ages of 40 and 49 are 36% less likely (OR
= .64, CI [.56, .73]) to have reported being having advanced directives in place than those
diagnosed between the ages of 50 and 59 (Table 4.8). pALS who are 60 and older at
diagnosis are more likely to report having advanced directives in place. The predicted
probabilities of reporting having completed advanced directives increase with age, from
45% for pALS diagnosed between the ages of 18-49, to 99% for pALS diagnosed at ages
80 and older (Figure 4.6).
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Further, as hypothesized, those who are older at diagnosis are more likely to
report being enrolled in hospice care (Table 4.9). pALS diagnosed between the ages of 60
and 69 are 188% more likely to report being enrolled in hospice (OR = 2.88, CI [2.10,
3.96]), and those who are diagnosed between the ages of 70 and 79 are 183% more likely
to report hospice enrollment (OR = 2.83, CI [1.86, 4.30]) than those who are diagnosed
between the ages of 50 and 59. pALS diagnosed over the age of 80 are more likely report
enrollment in hospice care as well (OR = 7.21, CI [3.35, 15.51]).
Marital status and medical or supportive care. Hypothesis 2 states that pALS
who are unmarried compared to those who are married will be less likely to report all
types of medical or supportive care except for advanced directives and enrollment in
hospice care. Given the results, Hypothesis 2 is partially supported. Tables 4.6 and 4.7
illustrate that pALS who are unmarried are 26% less likely to report participating in a
research study (OR = .74, CI [.64, .86]), and 27% less likely to report genetic testing (OR
= .73, [.63, .85]).
In regard to Riluzole use, which may extend survival by a few months (Dorst et
al., 2018), unmarried pALS were 38% more likely than married pALS to report never
taking Riluzole compared to currently taking Riluzole (RR = 1.38, CI [1.24, 1.55]) (Table
4.10). Unmarried pALS are 135% more likely to report having discontinued attending an
MDC versus currently attending compared to married pALS (RR = 2.35, CI [1.88, 2.93])
(Table 4.11).
Several types of medical care or supportive care were just as likely to be reported
by unmarried and married pALS. There was no difference in wheelchair or scooter use
(OR = .98, CI [.87, 1.10]), non-invasive ventilator use (OR = .98, CI [.87, 1.11]), or
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assistive communication device (OR = 1.04, CI [.88, 1.23]) by marital status (Tables 4.2,
4.3, and 4.5). In addition, unmarried pALS are no more or less likely to report never
attending an MDC versus currently attending when compared to their married peers (RR
= .99, CI [.67, .99]) (Table 4.11). Surprisingly, Table 4.8 demonstrates that unmarried
pALS are no more or less likely to report having advanced directives in place than their
married peers, as there is a greater need for advanced directives in the case of unmarried
pALS who are unable to communicate and do not have a spouse or next of kin to do so
for them (OR = 1.10, CI [.97, 1.25]).
Finally, pALS who are single are 122% more likely to report invasive ventilator
use (OR = 2.22, CI [1.53, 3.20]) (Table 4.4). The predicted probability of unmarried
pALS to report invasive ventilator use is 2.9%, whereas the predicted probability for
married pALS is 1.4% (Figure 4.7). The increased odds of invasive ventilation use being
reported by unmarried pALS is unexpected, given the high-level of care required with a
tracheostomy and mechanical ventilation and the need for in-home care cannot be met by
a spouse or partner. pALS who are unmarried are 141% more likely to report having
enrolled in hospice care in comparison to their married peers (OR = 2.41, CI [1.92, 3.02])
(Table 4.9). The probability of unmarried pALS reporting hospice enrollment is 7%,
compared to 3% for married pALS (Figure 4.8).
Social position and medical or supportive care. Social position is associated
with some of the medical and supportive care reported by pALS. Table 4.2 reports the
results for wheelchair or scooter use. Women are 22% more likely than men to report
wheelchair or scooter use (OR = 1.22, CI [1.10, 1.35]). This finding is surprising, as
women are more likely to develop bulbar onset ALS, and pALS with bulbar onset are less
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likely to report wheelchair or scooter use (OR = .45, CI [.39, .51]). The finding may be
due to women socialized to being more dependent on others for their needs, in this case,
movement. Alternatively, men may feel that using assistive devices, such as a wheelchair,
may be a threat to their masculinity and do not want to be seen as impaired. pALS with a
college degree or higher are 18% more likely to report wheelchair or scooter use than
those without a college degree (OR = 1.18, CI [1.04, 1.35]). There is no difference in
wheelchair or scooter use by race/ethnicity (OR = .85, [.64, 1.14]) or by marital status
(OR = .98, CI [.87, 1.10]).
Social position was associated with reported non-invasive ventilation, although in
unexpected ways (Table 4.3). Racial/ethnic minorities are 76% more likely to report noninvasive ventilator use compared to Whites (OR = 1.76, CI [1.36, 2.27]). Women were
20% less likely to use non-invasive ventilation compared to men with ALS (OR = .80, CI
= .72, .89]). Those with a college education or more were 13% more likely to report noninvasive ventilator use (OR = 1.13, CI [1.02, 1.24]). Social position, again, seems to
shape invasive ventilation in unexpected ways (Table 4.4). Minorities were 509% more
likely to report invasive ventilator use than Whites (OR = 6.09, CI [3.76, 9.84]), which is
unexpected due to the previous literature on health disparities that suggests minorities
would be less likely to access this type of care. The population of racial/ethnic minorities
in the National ALS Registry is small and logistic regression does not handle small cell
counts well. Therefore, to substantiate the results of the logistic regression I performed a
sensitivity analysis using a complementary log-log regression which returned a similar
odds ratio and confidence interval to the logistic regression (OR = 5.55, CI [3.56, 8.63]).
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The predicted probability for reporting invasive ventilation for racial/ethnic minorities is
7.5%, compared to the predicted probability for whites of 1.5% (Figure 4.9).
Women were 51% less likely to report invasive ventilator use than men (OR =
.49, CI [.33, .73]). The findings for both non-invasive and invasive ventilation use means
that the associations for social position are perhaps more about personal and cultural
expectations and less about social power at the time of the decision-making.
As expected, racial/ethnic minorities are 45% less likely than Whites to report the
use of an assistive communication device (OR = .55, [.35, .87]), however, women were
99% more likely to report using an assistive communication device than men (OR = 1.99,
CI [1.72, 2.31]) (Table 4.5). pALS with a college education or more were more likely to
report the use of an assistive communication device (OR = 1.18, CI [1.03, 1.36]).
pALS with higher education also have a higher likelihood of reporting
participation in a research study or genetic testing. pALS with a higher level of education
were 69% more likely to report participating in a research study (OR = 1.69, CI [1.51,
1.90]) and 13% more likely to report having genetic testing done (OR = 1.13, [1.00,
1.27]) (Table 4.6 and 4.7). As previously described in chapters 1 and 2, this may mean
that clinical trials suffer from issues of representation, which may lead to promising
treatments failing when introduced into the larger population.
Women are 25% less likely than men to report having advanced directives in
place than men (OR = .75, CI [.68, .83]). This finding is interesting, as women are often
socialized to worry about their family, and advanced directives are often thought to lessen
the burden on the family members at the end of life. pALS with higher levels of
education are 57% more likely than those with lower levels of education to report having
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advanced directives in place (OR = 1.57, CI [1.42, 1.73]) (Table 4.8). Women are 30%
less likely than men to report enrollment in hospice care (OR = .70, CI [.55, .89]) (Table
4.9). pALS with higher levels of education are just as likely to report being enrolled in
hospice as pALS with lower education levels (OR = 1.17, CI [.94, 1.45]). This finding
may illustrate that hospice care, as it is often free and/or covered by Medicare, may not
reflect the same disparities by education level.
The use of Riluzole varies by social position (Table 4.10). There are three
categories of Riluzole use in the ALS Registry; currently using, discontinued using, and
have never used. Racial/ethnic minorities are 49% less likely to report never taking
Riluzole than Whites (RR = .51, CI [.38, .68]), however, are no more or less likely to
report having discontinued its use (RR = 1.05, CI [.73, 1.52]). Women are more likely
than men to report having never taken Riluzole (RR = 1.28, CI [1.16, 1.41]) and to have
discontinued the use of Riluzole (OR = 1.33, CI [1.15, 1.54]) versus reporting the current
use of Riluzole. pALS with higher levels of education are 21% less likely to report
having never taken Riluzole than pALS with lower levels of education (RR = .79, CI =
[.72, .86]), and are 29% more likely to report having discontinued the use of Riluzole
(RR = 1.29, CI = [1.11, 1.50]). There is debate over the actual effectiveness of Riluzole,
and those who choose not to take it may find it cost prohibitive, or potentially have
reasoned it is not effective enough in slowing their symptoms to justify the continued
cost.
Social position further shapes who attends an MDC (Table 4.11). Minorities are
81% more likely to report having never attending an MDC compared to currently
attending an MDC, in contrast to their White peers (RR = 1.81, CI [1.38, 2.37]). Women,
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when compared to men, are 24% more likely to report never attending an MDC clinic
versus currently attending (RR = 1.24, CI [1.11, 1.39]), and are 21% less likely to report
discontinued attendance at an MDC compared to currently attending (RR = .79, [.63,
.99]. pALS with higher levels of education, in contrast to pALS with lower levels of
education, are 35% less likely to report never attending an MDC (RR = .65, CI [.50,
.66]), however, they are no more or less likely to report having discontinued attendance at
an MDC (RR = .93, CI [.75, 1.14]), when compared to pALS currently attending an
MDC. The results indicate that social position is associated with accessing what
physicians regard as the ‘gold standard’ of care and may be indicative of barriers to
attendance such as cost or travel distance.
Participation in research studies and genetic testing by gender and
race/ethnicity. Social position is associated with the report of participation in a research
study yet is not associated with genetic testing (Tables 4.6 and 4.7). Racial/ethnic
minorities are 39% less likely to have participated in a research study than Whites (OR =
.61, CI [.44, .86]), with the predicted probability of participating in a research study of
15% for racial/ethnic minorities compared to 22% for whites (Figure 4.10). There was no
association with race/ethnicity and genetic testing. Women were 21% less likely to report
participating in a research study (OR = .79, CI [.70, .88]) and 34% less likely to report
having genetic testing done (OR = .66, CI [.58, .74]) than men. The predicted probability
for participating in a research study is 20%, and the predicted probability of genetic
testing is 16% for women, compared to 24% and 23% respectively for men (Figures 4.11
and 4.12).
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Race/ethnicity and hospice care. Contrary to Hypothesis 3a, racial/ethnic
minority status is not associated with enrollment in hospice. Racial/Ethnic minorities are
no more or less likely to report being enrolled in hospice than Whites (OR = 1.26, CI
[.71, 2.26]).
Discussion
Life Course Theory and the Shaping of Medical and Supportive Care
Addressing the gaps in care provision for ALS is an important part of improving
the quality of life for people with ALS (Goutman & Simmons, 2018). As part of
understanding the gaps in care for those with ALS it is important to determine where, as
well as why, gaps in care exist. Using life course theory and fundamental cause theory as
a framework for model creation, I explored how the timing of an ALS diagnosis, as well
as social position, shapes the medical care reported by people diagnosed with ALS in the
National ALS Registry. Although it is difficult to fully grasp why gaps in care exist and if
these gaps are problematic in every case, the results do show where there are differences
by both position in the life course and social position.
The timing of an ALS diagnosis in the life course does shape the types of care
people with ALS chose to obtain. pALS who are older than 59 are less likely to report
engaging in most types of medical and supportive care. These findings are expected when
viewed through a life course lens. Qualitative research has demonstrated that people who
are age 70 or over when diagnosed with ALS tend to be more accepting of the natural
course of the disease than those in early-to-mid adulthood (Foley et al., 2014). Death, in
the form of the diagnosis of a disease such as ALS, in later adulthood and old age may be
more expected as part of the life course after reaching many previous life transition
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milestones (Elder & Rockwell, 1979; Foley et al., 2014). When death is already expected
in the short(er) term, the addition of an ALS diagnosis may cause people to adjust their
goals for care, placing a higher value on spending time with family and limiting
interventions to prevent the inevitable outcome (Kotter-Grühn et al., 2010; Foley et al.,
2014). Therefore, it was not surprising that older adults were more likely to report
enrollment in hospice care as well as having advanced directives in place, as these are
often acknowledgements of an anticipated death.
The diagnosis of ALS and the likelihood of a fatal outcome within a few years,
however, would be considered an off-time transition in young adulthood or middle ages,
as they are often in the prime of their careers, raising young children, and potentially
caring for elderly parents (Elder & Rockwell, 1979). The prospect of death leaves young
people feeling cheated of a full life and robbed of their remaining years, and leaves those
in middle age anxious regarding unfinished plans and responsibilities (Kalish, 1985). Just
as older adults who expect death and thus make decisions to not forestall death, those
earlier in the life course opt to do everything and anything to prevent death. Therefore,
the higher likelihood of pALS in the early part of the life course to pursue every type of
medical or supportive care is expected. In contrast, care for older adults is often
conceptualized as dependent on the value placed on their lives and a differential in the
availability of resources, however, these findings illustrate it may be more dependent the
sense of the on-time versus off-time nature of a diagnosis. Therefore, what appears to be
gaps in care for older pALS may be more of an intentional decision-making process
among older pALS.
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The one exception to the expected findings was for non-invasive ventilation. Age
at diagnosis is not associated overall with non-invasive ventilation (e.g. Bi-PAP or CPAP machine). Only pALS diagnosed between the ages of 18 and 49 showed a lower use
of non-invasive ventilation, and those who were between the ages of 60 and 69 were
more likely to report the use of non-invasive ventilation. One reason for this may be that
non-invasive ventilation is the standard of care for pALS who are beginning to have
difficulty breathing. In addition, the use of a Bi-PAP or C-PAP machine has been
normalized as a supportive therapy for those with sleep apnea, which may suggest to
pALS that non-invasive ventilation is perhaps within the realm of normal behavior rather
than supportive care and is a potential area for future research. The widespread, non-age
dependent, use of non-invasive ventilation is an important finding, as those who use noninvasive ventilation have longer survival times than those who do not (Lechtzin et al.,
2007).
Marital status is associated with use of medical and supportive care. Unmarried
pALS are less likely to report participating in a research study and genetic testing and are
more likely to report discontinuing Riluzole use and having never attended an MDC.
Several explanations for this exist. Unmarried pALS do not have a supportive partner to
ensure they are able to be transported to clinical trial visits or MDC appointments,
meaning unmarried pALS do not opt into research studies as often, as well as discontinue
their MDC attendance once they are no longer able to drive or travel unassisted (Spataro
et al., 2017). In addition, without a partner encouraging the continued use of Riluzole for
its perceived benefits of extending life, unmarried pALS might be more apt to stop its use
(Spataro et al., 2017). Finally, genetic testing is often seen as a tool to warn children of a
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potentially genetic disease, and if unmarried pALS do not have children or are not close
with their children, they may forgo such testing (Crook et al., 2017; van Es et al., 2017).
From the perspective of life course theory, it is surprising that unmarried pALS
are much more likely to report invasive ventilation than their married peers. Invasive
ventilation is less often adopted overall by pALS in the United States, which is reflected
in the National ALS Registry, because of the prohibitive cost of round-the-clock care. In
addition, many pALS are concerned over the potential burden placed on informal
caregivers, both in providing an extraordinarily complex level of care and the financial
cost that must be assumed. For unmarried pALS, it may be that when the costs can be
managed and professional care can be brought into the home, then the perception of
burden is lessened, and invasive ventilation is viewed as a reasonable choice. A second
explanation also exists, as many pALS are placed on invasive ventilation as a result of
complications of ALS, including pneumonia and other infections. Without having a
partner as the next of kin to verbalize pALS wishes or to ensure advanced directives and
DNR orders are communicated, unmarried pALS may be more likely to be placed on
invasive ventilation. For some pALS, invasive ventilation can be discontinued once the
crisis has passed, however, at least some remain on invasive ventilation indefinitely
(Cazzolli and Oppenheimer, 1996; Benditt, 2002). To fully understand the patterns from
the survey data, adding a qualitative study would be ideal.
Social Position and the Shaping of Medical and Supportive Care
Social position does shape some of the medical and supportive care reported by
pALS, although not always in ways that are consistent with the research on health
disparities using a fundamental cause and the social determinants of health framework.
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Women, in comparison to men, are less likely to report using non-invasive and
invasive ventilation, completing advanced directives or enrolling in hospice care, and are
more likely to report never using or discontinuing the use of Riluzole. Women are also
more likely to report never attending an MDC. Women, however, are more likely to
report the use of a wheelchair or scooter and are less likely to report discontinuing
attendance at an MDC. These differences may be in part due to differences in the disease
course for men and women, which I attempt to control for with the inclusion of onset
location; however, there are several other potential explanations. For example, previous
research in gender differences in medical decision-making about stroke care demonstrates
men and women do not differ in preference for interventions, although women were more
dissatisfied with the provision of information on interventions (Crawford et al., 2000;
Kapral et al., 2006; Saposnik et al., 2009). Women may need additional information from
their providers to understand the risks and benefits of interventions with ALS and may
avoid the intervention if their questions go unanswered. Further, many studies have
shown that women are neglected in medical research and treated differently by the
healthcare system. For example, cardiac care has been researched as a disease of men,
men’s symptoms are taken more seriously, and men are treated more aggressively than
women (McMurray et al., 1991; Gay, 2018). As ALS is viewed as a disease of men, it
may be that women are subject to the same types of biases from researchers and
providers as are found in cardiac care and suggests a need for additional qualitative
research with women diagnosed with ALS and their healthcare providers. Overall, the
differences in care are concerning, especially within the context of bias.
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Differences in education, which may be thought of as a proxy of socioeconomic
status, also shaped the care reported by pALS. pALS with higher levels of education were
more likely to report wheelchair or scooter use, the use of a non-invasive ventilator, using
an assistive communication device, and of having advanced directives in place.
Education also influenced the use of Riluzole, with fewer pALS with higher levels of
education reporting having never taken Riluzole, and more stating that they have
discontinued its use. pALS with higher levels of education are less likely to report having
never attended an MDC than their peers with lower levels of education. Moreover, pALS
with higher levels of education were more likely to participate in research studies and to
have had genetic testing performed. The potential reason for the differences in care
reported by education level are threefold. The first is that ALS onset is different for those
with lower levels of education, as noted in chapter one and two, therefore care needs are
different and are not completely captured in the registry data. Second, education acts as a
proxy of socioeconomic status, and those with higher levels of education are more able to
afford and access medical and supportive care. Finally, it may be that higher levels of
education allow pALS to acquire, evaluate, and use information regarding their diagnosis
in a way that informs their choices in care differently and allows pALS with higher levels
of education to advocate for the care they need (Mirowsky and Ross, 2010). In any case,
it is important to consider education in the development of interventions and the
provision of care for pALS as this appears to be one source of the gaps in care.
The pALS identified as belonging to a racial/ethnic minority group in the National
ALS Registry are less likely to report using an assistive communication device and are
more likely to report having never attended an MDC clinic, both of which can be
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expensive and difficult to access. There were no differences by race/ethnicity for the use
of a wheelchair or scooter, however, this may be affected by other findings including the
use of non-invasive and invasive ventilation.
pALS identified as racial/minorities in the sample were much more likely to
report non-invasive and invasive ventilation. Given the potential for care disparities to
exist in ALS, the two forms of ventilation are areas one would expect to see disparities
given the issues of cost and/or access. Smaller clinic-based studies have also noted an
increase in use of both types of ventilation for Black American pALS, with invasive
ventilation being up to eight times more likely compared to White-American pALS
(Quadri et al., 2019; Gungogdu et al., 2013). Although other studies have found
comparable results, few studies have attempted to understand these differences. One
reason for the difference could be that racial and ethnic minority populations present with
far more advanced ALS or progress to later stages of the disease more quickly, or for
complications for ALS to arise more often, leading to a higher than expected number of
racial and ethnic minorities using invasive ventilation (Ceriana et al., 2017; Rodriguez et
al., 2018).
Previous work in understanding why pALS choose to use invasive ventilation has
focused on the idea that invasive ventilation is ‘life-saving’, meaning pALS who opt to
pursue invasive ventilation believe they will live significantly longer with it than without
and allowing them to live when they might otherwise die (Lemoignan and Ells, 2010).
Given the difference in life expectancy for racial minorities in the United States, Black
Americans are more likely to experience the death of a parent, a child, a sibling, or other
loved ones (Umberson et al., 2017). In light of the higher numbers of deaths witnessed,
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Black Americans may be more likely to opt into invasive ventilation to stay alive—
preventing the loss of another family member—not only for their own desire to live but
in order to protect their families. Developing an understanding of how the differences in
the adoption of invasive ventilation may be rooted in a deeper history of racism in the
United States is a critical area for future research.
Gender and race/ethnicity in research participation and genetic testing.
Social position, in the form of gender and race/ethnicity, is associated with participation
in a research study, but is not associated with genetic testing. Women were less likely to
report participating in research studies and in genetic testing, yet minorities were less
likely to participate in research studies. As discussed in both chapters one and two,
clinical trials for ALS treatments suffer from widespread failure (e.g. treatments are
ineffective), and the majority of trial participants are young, white, and male, with limb
onset (Chiò et al., 2011; Mitsumoto et al., 2014). As discussed in the section of
differences between the types of care reported by men and women, it is important to
include women and racial/ethnic minority groups in clinical trials to ensure the trials and
resulting treatments are not solely geared to white men, over and above increasing the
potential for successful clinical trials.
Race/ethnicity and hospice care. Race and ethnicity are not associated with
enrollment in hospice. Minorities are no more or less likely to report being enrolled in
hospice than whites. Although studies examining the use of hospice for cancer diagnosis
have previously shown minorities enter hospice less often than whites which may be due
to barriers such as access to and knowledge of hospice care and cultural concerns (Virnig
et al., 2002; Connor et al., 2008; Turkman et al., 2019), ALS diagnosis does not reflect
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the same disparities. ALS is a fatal diagnosis and has no cure and little in the way of
treatment, however, whereas cancer diagnoses are less certain and may present more
options for a potential cure and the option to attempt to extend life. Additionally, the lack
of association between race/ethnicity and hospice care may be due to the increase in use
of invasive ventilation in racial/ethnic minority groups.
Limitations
There are a number of limitations to consider with this study. The first is the
nature of the National ALS Registry. The National ALS Registry has been designed for
biomedical and epidemiological research, and therefore limits the work of the social
scientist, however, many of the needed components to understand where disparities in
care exist are available. The ALS Registry is reliant on patient self-reporting data and
may be subject to recall bias and bias due to self-identification. Further, the registry is a
large non-random sample that is opt-in and is therefore not generalizable to the ALS
population.
Another limitation is the issue of missing data. Unlike previous studies in the
dissertation, I was unable to include proximal risk factors into the analysis of medical and
supportive care due to the inability of the imputation model to converge. The large
amount of missing data for some variables (e.g. health insurance), as well as the small
number of pALS who reported accessing some types of medical and supportive care (e.g.
invasive ventilation), required the omission of these variables. Future studies should
attempt to account for proximal risk factors to better understand how they may influence
the decision to access certain types of medical and supportive care.
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In addition, the registry is available in an online format only, which may limit
access and cause the registry to reflect a younger, white, and a more educated patient
sample. The registry sample provided by the CDC is less racially diverse than the overall
registry which includes Medicare and Veteran’s Association claims data. There are
several potential reasons for this, including access to computers that are required for selfregistration; reduced awareness of the registry; and reduced participation in areas with
substantial nonwhite populations (Kaye et al., 2018). In addition, while the sample size
overall is robust, smaller numbers of specific populations, such as non-white patients,
limits the ability to do intersectional analysis to better understand the relationship of
social position and ALS. Finally, the limited access to data due to reidentification risks
limit the analysis to a small number of survey modules, which prevents a fuller picture of
the experience of ALS. Even with these limitations, the National ALS Registry is the
most comprehensive, geographically diverse sample of people diagnosed with ALS.
Conclusion
The analyses of disparities in medical care contributes to the knowledge of both
sociology and ALS. Position in the life course also shapes the experience care reported
by pALS, although not always in ways theory would posit. There are many potential
reasons for these findings, including a sense of burden, access and knowledge, and a fear
or acceptance of death.
Medical care is shaped by social position, as suggested by fundamental cause
theory. These theories do highlight the differences in medical and supportive care,
however, some of the findings actually run counter to the theories’ predictions.
Therefore, although fundamental cause theory works fairly well in the case of a specific
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disease, sociological theories created for the more general social experiences (e.g. who
will get a disease and who will not) may need to be adjusted to reflect the differences in
experiencing specific diseases. Further, adjustment of current theories in the sociology of
health and illness allow for their use in exploring the connection between the social world
and the experience and care for those diagnosed with the specific disease in question
(Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008). In addition, the results
from this work again reaffirm the need for a sociology of disease, as dealing with the care
needs for a specific disease, such as ALS, is different from many other diseases. Future
research should address the potential reasons why life course theory and fundamental
cause theory drive findings that are different among people already diagnosed with ALS
compared to the bigger picture of general illness, in order to better adjust the theories in a
sociology of disease framework.
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Table 4.1 Descriptive Statistics for Medical and Supportive Care (N = 9789)
Pre-Imputation
Post-Imputation Percentage
Variable
Frequency Percent
Powerchair/Scooter
No
6961
71.11
72.12
Yes
2680
27.38
27.88
Missing
148
1.51
0
Total
9789
100.00
100.00
Non-Invasive Ventilation
No
6837
69.84
71.31
Yes
2760
28.19
28.69
Missing
192
1.96
0
Total
9789
100.00
100.00
Invasive Ventilation
No
9402
96.05
98.34
Yes
160
1.63
1.66
Missing
227
2.32
0
Total
100.00
100.00
100.00
Assistive Communication Device
No
8381
85.62
87.31
Yes
1221
12.47
12.69
Missing
187
1.91
0
Total
9789
100.00
100.00
Genetic Testing Done
No
7115
72.68
79.76
Yes
1774
18.12
20.24
Missing
900
9.19
0
Total
9789
100.00
100.00
Participate in Research Study
No
7460
76.21
77.86
Yes
2123
21.72
22.14
Missing
203
2.07
0
Total
9789
100.00
100.00
Advanced Directives in Place
No
2985
30.49
31.11
Yes
6604
67.46
68.89
Missing
200
2.04
0
Total
9789
100.00
100.00
Hospice
No
9232
94.31
95.77
Yes
407
4.16
4.23
Missing
150
1.53
0
Total
9789
100.00
100.00
Riluzole Use
Never Used
3656
37.35
37.88
Used to Take
1110
11.34
11.48
Currently Use
4894
49.99
50.64
Missing
129
1.32
0
Total
9789
100.00
100.00
Multidisciplinary Clinic
Never Attended
2342
23.92
24.61
Previously Attended but No Longer
430
4.39
4..49
Currently Attend
6790
69.36
70.90
Missing
227
2.32
0
Total
9789
100.00
100.00
Age at Diagnosis
18-39 (0)
427
4.36
4.36
40-49 (1)
1382
14.12
14.12
50-59 (2)
2916
29.79
29.79
60-69 (3)
3522
35.99
35.99
70-79 (4)
1406
14.37
14.36
80+ (5)
134
1.37
1.37
Missing
2
.02
0
Total
9789
100.00
100.00
Onset Location
Limb (0)
7169
73.24
73.61
Speech/Swallowing (1)
2003
20.46
20.59
Trunk/Global (2)
564
5.76
5.80
Missing
53
.54
0
Total
9789
100.00
100.00
Race/Ethnicity
White (0)
9513
97.18
97.18
Racial/Ethnic Minority (1)
276
2.82
2.82
Missing
0
0
0
Total
9789
100.00
100.00
Gender
Male (0)
5861
59.87
59.87
Female (1)
3928
40.13
40.13
Missing
0
0
0
Total
9789
100.00
100.00
Education
Less than a College Degree (0)
3426
35.00
35.00
College Degree or More (1)
6363
65.00
65.00
Missing
0
0
0
Total
9789
100.00
100.00
Veteran Status
Civilian or Other (0)
7473
76.34
76.40
Veteran (1)
2309
23.59
23.60
Missing
7
.07
0
Insurance
One
1976
20.19
50.17
Two
1823
18.62
43.72
Three
259
2.65
6.11
Missing
5731
58.55
0
Total
9789
100.00
100.00
Marital Status
Married or Cohabitating (0)
7998
81.70
81.80
Never Married, Separated, Divorced, Widowed (1)
1779
18.17
18.20
Missing
12
.12
0
Total
9789
100.00
100.00
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Table 4.2 Logistic Regression Predicting Odds of Reporting Wheelchair or Power Scooter Use (N=9789)

Model 1: Age Only

Model 2: Age and
Onset Location

Model 3: Age, Onset
Location, and Social
Position

Model 4: Age, Onset
Location, Social
Position, and Veteran
Status
Odds
Confidence
Ratio
Interval

Model 5: Age, Onset
Location, Social Position,
Veteran Status, and
Resources
Odds
Confidence
Ratio
Interval

Dependent
Odds Confidence Odds Confidence Odds
Confidence
Variable
Ratio
Interval
Ratio
Interval
Ratio
Interval
Age at
Diagnosis (ref=
50-59)
18-39
1.36 ** 1.09, 1.69 1.25 * 1.00, 1.55 1.22
.98, 1.53 1.23
40-49
1.11
.97, 1.27 1.11
.97, 1.28 1.12
.97, 1.29 1.12
60-69
.86 **
.77, .95
.90
.81, 1.01 .90
.81, 1.00
.89 *
70-79
.57 *** .49, .67
.60 *** .51, .70
.61 ***
.52, .71
.60 ***
80+
.79
.53, 1.17 .88
.59, 1.32 .90
.60, 1.36
.88

.99, 1.53
.98, 1.29
.80, 1.00
.51, .70
.59, 1.33

1.20
1.13
.74 ***
.45 ***
.56 **

(.96, 1.50)
(.98, 1.30)
(.65, .83)
(.38, .53)
(.36, .86)

Onset Location
(ref=Limb)
Bulbar
Trunk/Global

.47 ***
1.05

.42, .54
.87, 1.28

.47 ***
1.07

.41, .53
.89, 1.30

.47 ***
1.08

.41, .53
.90, 1.31

.45 ***
1.01

(.39, .51)
(.83, 1.23)

Racial/Ethnic
Minority

.90

.68, 1.19

.90

**

.68, 1.19

.85

(.64, 1.14)

Female

1.12 *

1.02, 1.23

1.15 **

1.04, 1.27

1.22 ***

(1.10, 1.35)

College Degree
or More

1.18 ***

1.07, 1.29

1.17 ***

1.06, 1.29

1.11

*

(1.01, 1.23)

.93

.83, 1.05

1.18

**

(1.04, 1.35)

1.92 ***
2.90 ***

(1.63, 2.26)
(2.21, 3.80)

.98

(.87, 1.10)

Civilian
Number of
Types of
Insurance (ref=
One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant
.43 *** .39, .46
+ p < .10, *p < .05, **p < .01, ***p < .001

.41 ***

.37, .46

.43 ***

.37, .50

.29

***

(.24, .34)
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Table 4.3 Logistic Regression Predicting Odds of Reporting Non-Invasive Ventilation (N=9789)

Model 1: Age Only

Dependent
Odds
Variable
Ratio
Age at
Diagnosis (ref=
50-59)
18-39
.52 ***
40-49
1.13
60-69
1.15 *
70-79
1.50 ***
80+
.87

Confidence
Interval

Model 3: Age, Onset
Location, and Social
Position

Odds
Ratio

Odds
Ratio

Confidence
Interval

Model 4: Age, Onset
Model 5: Age, Onset
Location, Social Position Location, Social Position,
and Veteran Status
Veteran Status, and
Resources
Confidence
Odds
Confidence
Odds
Confidence
Interval
Ratio
Interval
Ratio
Interval

.58 *** (.44, .78) .60 *** (.45, .79)
.60 ***
1.15
(1.00, 1.33) 1.12
(.97, 1.30) 1.12
1.11
(.99, 1.24) 1.12 * (1.00, 1.26) 1.12
1.37 *** (1.19, 1.58) 1.39 *** (.53, 1.31) 1.37 ***
.80
(.51, 1.24) .83
.82

(.45, .80)
(.97, 1.30)
(1.00, 1.25)
(1.19, 1.59)
(.52, 1.28)

.58 ***
1.12
1.01
1.18 *
.64

(.44, .78)
(.97, 1.30)
(.89, 1.13)
(1.00, 1.38)
(.41, 1.03)

1.51 *** (1.35, 1.68) 1.55 *** (1.39, 1.73) 1.56 ***
3.93 *** (3.29, 4.70) 3.87 *** (3.23, 4.63) 3.90 ***

(1.40, 2.31)
(3.26, 4.67)

1.54 ***
3.78 ***

(1.38, 1.72)
(3.15, 4.54)

Racial/Ethnic
Minority

1.80 *** (1.40, 2.31) 1.80 ***

(1.40, 2.31)

1.76 ***

(1.36, 2.27)

Female

.76 ***

College Degree
or More

1.17 **

Onset Location
(ref=Limb)
Bulbar
Trunk/Global

(.39, .69)
(.98, 1.30)
(1.03, 1.28)
(1.31, 1.72)
(.56, 1.34)

Model 2: Age and
Onset Location

(.69, .83)

.77 ***

(1.06, 1.29) 1.17 **

Veteran

.95

(.70, .85)

.80

***

(.72, .89)

(1.06, 1.28)

1.13

*

(1.02, 1.24)

(.84, 1.06)

1.09

(.93, 1.23)

1.49 ***
1.70 **

(1.27, 1.74)
(1.19, 2.44)

.98

(.87, 1.11)

Number of
Types of
Insurance (ref=
One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant
.36 *** (.33, .39) .31 ***
+ p < .10, *p < .05, **p < .01, ***p < .001

(.28, .34)

.30 ***

(.27, .34)

.31 ***

(.27, .36)

.25

***

(.21, .30)
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Table 4.4 Logistic Regression Predicting Odds of Reporting Invasive Ventilation (N=9789)

Model 1: Age Only

Dependent
Odds
Variable
Ratio
Age at
Diagnosis (ref=
50-59)
18-39
.85
40-49
2.00 ***
60-69
.53 **
70-79
.10 ***
80+
.42

Confidence
Interval

Model 2: Age and
Onset Location

Model 3: Age, Onset
Location, and Social
Position

Odds
Ratio

Odds
Ratio

Confidence
Interval

Confidence
Interval

Model 4: Age, Onset
Location, Social
Position, and Veteran
Status
Odds
Confidence
Ratio
Interval

(.38, 1.88) 1.14
(.51, 2.53) 1.23
(.55, 2.75) 1.29
(1.37, 2.92) 2.14 *** (1.46, 3.14) 2.05 *** (1.39, 3.01) 2.10 ***
(.35, .81)
.50 *** (.33, .76)
.51 **
(.34, .78)
.45 ***
(.03, .33)
.08 *** (.03, .26)
.08 *** (.03, .27)
.07 ***
(.06, 3.03) .37
(.05, 2.65) .39
(.05, 2.83)
.28

Onset Location
(ref=Limb)
Bulbar
Trunk/Global

Model 5: Age, Onset
Location, Social Position,
Veteran Status, and
Resources
Odds
Confidence
Ratio
Interval

(.58, 2.88)
(1.43, 3.09)
(.30, .70)
(.02, .22)
(.04, 2.09)

1.31
2.14 ***
.52 **
.08 ***
.43

(.58, 2.95)
(1.44, 3.16)
(.33, .82)
(.02, .27)
(.05, 3.49)

1.97 *** (1.33, 2.90) 2.01 *** (1.36, 2.98) 2.03 *** (1.37, 3.01)
7.56 ***
(4.99,
7.59 *** (4.96, 11.61) 8.34 *** (5.41, 12.85)
11.44)

2.19 ***
8.46 ***

(1.47, 3.26)
(5.44, 13.14)

(3.70, 9.40)

6.09 ***

(3.76, 9.84)

Racial/Ethnic
Minority

5.84 *** (3.67, 9.30) 5.90 ***

Female

.53 ***

(.37, .76)

.60 **

(.41, .88)

.49 ***

(.33, .73)

College Degree
or More

.95

(.68, 1.34)

.92

(.65, 1.29)

.97

(.68, 1.37)

.54 **

(.36, .79)

.45 ***

(.29, .70)

.82
.28

(.49, 1.39)
(.06, 1.32)

Civilian
Number of
Types of
Insurance (ref=
One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant

.02 ***

(.02, .03)

+ p < .10, *p < .05, **p < .01, ***p < .001

.01 ***

(.01, .02)

.02 ***

(.01, .02)

.02 ***

(.02, .04)

2.22 ***
.02 ***

(1.53, 3.20)
(.01, .04)
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Table 4.5 Logistic Regression Predicting Odds of Reporting using an Assistive Communication Device (N=9789)

Model 1: Age Only

Model 2: Age and
Onset Location

Model 3: Age, Onset
Model 4: Age, Onset
Model 5: Age, Onset
Location, and Social Location, Social Position, Location, Social Position,
Position
and Veteran Status
Veteran Status, and
Resources
Odds
Confidence
Odds
Confidence Odds Ratio Confidence
Ratio
Interval
Ratio
Interval
Interval

Dependent
Odds Confidence
Variable
Ratio
Interval
Age at Diagnosis
(ref 50-59)
18-39
.54 *** (.37, .78)
40-49
1.09
(.91, 1.31)
60-69
.82 ** (.71, .95)
70-79
.69 *** (.56, .85)
80+
1.28
(.80, 2.02)

Odds
Ratio

Confidence
Interval

.78
1.10
.65 ***
.55 ***
.87

(.84, 1.16)
(.91, 1.34)
(.56, .76)
(.44, .68)
(.53, 1.42)

.76
1.16
.61 ***
.51 ***
.81

(.52, 1.11)
(.95, 1.41)
(.51, .71)
(.41, .63)
(.49, 1.33)

.71
1.17
.52 ***
.39 ***
.57
*

(.48, 1.06)
(.96, 1.42)
(.43, .62)
(.31, .50)
(.33, .98)

Onset Location
(ref=Limb)
Bulbar
Trunk/Global

6.33 *** (5.54, 7.23) 6.20 *** (5.42, 7.09) 6.28 ***
1.36 * (1.01, 1.85) 1.49 * (1.07, 1.98) 1.51 **

(5.48, 7.18)
(1.11, 2.05)

6.30 ***
1.46 *

(5.50, 7.23)
(1.07, 1.99)

.74
1.14
.62 ***
.53 ***
.87

(.50, 1.08)
(.94, 1.38)
(.53, .73)
(.43, .66)
(.53, 1.43)

Racial/Ethnic
Minority

.56 **

(.36, .88)

Female

1.70 *** (1.50, 1.94) 1.87 ***

(1.62, 2.15)

1.99 ***

(1.72, 2.31)

College Degree or
More

1.26 *** (1.10, 1.44) 1.25 **

(1.09, 1.43)

1.18

(1.03, 1.36)

(.62, .87)

.86

(.71, 1.04)

2.07 ***
1.81 *

(1.64, 2.63)
(1.05, 3.11)

1.04

(.88, 1.23)

Civilian

.56 **

.74 ***

(.36, .87)

Number of Types
of Insurance (ref=
One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant
.16 *** (.15, .18) .10 *** (.09, .11)
+ p < .10, *p < .05, **p < .01, ***p < .001

.07 ***

(.06, .08)

.08 ***

(.07, .10)

.55

.06

**

*

***

(.35, .87)

(.04, .07)
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Table 4.6 Logistic Regression Predicting Odds of Reporting Participating in a Research Study (N=9789)

Model 1: Age Only

Model 2: Age and
Onset Location

Model 3: Age, Onset
Model 4: Age, Onset
Model 5: Age, Onset
Location, and Social Location, Social Position, Location, Social Position,
Position
and Veteran Status
Veteran Status, and
Resources
Odds
Confidence
Odds
Confidence Odds Ratio Confidence
Ratio
Interval
Ratio
Interval
Interval

Dependent
Odds Confidence
Variable
Ratio
Interval
Age at Diagnosis
(ref 50-59)
18-39
1.85 *** (1.49, 2.30)
40-49
1.37 *** (1.19, 1.58)
60-69
.77 *** (.68, .86)
70-79
.37 *** (.31, .45)
80+
.13 *** (.05, .33)

Odds
Ratio

Confidence
Interval

1.83 ***
1.36 ***
.76 ***
.38 ***
.13 ***

(1.47, 2.28)
(1.18, 1.57)
(.67, .85)
(.32, .46)
(.05, .32)

1.88 *** (1.51, 2.35) 1.87 ***
1.34 *** (1.16, 1.55) 1.34 ***
.75 *** (.67, .85)
.76 ***
.40 *** (.33, .48)
.41 ***
.14 *** (.06, .34)
.15 ***

(1.50, 2.34)
(1.15, 1.54)
(.67, .86)
(.33, .49)
(.06, .36)

1.85
1.35
.63
.30
.09

***
***
***
***
***

(1.47, 2.33)
(1.17, 1.57)
(.55, .72)
(.25, .37)
(.04, .23)

Onset Location
(ref=Limb)
Bulbar
Trunk/Global

1.15 * (1.02, 1.30) 1.19 ** (1.05, 1.35) 1.19 **
.31 *** (.23, .43) .31 *** (.23, .43)
.31 ***

(1.05, 1.35)
(.22, .42)

1.16 *
.28 ***

(1.02, 1.32)
(.20, .39)

Racial/Ethnic
Minority

.65 **

(.47, .91)

.65 **

(.47, .91)

.61

**

(.44, .86)

Female

.74 ***

(.67, .82)

.72 ***

(.65, .81)

.79

***

(.70, .88)

College Degree or
More

1.79 *** (1.60, 2.01) 1.80 ***

Civilian

1.11

(1.61, 2.01)

1.69 ***

(1.51, 1.90)

(.97, 1.26)

1.41 ***

(1.22, 1.63)

1.88 ***
3.02 ***

(1.59, 2.23)
(2.13, 4.28)

Number of Types
of Insurance (ref=
One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant
.33 *** (.30, .36) .33 *** (.30, .36)
+ p < .10, *p < .05, **p < .01, ***p < .001

.25 ***

(.22, .28)

.23 ***

(.20, .27)

.74

***

(.64, .86)

.16

***

(.13, .19)
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Table 4.7 Logistic Regression Predicting Odds of Reporting Genetic Testing (N=9789)

Model 1: Age Only

Model 2: Age and
Onset Location

Model 3: Age, Onset
Model 4: Age, Onset
Model 5: Age, Onset
Location, and Social Location, Social Position, Location, Social Position,
Position
and Veteran Status
Veteran Status, and
Resources
Odds
Confidence
Odds
Confidence Odds Ratio Confidence
Ratio
Interval
Ratio
Interval
Interval

Dependent
Odds Confidence
Variable
Ratio
Interval
Age at Diagnosis
(ref 50-59)
18-39
2.05 *** (1.63, 2.58)
40-49
1.47 *** (1.25, 1.72)
60-69
.85 ** (.74, .97)
70-79
.50 *** (.41, .61)
80+
.50 ** (.28, .87)

Odds
Ratio

Confidence
Interval

1.99 ***
1.47 ***
.86 *
.51 ***
.51 *

(1.58, 2.51)
(1.25, 1.72)
(.75, 1.72)
(.42, .62)
(.29, .90)

Onset Location
(ref=Limb)
Bulbar
Trunk/Global

.85 *
.79

(.75, .98) .89
(.60, 1.02) .76 *

(.78, 1.02)
(.58, .99)

.89
.77

Racial/Ethnic
Minority

.67 *

(.46, .97)

.67

Female

.63 ***

(.56, .70)

College Degree or
More

1.15 **

2.12 *** (1.67, 2.67) 2.12 ***
1.45 *** (1.24, 1.71) 1.46 ***
.87 *
(.78, .99)
.86 *
.51 *** (.42, .62)
.51 ***
.53 *
(.30, .94)
.53 *

(1.68, 2.68)
(1.24, 1.72)
(.75, .99)
(.42, .62)
(.30, .93)

2.17 ***
1.49 ***
.89
.53 ***
.64

(1.71, 2.74)
(1.26, 1.76)
(.77, 1.03)
(.43, .66)
(.34, 1.19)

*

(.78, 1.02)
(.59, 1.00)

.90
.79

(.78, 1.03)
(.60, 1.04)

*

(.46, .97)

.71

(.49, 1.01)

.63 **

(.56, .71)

.66

***

(.58, .74)

(1.03, 1.29)

1.13

*

(1.00, 1.27)

(.84, 1.10)

.88

(1.03, 1.29) 1.15 *

Civilian

.96

Number of Types
of Insurance (ref=
One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant
.27 *** (.24, .29) .28 *** (.26, .31)
+ p < .10, *p < .05, **p < .01, ***p < .001

.30 ***

(.26, .34)

.31 ***

(.26, .36)

(.75, 1.03)

.98
.57

*

.73

***

.35

***

(.79, 1.22)
(.34, .97)
(.63, .85)

(.29, .43)
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Table 4.8 Logistic Regression Predicting Odds of Reporting Having Advanced Directives (N=9789)

Model 1: Age Only

Model 2: Age and
Onset Location

Dependent
Odds Confidence Odds Confidence
Variable
Ratio
Interval
Ratio
Interval
Age at Diagnosis
(ref 50-59)
18-39
.42 *** (.34, .53) .44 *** (.36, .55)
40-49
.65 *** (.57, .74) .66 *** (.58, .75)
60-69
2.15 *** (1.93, 2.40) 2.13 *** (1.91, 2.38)
70-79
4.05 *** (3.41, 4.81) 3.92 *** (3.30, 4.66)
80+
83.53 *** (11.66, 82.41 *** (11.50,
598.25)
590.3)
Onset Location
(ref=Limb)
Bulbar
Trunk/Global

Model 3: Age, Onset
Model 4: Age, Onset
Model 5: Age, Onset
Location, and Social Location, Social Position, Location, Social Position,
Position
and Veteran Status
Veteran Status, and
Resources
Odds
Confidence
Odds
Confidence Odds Ratio Confidence
Ratio
Interval
Ratio
Interval
Interval
.45 *** (.36, .55)
.45
.65 *** (.57, .74)
.65
2.18 *** (1.95, 2.43) 2.14
4.25 *** (3.58, 4.07) 4.09
97.56 ***
(13.60,
93.97
699.84)

1.11
(.99, 1.25) 1.16 ** (1.03, 1.30)
2.15 *** (1.70, 2.72) 2.20 *** (1.73, 2.81)

*** (.36, .56)
*** (.57, .75)
*** (1.91, 2.39)
*** (3.43, 4.89)
*** (13.10, 674,
40)

.43
.64
1.83
3.25
61.18

***
(.34, .54)
***
(.56, .74)
*** (1.61, 2.08)
*** (2.68, 3.94)
*** (8.43, 444.05)

1.17 ** (1.04, 1.31)
2.25 *** (1.77, 2.87)

1.14
2.13

*
*

(1.01, 1.29)
(1.68, 2.73)

Racial/Ethnic
Minority

.41 ***

(.31, .53)

.41 ***

(.31, .53)

.37

***

(.29, .49)

Female

.69 ***

(.63, .76)

.73 ***

(.66, .80)

.75

***

(.68, .83)

College Degree or
More

1.64 *** (1.49, 1.80)

Civilian

1.62 *** (1.48, 1.79)

1.57 ***

(1.42, 1.73)

.83

1.04

(.91, 1.20)

1.83 ***
2.73 ***

(1.52, 2.22)
(1.62, 4.60)

1.10

(.97, 1.25)

1.01

(.84, 1.22)

**

(.73, .95)

Number of Types
of Insurance
(ref= One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant
1.60 *** (1.48, 1.72) 1.51 *** (1.39, 1.63) 1.64 ***
+ p < .10, *p < .05, **p < .01, ***p < .001

1.48 *** (1.28, 1.71)
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Table 4.9 Logistic Regression Predicting Odds of Reporting Hospice Care (N=9789)

Model 1: Age Only

Dependent
Variable
Age at Diagnosis
(ref= 50-59)
18-39
40-49
60-69
70-79
80+
Onset Location
(ref=Limb)
Bulbar
Trunk/Global

Model 2: Age and
Onset Location

Odds Confidence Odds
Ratio
Interval
Ratio

Confidence
Interval

1.42
(.79, 2.54) 1.51
1.07
(.71, 1.62) 1.08
2.55 *** (1.93, 3.38) 2.49 ***
2.82 *** (1.63, 3.19) 2.17 ***
5.34 *** (2.97, 9.61) 5.09 ***

(.84, 2.72)
(.72, 1.63)
(1.89, 3.30)
(1.55, 3.05)
(2.82, 9.17)

Model 3: Age, Onset
Model 4: Age, Onset
Model 5: Age, Onset
Location, and Social Location, Social Position, Location, Social Position,
Position
and Veteran Status
Veteran Status, and
Resources
Odds
Confidence
Odds
Confidence Odds Ratio Confidence
Ratio
Interval
Ratio
Interval
Interval
1.51
(.84, 2.72) 1.47
1.07
(.71, 1.62) 1.05
2.50 *** (1.89, 3.31) 2.63 ***
2.19 *** (1.56, 3.07) 2.40 ***
5.18 *** (2.87, 9.35) 5.92 ***

1.32 * (1.04, 1.66) 1.31 *
1.70 ** (1.18, 2.44) 1.71 **

(.82, 2.65)
(.69, 1.59)
(1.98, 3.48)
(1.70, 3.38)
(3.26, 10.77)

1.47
1.02
2.88 ***
2.83 ***
7.21 ***

(.81, 2.66)
(.67, 1.55)
(2.10, 3.96)
(1.86, 4.30)
(3.35, 15.51)

(1.04, 1.66) 1.29 *
(1.19, 2.45) 1.62 **

(1.02, 1.64)
(1.13, 2.34)

1.29 *
1.65 **

(1.02, 1.64)
(1.13, 2.40)
(.71, 2.26)

Racial/Ethnic
Minority

1.30

(.73, 2.30)

1.32

(.75, 2.34)

1.26

Female

1.01

(.82, 1.24)

.87

(.69, 1.09)

.70

College Degree or
More

1.07

(.86, 1.32)

1.08

(.87, 1.33)

1.17

(.94, 1.45)

1.53 ***

(1.16, 2.01)

1.33

(.94, 1.87)

.75
.38

(.40, 1.43)
(.10, 1.38)

2.41 ***

(1.92, 3.02)

.02 ***

(.01, .03)

Civilian
Number of Types
of Insurance (ref=
One type)
Two Types
Three Types
Never Married,
Separated,
Divorced
Constant
.02 *** (.02, .03)
+ p < .10, *p < .05, **p < .01, ***p < .001

.02 ***

(.02, .03)

.02 ***

.01, .02

**

(.55, .89)
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Table 4.10 Multinomial Logistic Regression Predicting Odds of Riluzole Use (n = 9789)
Base Outcome = Currently Use Riluzole
Model 1: Age Only
Never Used
Age at Diagnosis (ref OR
CI
50-59)
18-39
.83
(.66,
1.05)
40-49
.99
(.86,
1.14)
60-69
1.06
(.95,
1.18)
70-79
1.05
(.91,
1.21)
80+
2.20 *** (1.53,
3.18)
Onset Location
(ref=Limb)
Bulbar
Trunk/Global
Racial/Ethnic
Minority
Female
College Degree or
More
Civilian

Model 2: Age and
Onset Location

Discontinued
Never Used
OR
CI OR
CI

Discontinued
OR
CI

1.01

.88

.98

1.00

.85

(.75,
1.36)
(.69,
1.03)
.87 *** (.49,
.67)
.62 *** (.50,
.77)
.34 * (.13,
.85)
.85

(.69,
1.10)
(.87,
1.15)
1.05
(.94,
1.17)
1.01
(.88,
1.16)
2.17 *** (1.50,
3.12)

(.73,
1.32)
(.69,
1.03)
.89 *** (.50,
.69)
.62 *** (.50,
.77)
.36 * (1.62,
2.36)

Model 3: Age, Onset Location,
and Social Position
Never Used
OR
CI

Model 4: Age, Onset Location, Model 5: Age, Onset Location,
Social Position, and Veteran
Social Position, Veteran Status,
Status
and Resources
Discontinued
Never Used
Discontinued
Never Used
Discontinued
OR
CI OR
CI OR
CI OR
CI OR
CI

.83

.94

.81

.81

1.02

.85

(.64,
1.02)
(.87,
1.16)
1.09
(.97,
1.22)
1.10
(.93,
1.30)
2.41 *** (1.62,
3.58)

.93

.86

(.64,
1.03)
(.88,
1.17)
1.07
(.96,
1.19)
1.06
(.92,
1.22)
2.23 *** (1.54,
3.25)

.93

1.03

1.00

.86

.62
(.52,
.75)
1.88 *** (1.44,
2.47)
1.02
(.71,
1.47)
1.40 *** (1.22,
1.61)
1.30 *** (1.12,
1.51)

1.05

.62 *** (.51.
.75)
1.84 *** (1.40,
2.41)
1.02
(.71,
1.47)
1.32 *** (1.14,
1.52)
1.31 *** (1.13,
1.52)
1.22 * (1.02,
1.45)

1.06

(.95,
1.18)
1.98 *** (1.63,
2.40)
.51 *** (.38,
.68)
1.28 *** (1.16,
1.41)
.79 *** (.72,
.86)
1.33 *** (1.16,
1.52)

.62 *** (.51,
.75)
1.89 *** (1.43,
2.48)
1.05
(.73,
1.52)
1.33 *** (1.15,
1.54)
1.29 *** (1.11,
1.50)
1.16
(.96,
1.41)

1.00

1.01

.71

.76

(.65,
1.05)
(.90,
1.19)
1.03
(.93,
1.15)
.99
(.86,
1.14)
2.01 *** (1.39,
2.92)

1.10

(.99, .64 *** (.53, 1.06
(.96,
1.23)
.78)
1.18)
1.96 *** (1.62, 1.80 *** (1.37, 2.05 *** (1.69,
2.36)
2.35)
2.48)
.52 *** (.39,
.69)
1.51 *** (1.38,
1.65)
.76 *** (.70,
.84)

(.70,
1.27)
(.70,
1.05)
.58 *** (.50,
.69)
.64 *** (.51,
.79)
.37 * (.15,
.95)

(.94,
1.17)
1.97 *** (1.63,
2.39)
.52 *** (.39,
.69)
1.36 *** (1.23,
1.50)
.77 *** (.71,
.85)
1.39 *** (1.24,
1.56)

Number of Types of
Insurance (ref= One
type)
Two Types
Three Types
Never Married,
Separated, Divorced
Constant

.72 *** (.68, .30 *** (.27, .67 *** (.63,
.78)
.33)
.75)
+ p < .10, *p < .05, **p < .01, ***p < .001

.31 *** (.28,
.35)

.71 *** (.64,
.79)

.23 *** (.19,
.27)

.56 *** (.49,
.65)

(.69,
1.25)
(.70,
1.04)
.60 *** (.51,
.70)
.68 *** (.54,
.83)
.40 * (.16,
1.01)

(.85,
1.19)
(.50,
1.01)
1.38 *** (1.24,
1.55)
.20 *** (.16, .56 *** (.47,
.24)
.66)

(.69,
1.26)
(.70,
1.05)
.60 *** (.51,
.72)
.68 *** (.54,
.86)
.44
(.17,
1.12)

(.80,
1.29)
(.48,
1.19)
.87
(.72,
1.05)
.21 *** (.16,
.27)
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Table 4.11 Multinomial Logistic Regression Predicting Odds of Attending a Multidisciplinary Clinic (n = 9789)
Base Outcome = Currently Attend a Multidisciplinary Clinic
Model 1: Age Only
Never Attended Discontinued
OR
CI
OR
CI

Never Attended Discontinued
OR
CI
OR
CI

Never Attended Discontinued
OR
CI
OR
CI

Model 4: Age, Onset Location,
Social Position, and Veteran
Status
Never Attended Discontinued
OR
CI
OR
CI

Age at Diagnosis
(ref 50-59)
18-39

.95

1.48

.94

1.46

.81

1.00

.81

(.95,
2.30)
(.57,
1.13)
(.83,
1.34)
(.74,
1.41)
(1.05,
4.08)

.95

1.00

(.94,
2.28)
(.57,
1.13)
(.83,
1.34)
(.74,
1.42)
(1.07,
4.14)

.93

40-49

(.80,
1.29)
(.39,
1.08)

(.80,
1.29)
(.38,
1.07)
(.62,
2.12)
(.77,
1.17)
(.73,
1.10)

60-69
70-79
80+

(.74,
1.22)
(.86,
1.16)
.96
(.86,
1.08)
1.21 ** (1.04,
1.40)
1.42
(.96,
2.09)

1.05
1.02
2.11 *

(.95,
2.30)
(.58,
1.14)
(.83,
1.34)
(.74,
1.40)
(1.07,
4.13)

Model 2: Age and Onset
Location

Model 3: Age, Onset Location,
and Social Position

(.73,
1.21)
(.86,
1.16)
.97
(.86,
1.09)
1.21 ** (1.04,
1.40)
1.44
(.98,
2.13)

Onset Location
(ref=Limb)
Bulbar

.90

Trunk/Global

1.13

1.05
1.03
2.11 *

(.80, 1.01
1.02)
(.93, .65
1.38)

Racial/Ethnic
Minority
Female
College Degree or
More
Civilian

(.72,
1.20)
(.85,
1.16)
(.86,
1.09)
(1.00,
1.34)
(.89,
1.94)

1.48

.88 *

(.78,
1.00)
(.94,
1.39)
1.66 *** (1.28,
2.17)
1.20 *** (1.09,
1.33)
.63 *** (.57,
.69)

1.02

1.13

.64

1.00
.97
1.16
1.31

.80
1.06
1.02
2.08 *

1.15
.95
.90

(.73,
1.22)
(.87,
1.18)
(.84,
1.06)
(.94,
1.27)
(.82,
1.79)

1.47

.89

(.79,
1.01)
(.96,
1.43)
1.67 *** (1.28,
2.17)
1.32 *** (1.19,
1.47)
.62 *** (.56,
.68)
.78 *** (.67,
.86)

1.01

1.18

.63

1.01
.94
1.09
1.21

.80
1.06
1.04
2.12 *

1.15
.93
.90
1.08

Model 5: Age, Onset Location,
Social Position,
Veteran Status, and Resources
Never Attended Discontinued
OR
CI
OR
CI

(.94,
2.29)
(.57,
1.12)
(.83,
1.36)
(.75,
1.44)
(1.07,
4.20)

.99

(.77,
1.28)
(.87,
1.18)
1.15 * (1.02,
1.32)
1.51 *** (1.28,
1.78)
2.12 *** (1.38,
3.25)

1.44

1.01

.77

(.80,
1.29)
(.38,
1.06)
(.62,
2.12)
(.75,
1.16)
(.73,
1.11)
(.83,
1.39)

.91

1.01

Number of Types of
Insurance (ref= One
type)
Two Types
Three Types
Never Married,
Separated, Divorced
Constant
.34 *** (.31, .06 *** (.05,
.37)
.07)
+ p < .10, *p < .05, **p < .01, ***p < .001

.34 *** (.31,
.38)

.06 *** (.05,
.08)

.43 *** (.57,
.69)

.07 *** (.05,
.09)

.51 *** (.45,
.60)

.06 *** (.05,
.09)

1.29 *
1.81 ***
1.24 ***
.65 ***
.57 ***

(.81,
1.03)
(1.06,
1.60)
(1.38,
2.37)
(1.11,
1.39)
(.50,
.66)
(.38,
.56)

.46 *** (.38,
.56)
.30 *** (.22,
.40)
.99
(.67,
.97)
.81 * (.67,
.97)

.99
.97
1.79

.59 *
1.06
.79 *
.93
1.12

1.55 *

(.92,
2.26)
(.54,
1.08)
(.76,
1.28)
(.68,
1.39)
(.87,
3.68)
(.79,
1.29)
(.35,
1.00)
(.57,
1.96)
(.63,
.99)
(.75,
1.14)
(.83,
1.52)

(1.07,
2.23)
(.32,
1.98)
2.35 *** (1.88,
2.93)
.05 *** .03,
.07
.80

115
Figure 4.1 Predicted Probability of Wheelchair/Scooter Use by Age at Diagnosis
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Figure 4.2 Predicted Probability of Invasive Ventilation by Age at Diagnosis
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Figure 4.3 Predicted Probability of Assistive Communication Device Use by Age at
Diagnosis
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Figure 4.4 Predicted Probability of Participating in a Research Study by Age at
Diagnosis
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Figure 4.5 Predicted Probability of Genetic Testing by Age at Diagnosis
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Figure 4.6 Predicted Probability of Completing Advanced Directives by Age at
Diagnosis
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Figure 4.7 Predicted Probability of Invasive Ventilation by Marital Status
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Figure 4.8 Predicted Probability of Enrolling in Hospice by Marital Status
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Figure 4.9 Predicted Probability of Invasive Ventilation by Race/Ethnicity
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Figure 4.10 Predicted Probability of Participating in a Research Study by
Race/Ethnicity
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Figure 4.11 Predicted Probability of Participating in a Research Study by Gender
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Figure 4.12 Predicted Probability of Genetic Testing by Gender
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CHAPTER FIVE: SUMMARY OF RESULTS, CONCLUSION, AND FUTURE
WORK
Summary of Results and Conclusion
For the dissertation, I looked at how social position and position in the life course
shapes the experience of ALS. Currently, ALS is not well understood by either the
biological or the social sciences. Although research to understand the biological basis of
ALS is well underway, less social science research has focused on the experience of
ALS. There is a need, however, to explore how sociological perspectives can advance
knowledge even of diseases that are little understood, rare, and deadly. In the case of
ALS, the results of the dissertation show how a sociological perspective and sociological
theories (e.g. fundamental cause, life course) help develop a better understanding of the
disease process and experience of the disease by pALS, albeit with some adjustment.
Further, the findings presented here illustrate the need for a sociology of disease, in order
to better understand how the social world affects the experience of a particular disease,
rather than the general overview provided by the sociology of health and illness.
Overall, the dissertation shows that social position and position in the life course
are relevant to both the disease process and the lived experiences of pALS. The results
are useful to rethink the enrollment process for potential clinical trials and to understand a
potential reason why trials fail, and to begin improving access and communication of
ALS treatments to prevent health disparities among pALS. The dissertation further
contributes to the efforts to improve the quality of life for people with ALS. Finally, the
results from these studies supplies a potential opening for sociologists, epidemiologists,
biomedical researchers, and medical providers to engage in conversation across
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disciplines in developing new ways to understand ALS as a disease process and as a lived
experience.
The second chapter of the dissertation explored how social position shaped the
reported onset location at the time of an ALS diagnosis. Although there are still many
unanswered questions regarding who will eventually develop ALS, I use sociological
theories to understand the social dimensions of a disease that is often conceptualized as
purely biological. The results show that social position does shape the onset location of
ALS symptoms and that the mechanisms behind the onset of ALS are more complicated
than just accounting for exposures to proximate risk factors and biological differences.
Several potential explanations exist for these findings. Social position and position in the
life course could influence the perception of symptoms of ALS and where they begin.
Moreover, social position could be the trigger for a gene by environment interaction
which influences the biological development of symptoms and where they begin. Finally,
social position has been shown in previous work to influence access to healthcare
resources, allowing the symptoms to spread throughout the body before a diagnosis can
be made.
The goal of a sociology of disease in the case of ALS is to take the themes and
theories from the sociology of health and illness and focus attention on specific health
outcomes such as onset location. The goal of chapter two is not to point out collective
risk factors but to account for the multiple pathways in which the experience of the social
world may influence ALS onset location directly (Pescosolido, 2006; Timmermans and
Haas, 2008). For example, the onset location of ALS is determined through diagnostic
testing to determine the involvement of the nerves. The unrelenting progression that is
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characteristic of ALS, however, may mean that pALS who go through diagnostic testing
later in the disease course (e.g. due to the dismissal of symptoms as a sign of aging or of
a hard life) appear to have greater involvement of the nerves, leading to a distorted
clinical picture. A sociology of disease allows sociologists to think about how clinical
endpoints may appear to differ due to social stratification, such as race/ethnicity, gender,
and social class.
The third chapter examined how social position shapes the experience of
symptoms of ALS. Overall, the results show the importance of social position in
understanding symptom development and progression of ALS. Even though proximate
risks are often the sole factor considered in biomedical research on ALS symptom
development and disease progression, the results show education, gender, and age all
have a role over and above the proximate risks included in the models. As sociologists
have documented in earlier studies, many diseases consist of more than just exposure to
proximate risks, and ALS has many of the same tendencies. Moreover, the use of
fundamental cause theory, life course theory, and the social determinants of health help to
highlight where differences occur, although refinements are needed to use theories in the
sociology of health and illness in a disease to understand disparities. For example, guided
by fundamental cause theory, one would expect that those in less advantaged social
positions (e.g. minorities, women, lower levels of education) will report more time
between the development of ALS symptoms than their more advantaged peers. Results
indicate, however, that pALS with limited resources often have less time between
symptom onset and diagnosis than their more advantaged peers. Rather than an indicator
of greater access to resources, a diagnosis closer to the reported appearance of symptoms
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may be a sign of having less opportunity and resources to acknowledge the signs of a
disease that may at first seem to be a minor complaint. In the case of ALS, it may not be
that fundamental cause theory is not supported, but that sociologists need to adjust the
way they think about applying the theory. The results from this work reaffirms the need
for a sociology of disease, as dealing with a disease just prior to and after diagnosis is
different from understanding how disease can be prevented altogether.
Chapter four tested how position in the life course and social position has shaped
medical care decisions reported by people with ALS. Disparities in medical and
supportive care for pALS are clear in the National ALS Registry data, both by the timing
in the life course of diagnosis and by social position. Although the disparities by age at
diagnosis may be explained by the acceptance or refusal of death as the next stage of life,
disparities by social position are much more difficult to explain.
Medical care is shaped by social position, as suggested by fundamental cause
theory. Fundamental cause theory does highlight the differences in medical and
supportive care, however, some of the findings actually run counter to the theories’
predictions. Therefore, although fundamental cause theory works fairly well in the case
of a specific disease, sociological theories created for the more general social experiences
(e.g. who will get a disease and who will not) may need to be adjusted to reflect the
differences in experiencing specific diseases. Further, adjustment of current theories in
the sociology of health and illness allow for their use in exploring the connection between
the social world and the experience and care for those diagnosed with the specific disease
in question (Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008). Moreover, the
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results from this work again reaffirm the need for a sociology of disease, as dealing with
the care needs for a specific disease, such as ALS, is different from many other diseases.
Theories such as fundamental cause are often focused on the final outcomes of
disease (e.g. mortality) and the influence of social factors (e.g. socioeconomic status) on
those outcomes (Phelen et al., 2004). The focus on potential outcomes, such as the
development of disease or the risk of death from a disease, is a weakness of the sociology
of health and illness. Given the focus on the larger picture of outcomes, it is
understandable why sociologists often do not focus on diseases such as ALS with no
known cause or cure. Although ALS is universally fatal for those who are diagnosed, the
results presented in the dissertation demonstrate the lived experience of ALS (and
perhaps the disease itself) is influenced by the social position.
Given these findings, approaching ALS from a sociology of health and illness
perspective misses important connections between social position and the experience of
the disease itself. Therefore, the findings of the dissertation allow me to strongly echo
Timmermans and Haas’ (2008) call for a ‘sociology of disease,’ in which sociologists
explore the connection between the social world and disease. As a medical sociologist
who often focuses on one disease (e.g. ALS) and on clinical endpoints (e.g. onset
location, symptom development, medical and supportive care), the further development
of a sociology of disease allows for a better understanding of multiple pathways in which
the experience of the social world may influence disease directly (Pescosolido, 2006;
Timmermans and Haas, 2008). Moreover, testing the themes and theories from the
sociology of health and illness and focusing on the clinical endpoints for a specific
disease, such as I have done here with ALS, allows sociologists to understand when and
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how general overarching theories may need to be adjusted or conceptualized differently
to understand micro-level disease specific populations.
Although the current conceptualization of the theories may have their limitations
in the research and in the interpretation of the results, a larger limitation was the data
itself. Without the quest to understand the social context of ALS, as well a testing the
need for a sociology of disease, many of the limitations of the National ALS Registry
may not have been discovered. The limitations of the National ALS Registry reaffirm the
need to understand the specific social context of a disease, rather than a general overview
of illness on the macro-level.
The Limitations and Promise of the National ALS Registry
Limitations of the National ALS Registry
The National ALS Registry is one of several ALS registries in the United States,
including the Veterans Administration National Registry, the Argeo Paul Cellucci ALS
Registry of Massachusetts, and the Northeast ALS Consortium (NEALS) Upper Motor
Neuron Disease (UMND) Registry (Allen et al., 2008; Murphy et al., 2014; Abille and
Fraser, 2017). The National ALS Registry, however, is the most geographically diverse
ALS registry in the United States. In addition, the National ALS Registry is attached to
the national biobank repository, which allows individual data from the registry to be
matched with data from the biobank, allowing for detailed biomedical research into the
biological causes of ALS.
It is difficult, however, to define the ALS population in the United States. Coming
to a final diagnosis of ALS is a process of elimination, the cost of which can be in the
tens of thousands of dollars prior to insurance. (Kiernan et al., 2011; Obermann & Lyon,
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2015). The variability of the earliest symptoms can lead to incorrect diagnoses and
unnecessary medical procedures, culminating in a delayed diagnosis (Belsh and
Schiffman, 1996; Srinivasan et al., 2006). Further, the understanding of ALS as a disease
has changed to include frontotemporal dementia as a type of onset. Therefore, there is the
potential that pALS are missed due to misdiagnosis or diagnosis prior to new findings.
Moreover, if pALS are further into the progression of the disease, they may not take part
in the registry due to physical and psychological limitations or pALS may die before
completing the registration process. These limitations mean the National ALS Registry is
the best-case scenario and where researchers should see the fewest disparities, however,
disparities have been found across the three studies presented here.
With several potential registries to join, and limited time to do so given the nature
of ALS, and the potential for misdiagnosis or uncertainty of the diagnosis, not every case
may be counted in the National ALS Registry. For example, the latest CDC report
estimates there were 16,583 cases of definite ALS in the United States in 2015 and
(Mehta et al., 2018), however, the ALS Association estimates that up to 30,000 people
may be affected by ALS each year (ALSA, 2020), meaning that the National ALS
Registry may be missing up to 45% of the population of pALS. The incongruence of the
estimates from the CDC and ALSA highlights the difficulties in defining the true
population of pALS in the United States.
The National ALS Registry is available in an online format only, which may limit
access and cause the registry to reflect a younger, white, and educated patient sample.
The registry sample provided by the CDC is less racially diverse than the overall registry
which includes Medicare and Veteran’s Association claims data (Kaye et al., 2018).
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There are several potential reasons for this, including access to computers that are needed
for self-registration, reduced awareness of the registry, and reduced participation in areas
with substantial nonwhite populations.
The nature of the design of the National ALS Registry, with individual modules
the participant can complete at home on a schedule that works for their situation and their
physical and psychological limitations, is one that makes sense for a disease like ALS.
Although convenient and easier to use for the pALS, it does lead to issues with missing
data. With the exception of the first module about demographic information (e.g.
race/ethnicity, gender, education level), many of the questions in the dataset had at least
some missing data. The highest amounts of missing data were in the insurance module
and the clinical data module, which were added to the registry at a later date. At that time,
pALS were notified of a new module to complete via email. Given the short survival time
after a diagnosis of ALS, however, pALS may have been deceased at the time of the
notification. pALS may choose to do some modules with the intent of returning to finish
the others (e.g. with a caregiver or after retrieving information needed), but have their
health deteriorate to a point where they are unable to do so. Further, pALS may find the
modules to be too complex given their health situation and may forgo completing all the
individual modules.
An important feature of the National ALS Registry is that it was designed with
biomedical and epidemiological research in mind. Therefore, the registry is not ideal for
research from a social science perspective. For example, chapter one of the dissertation
supports earlier studies that show women are more likely to develop bulbar onset of ALS
even when accounting for proximate risk factors. Without more information on other
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types of exposures, including stress exposure and adverse childhood events, it is difficult
to parse out the full picture of why there is a statistically significant difference in the
onset location for women compare to men. Differences in onset location may be due to
both biological and social factors, and without access to both types of information in
registry data, both fields will suffer from incomplete analysis of the factors involved in
ALS development and progression.
Concerns about deductive identification severely limited the amount of
information available for the analyses. As ALS is rare, and participation in the registry is
voluntary, reidentification is a serious concern. Therefore, the CDC limits access to a
small number of survey modules. Although not ideal, the issue of reidentification does
limit the work that can be done with registry data. For example, the analysis presented in
chapter four may have benefited from more information on whether the pALS had
children or not. To access the information on the number of children, however, I would
have needed to relinquish access to other data important to answering the research
questions in the dissertation. Further, although the sample size overall is robust, smaller
numbers of specific populations, such as non-white patients, limits the ability to do
intersectional analysis. The inclusion of an intersectional approach may have further
clarified how social position shapes the onset location and symptom development for
pALS. Additionally, the non-random sample opt-in nature of the survey means the results
may not be generalizable to the ALS population as a whole.
The Potential Promise of the National ALS Registry
Although the National ALS Registry does pose some difficulties for researchers,
it is one of the few sources of information existing on pALS in the United States. The
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promise of the National ALS Registry in discovering treatments and cures for ALS is
clear, although with improvements it could be even more promising for social science
research. I present some possibilities for overcoming current barriers in the sections
below. Although only a brief outline of potential suggestions to enhance social science
research such as that done for the dissertation, the overall goal is to begin a conversation
on potential improvements to the registry.
Implementing mandatory reporting. Only Massachusetts requires the
mandatory reporting of ALS cases, which are then included in the Argeo Paul Cellucci
ALS Registry of Massachusetts. To fully define the ALS population in the United States,
the National ALS Registry needs to ensure every case is counted, which would require
mandatory reporting. Further, mandatory reporting would allow physicians and other
healthcare personnel to report protected health information including onset location,
ALSFR-R scores, symptom development, and clinical data to the registry, potentially
allowing for pALS to answer additional modules related to social and environmental risk
factors and reducing some respondent burden. Creating a mandatory reporting system
would help the registry increase its reach to pALS who are unable to access the current
registry, as well as ensuring more complete and accurate information for research.
Moreover, turning to a mandatory reporting system could increase sample sizes enough
to allow for intersectional analysis of social position.
Increase awareness of and aid for registry completion among pALS. One of
the flaws of the ALS Registry is the limited population from which data is collected. In
addition to a lack of access to the internet, caregivers and patients have limited time to
carry out an optional task such as a registry module due to the pressures of everyday
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medical care needs. One potential solution is to offer access to completing the survey in
clinics, as well as through organizations such as the ALS Association, Paralyzed Veterans
of America, and the Muscular Dystrophy Association, all of which are involved in
supporting the ALS community. Improving access, along with having a knowledgeable
person available to help navigate the registry and answer questions, would increase the
number of people taking part in the registry.
Including social factors in data collection. The results of the dissertation show
that social position shapes both the disease process and the lived experiences of ALS.
The inclusion of social factors, such as childhood adverse event scales, early life
socioeconomic status, and reporting of life event and chronic stressors in adulthood,
would provide additional valuable information on the potential interaction of the social
world and biological processes over the course of pALS lives. Further, including social
factors may help to determine where and why pALS may be facing disparities in
healthcare.
Future Work
The dissertation has posed new questions about the role of social position in the
disease course and lived experience of ALS. There are several potential avenues of
inquiry. The first, from a quantitative perspective, is the inclusion of early life
experiences, childhood exposure to proximate risk factors, and the experience of stress in
future research on ALS. Previous research has examined the effects of stress in ALS
through pathways related to hormones (e.g. cortisol) and damage to the nervous system
(e.g. oxidative stress) (Fidler et al, 2011; Bozzo et al., 2017), and stress exposure can
vary by social position and early life experiences. To study stress effects would require
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recruiting pALS to complete a survey asking comparable questions to the registry’s
clinical questions, demographic information, as well as measures such as the childhood
adverse events scale, childhood environmental exposures, and life events and chronic
stressors across the life course. Collecting data of this nature could help to further clarify
the interaction between the social and the biological in the development of ALS. Further,
researchers might consider an analysis of ALS subgroups using data from the National
ALS Registry. Exploring the potential subgroups using clinical data and data on social
position may help to clarify why some pALS respond to new treatments and adopt the
latest technologies, while others do not. In addition, gaining a better understanding of the
potential variation in experiences and responses among subgroups of pALS may be one
way to better understand what exposures and experiences may influence ALS
development and progression.
There is a need for qualitative research to understand the association between
social position and perceptions of ALS onset and symptom development. The meaning
and salience of biological symptoms are likely to differ for people with more or less
physically demanding jobs, regular medical care, and expectations for aging. For
example, many of the social position results, such as those for education, could be due to
a difference in exposures to proximate risks. The findings that social position matters
over and above proximate risk exposure, however, may be due to when symptoms are
perceived and become salient. People with lower levels of education usually have
different types of work demands than people with higher education. Jobs requiring more
physical labor could lead to pALS attributing symptoms to work-related exhaustion or as
the consequence of a hard life, whereas people with more education might find the
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symptoms harder to explain away. pALS with lower education could also attribute
symptoms to the expected effects of getting older or might not have access to affordable
medical care and thus ignore symptoms as long as possible in contrast to higher educated
people who are more likely to have insurance and regular medical visits. To better
understand how pALS make sense of symptoms prior to diagnosis, it will be valuable to
conduct interviews with pALS about how they understood the changes in their bodies
associated with ALS.
There is an important gap in the knowledge about how patient social position
affects medical decision making for people with ALS. A few of the most interesting
findings in chapter five are opposite of the hypothesized direction. One specific example
is the higher number of unmarried pALS and pALS who are racial or ethnic minorities
reporting adoption of invasive ventilation. Much of the research on health disparities runs
counter to these findings and poses an interesting question of why these pALS are
choosing this extremely expensive and care intensive treatment option. Qualitative work,
including interviews with pALS and their caregivers, would provide valuable information
to best interpret these results. Further, work to determine if the differences in the adoption
of invasive ventilation among racial and ethnic minorities are potentially rooted in a
deeper history of racism and its consequences is a critical area for future consideration.
Finally, the results of the studies presented in the dissertation support the need for
a sociology of disease. Future work should include adapting existing theories used in the
sociology of health and illness to better understand experiences of populations of people
who have developed a specific disease. As the results presented here show, the
experience of a disease like ALS differs from other diseases like cancer, and to
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understand differences in outcomes for patients requires a new and different perspective,
one offered by a sociology of disease.

141
REFERENCES
Adler, N. E., Boyce, T., Chesney, M. A., Cohen, S., Folkman, S., Kahn, R. L., & Syme, S. L.
(1994). Socioeconomic status and health: the challenge of the gradient. American
Psychologist, 49(1), 15.
Abille, V., Fraser, A., & Knorr, R. (2017). ALS Surveillance in Massachusetts: A one-of-a-kind
registry for tracking an elusive disease.
Al-Chalabi, A., Hardiman, O., Kiernan, M. C., Chiò, A., Rix-Brooks, B., & van den Berg, L. H.
(2016). Amyotrophic lateral sclerosis: Moving towards a new classification system. The
Lancet Neurology, 15(11), 1182–1194. https://doi.org/10.1016/S1474-4422(16)30199-5
Allen, K. D., Kasarskis, E. J., Bedlack, R. S., Rozear, M. P., Morgenlander, J. C., Sabet, A., ... &
Oddone, E. Z. (2008). The National Registry of Veterans with amyotrophic lateral
sclerosis. Neuroepidemiology, 30(3), 180-190.
Andersen, J. A. (2018). Amyotrophic Lateral Sclerosis and a" Death With Dignity". Omega,
30222818788254.
Appel, V., Stewart, S. S., Smith, G., & Appel, S. H. (1987). A rating scale for amyotrophic
lateral sclerosis: description and preliminary experience. Annals of Neurology: Official
Journal of the American Neurological Association and the Child Neurology
Society, 22(3), 328-333.
Arthur, K. C., Calvo, A., Price, T. R., Geiger, J. T., Chiò, A., & Traynor, B. J. (2016). Projected
increase in amyotrophic lateral sclerosis from 2015 to 2040. Nature Communications, 7,
12408.
Aschbacher, K., O’Donovan, A., Wolkowitz, O. M., Dhabhar, F. S., Su, Y., & Epel, E. (2013).
Good stress, bad stress and oxidative stress: insights from anticipatory cortisol
reactivity. Psychoneuroendocrinology, 38(9), 1698-1708.
Atsuta, N., Watanabe, H., Ito, M., Tanaka, F., Tamakoshi, A., Nakano, I., Aoki, M., Tsuji, S.,
Yuasa, T., Takano, H., Hayashi, H., Kuzuhara, S., & Sobue, G. (2009). Age at onset
influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis.
Journal of the Neurological Sciences, 276(1), 163–169.
https://doi.org/10.1016/j.jns.2008.09.024
Belsh, J. M., & Schiffman, P. L. (1996). The amyotrophic lateral sclerosis (ALS) patient
perspective on misdiagnosis and its repercussions. Journal of the Neurological
Sciences, 139, 110-116.
Benditt, J. O. (2002). Respiratory complications of amyotrophic lateral sclerosis. In Seminars in
respiratory and critical care medicine (Vol. 23, No. 03, pp. 239-247). Copyright© 2002
by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

142
Bodner, T. E. (2008). What improves with increased missing data imputations?. Structural
Equation Modeling: A Multidisciplinary Journal, 15(4), 651-675.
Bozzo, F., Mirra, A., & Carrì, M. T. (2017). Oxidative stress and mitochondrial damage in the
pathogenesis of ALS: New perspectives. Neuroscience Letters, 636, 3–8.
https://doi.org/10.1016/j.neulet.2016.04.065
Braveman, P. A., Cubbin, C., Egerter, S., Chideya, S., Marchi, K. S., Metzler, M., & Posner, S.
(2005). Socioeconomic status in health research: one size does not fit all. JAMA, 294(22),
2879-2888.
Braveman, P., Egerter, S., & Williams, D. R. (2011). The social determinants of health: coming
of age. Annual Review of Public Health, 32, 381-398.
Brown, R. C., Lockwood, A. H., & Sonawane, B. R. (2005). Neurodegenerative diseases: an
overview of environmental risk factors. Environmental Health Perspectives, 113(9),
1250-1256.
Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. New England Journal of
Medicine, 377(2), 162-172.
Bryan, L., Kaye, W., Antao, V., Mehta, P., Muravov, O., & Horton, D. K. (2016). Preliminary
Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey
Data. PLoS ONE, 11(4). https://doi.org/10.1371/journal.pone.0153683
Caller, T. A., Field, N. C., Chipman, J. W., Shi, X., Harris, B. T., & Stommel, E. W. (2012).
Spatial clustering of amyotrophic lateral sclerosis and the potential role of
BMAA. Amyotrophic Lateral Sclerosis, 13(1), 25-32.
Caller, T., Henegan, P., & Stommel, E. (2018). The Potential Role of BMAA in
Neurodegeneration. Neurotoxicity Research, 33(1), 222–226.
https://doi.org/10.1007/s12640-017-9752-7
Carr, D., Freedman, V. A., Cornman, J. C., & Schwarz, N. (2014). Happy Marriage, Happy Life?
Marital Quality and Subjective Well-being in Later Life. Journal of Marriage and
Family, 76(5), 930–948. https://doi.org/10.1111/jomf.12133
Carter, Chelsey. 2019.“‘It’s a White Disease!’” Anthropology News website, February 11, 2019.
DOI: 10.1111/AN.1091
Cassileth, B. R., Lusk, E. J., Miller, D. S., Brown, L. L., & Miller, C. (1985). Psychosocial
correlates of survival in advanced malignant disease?. New England Journal of
Medicine, 312(24), 1551-1555.
Cazzolli, P. A., & Oppenheimer, E. A. (1996). Home mechanical ventilation for amyotrophic
lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure
ventilation. Journal of the Neurological Sciences, 139, 123-128.

143
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A.
(1999). The ALSFRS-R: a revised ALS functional rating scale that incorporates
assessments of respiratory function. Journal of the Neurological Sciences, 169(1), 13–21.
https://doi.org/10.1016/S0022-510X(99)00210-5
Ceriana, P., Surbone, S., Segagni, D., Schreiber, A., & Carlucci, A. (2017). Decision-making for
tracheostomy in amyotrophic lateral sclerosis (ALS): a retrospective study. Amyotrophic
Lateral Sclerosis and Frontotemporal Degeneration, 18(7-8), 492-497.
Chiò, A., Benzi, G., Dossena, M., Mutani, R., & Mora, G. (2005). Severely increased risk of
amyotrophic lateral sclerosis among Italian professional football players. Brain, 128(3),
472–476. https://doi.org/10.1093/brain/awh373
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., ... & Eurals
Consortium. (2009). Prognostic factors in ALS: a critical review. Amyotrophic Lateral
Sclerosis, 10(5-6), 310-323.
Chiò, A., Canosa, A., Gallo, S., Cammarosano, S., Moglia, C., Fuda, G., ... & Gabriele, M.
(2011). ALS clinical trials: do enrolled patients accurately represent the ALS
population?. Neurology, 77(15), 1432-1437.
Coakley, M., Fadiran, E. O., Parrish, L. J., Griffith, R. A., Weiss, E., & Carter, C. (2012).
Dialogues on diversifying clinical trials: successful strategies for engaging women and
minorities in clinical trials. Journal of Women's Health, 21(7), 713-716.
Cohen, P., West, S. G., & Aiken, L. S. (2014). Applied Multiple Regression/Correlation Analysis
for the Behavioral Sciences. Psychology Press.
Collins, P. H. (1990). Black feminist thought in the matrix of domination. Black Feminist
Thought: Knowledge, Consciousness, and the Politics of Empowerment, 138, 221-238.
Connor, S. R. (2008). Development of hospice and palliative care in the United States. OMEGAJournal of Death and Dying, 56(1), 89-99.
Crawford, B. M., Meana, M., Stewart, D., & Cheung, A. M. (2000). Treatment decision making
in mature adults: gender differences. Health Care for Women International, 21(2), 91104.
Crook, A., Williams, K., Adams, L., Blair, I., & Rowe, D. B. (2017). Predictive genetic testing
for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling
considerations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18(78), 475-485.
de Jong, S. W., Huisman, M. H. B., Sutedja, N. A., van der Kooi, A. J., de Visser, M., Schelhaas,
H. J., Fischer, K., Veldink, J. H., & van den Berg, L. H. (2012). Smoking, Alcohol
Consumption, and the Risk of Amyotrophic Lateral Sclerosis: A Population-based Study.
American Journal of Epidemiology, 176(3), 233–239. https://doi.org/10.1093/aje/kws015

144
Del Aguila, M. A., Longstreth, W. T., McGuire, V., Koepsell, T. D., & Van Belle, G. (2003).
Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology, 60(5),
813-819.
D’Amico, E., Factor-Litvak, P., Santella, R. M., & Mitsumoto, H. (2013). Clinical perspective on
oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radical Biology and
Medicine, 65, 509-527.
Diez Roux, A. V. (2012). Conceptual approaches to the study of health disparities. Annual
Review of Public Health, 33, 41-58.
Dorst, J., Ludolph, A. C., & Huebers, A. (2018). Disease-modifying and symptomatic treatment
of amyotrophic lateral sclerosis. Therapeutic Advances in Neurological Disorders, 11,
1756285617734734.
Dupuis, L., Pradat, P.-F., Ludolph, A. C., & Loeffler, J.-P. (2011). Energy metabolism in
amyotrophic lateral sclerosis. The Lancet Neurology, 10(1), 75–82.
https://doi.org/10.1016/S1474-4422(10)70224-6
Elder Jr, G. H. (1994). Time, human agency, and social change: Perspectives on the life
course. Social Psychology Quarterly, 4-15.
Elder Jr, G. H., & Rockwell, R. C. (1979). The life-course and human development: An
ecological perspective. International Journal of Behavioral Development, 2(1), 1-21.
Elder, G. H. (1998). The Life Course as Developmental Theory. Child Development, 69(1), 1–
12. https://doi.org/10.1111/j.1467-8624.1998.tb06128.x
Enders, C. K. (2006). A primer on the use of modern missing-data methods in psychosomatic
medicine research. Psychosomatic Medicine, 68(3), 427-436.
Fang, F., Quinlan, P., Ye, W., Barber, M. K., Umbach, D. M., Sandler, D. P., & Kamel, F.
(2009). Workplace exposures and the risk of amyotrophic lateral sclerosis. Environmental
Health Perspectives, 117(9), 1387-1392.
Ferraro, K. F., & Farmer, M. M. (1996). Double jeopardy, aging as leveler, or persistent health
inequality? A longitudinal analysis of white and black Americans. The Journals of
Gerontology Series B: Psychological Sciences and Social Sciences, 51(6), S319-S328.
Ferraro, K. F., Shippee, T. P., & Schafer, M. H. (2009). Cumulative inequality theory for
research on aging and the life course.
Ferraro, K. F., Schafer, M. H., & Wilkinson, L. R. (2016). Childhood disadvantage and health
problems in middle and later life: Early imprints on physical health?. American
Sociological Review, 81(1), 107-133.
Fidler, J. A., Treleaven, C. M., Frakes, A., Tamsett, T. J., McCrate, M., Cheng, S. H.,
Shihabuddin, L. S., Kaspar, B. K., & Dodge, J. C. (2011). Disease progression in a mouse

145
model of amyotrophic lateral sclerosis: The influence of chronic stress and
corticosterone. The FASEB Journal, 25(12), 4369–4377. https://doi.org/10.1096/fj.11190819
Foley, G., Timonen, V., & Hardiman, O. (2014). Acceptance and Decision Making in
Amyotrophic Lateral Sclerosis From a Life-Course Perspective. Qualitative Health
Research, 24(1), 67–77. https://doi.org/10.1177/1049732313516545
Freese, J., & Lutfey, K. (2011). Fundamental Causality: Challenges of an Animating Concept for
Medical Sociology. In B. A. Pescosolido, J. K. Martin, J. D. McLeod, & A. Rogers
(Eds.), Handbook of the Sociology of Health, Illness, and Healing: A Blueprint for the
21st Century (pp. 67–81). Springer. https://doi.org/10.1007/978-1-4419-7261-3_4
Gay, J. (2018). The Health of Women: A Global Perspective. Routledge.
Georgoulopoulou, E., Fini, N., Vinceti, M., Monelli, M., Vacondio, P., Bianconi, G., ... &
Mandrioli, J. (2013). The impact of clinical factors, riluzole and therapeutic interventions
on ALS survival: a population based study in Modena, Italy. Amyotrophic Lateral
Sclerosis and Frontotemporal Degeneration, 14(5-6), 338-345.
Geronimus, A. T. (1992). The weathering hypothesis and the health of African-American women
and infants: evidence and speculations. Ethnicity & Disease, 2(3), 207-221.
Geronimus, A. T., Bound, J., Waidmann, T. A., Colen, C. G., & Steffick, D. (2001). Inequality in
life expectancy, functional status, and active life expectancy across selected black and
white populations in the United States. Demography, 38(2), 227-251.
Gevitz, N. (1986). Sociology in Medicine. JAMA, 256(19), 2742-2742.
Glass, T. A., & Mcatee, M. J. (2005). Extending Horizons, Envisioning The Future.
Glass, T. A., & McAtee, M. J. (2006). Behavioral science at the crossroads in public health:
extending horizons, envisioning the future. Social science & medicine, 62(7), 1650-1671.
Goosby, B. J., & Heidbrink, C. (2013). The transgenerational consequences of discrimination on
African‐American health outcomes. Sociology Compass, 7(8), 630-643.
Goutman, S. A., & Simmons, Z. (2018). Symptom management in ALS: we can do better.
Muscle & Nerve, 57(1), 1.
Gundogdu, B., Al-Lahham, T., Kadlubar, F., Spencer, H., & Rudnicki, S. A. (2014). Racial
differences in motor neuron disease. Amyotrophic Lateral Sclerosis & Frontotemporal
Degeneration, 15(0), 114–118. https://doi.org/10.3109/21678421.2013.837930
Harris, Y., Gorelick, P. B., Samuels, P., & Bempong, I. (1996). Why African Americans may not
be participating in clinical trials. Journal of the National Medical Association, 88(10),
630.

146
Haverkamp, L. J., Appel, V., & Appel, S. H. (1995). Natural history of amyotrophic lateral
sclerosis in a database population Validation of a scoring system and a model for survival
prediction. Brain, 118(3), 707-719.
Horton, D. K., Graham, S., Punjani, R., Wilt, G., Kaye, W., Maginnis, K., … Mehta, P. (2018).
A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and
their proximity to multidisciplinary ALS clinics, 2013. Amyotrophic Lateral Sclerosis
and Frontotemporal Degeneration, 19(1–2), 126–133.
https://doi.org/10.1080/21678421.2017.1406953
Househam, E., & Swash, M. (2000). Diagnostic delay in amyotrophic lateral sclerosis: what
scope for improvement?. Journal of the Neurological Sciences, 180(1-2), 76-81.
Howard, G., Anderson, R. T., Russell, G., Howard, V. J., & Burke, G. L. (2000). Race,
socioeconomic status, and cause-specific mortality. Annals of epidemiology, 10(4), 214223.
Ingre, C., Roos, P. M., Piehl, F., Kamel, F., & Fang, F. (2015). Risk factors for amyotrophic
lateral sclerosis. Clinical Epidemiology, 7, 181–193.
https://doi.org/10.2147/CLEP.S37505
Iwasaki, Y., Ikeda, K., & Kinoshita, M. (2001). The diagnostic pathway in amyotrophic lateral
sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2(3), 123126.
Jaiswal, M. K. (2019). Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis
drugs. Medicinal Research Reviews, 39(2), 733-748.
Kalish, R. (1985). Coping with death. The Final Transition, 5, 11.
Kapral, M. K., Devon, J., Winter, A. L., Wang, J., Peters, A., & Bondy, S. J. (2006). Gender
differences in stroke care decision-making. Medical Care, 70-80.
Kaye, W. E., Wagner, L., Wu, R., & Mehta, P. (2018). Evaluating the completeness of the
national ALS registry, United States. Amyotrophic Lateral Sclerosis and Frontotemporal
Degeneration, 19(1–2), 112–117. https://doi.org/10.1080/21678421.2017.1384021
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., ... & Zoing, M.
C. (2011). Amyotrophic lateral sclerosis. Lancet (London, England), 377(9769), 942.
Kleykamp, M. A. (2006). College, jobs, or the military? Enlistment during a time of war. Social
Science Quarterly, 87(2), 272-290.
Kotter-Grühn, D., Grühn, D., & Smith, J. (2010). Predicting one’s own death: the relationship
between subjective and objective nearness to death in very old age. European Journal of
Ageing, 7(4), 293-300.

147
Kraemer, M., Buerger, M., & Berlit, P. (2010). Diagnostic problems and delay of diagnosis in
amyotrophic lateral sclerosis. Clinical Neurology and Neurosurgery, 112(2), 103-105.
Lechtzin, N., Scott, Y., Busse, A. M., Clawson, L. L., Kimball, R., & Wiener, C. M. (2007).
Early use of non‐invasive ventilation prolongs survival in subjects with
ALS. Amyotrophic Lateral Sclerosis, 8(3), 185-188.
Lemoignan, J., & Ells, C. (2010). Amyotrophic lateral sclerosis and assisted ventilation: how
patients decide. Palliative & Supportive Care, 8(2), 207-213.
Levine, S. (1987). The changing terrains in medical sociology: emergent concern with quality of
life. Journal of Health and Social Behavior, 1-6.
Link, B. G. (2008). Epidemiological sociology and the social shaping of population
health. Journal of Health and Social Behavior, 49(4), 367-384.
Link, B. G., & Phelan, J. (1995). Social conditions as fundamental causes of disease. Journal of
Health and Social Behavior, 80-94.
Longstreth, W. T., McGuire, V., Koepsell, T. D., Wang, Y., & Belle, G. van. (1998). Risk of
Amyotrophic Lateral Sclerosis and History of Physical Activity: A Population-Based
Case-Control Study. Archives of Neurology, 55(2), 201–206.
https://doi.org/10.1001/archneur.55.2.201
Louwerse, E. S., Visser, C. E., Bossuyt, P. M. M., & Weverling, G. J. (1997). Amyotrophic
lateral sclerosis: mortality risk during the course of the disease and prognostic factors.
Journal of the Neurological Sciences, 152, s10–s17. https://doi.org/10.1016/S0022510X(97)00238-4
Lutfey, K., & Freese, J. (2005). Toward some fundamentals of fundamental causality:
Socioeconomic status and health in the routine clinic visit for diabetes. American Journal
of Sociology, 110(5), 1326-1372.
Lyman, K. A. (1989). Bringing the social back in: A critique of the biomedicalization of
dementia. The Gerontologist, 29(5), 597-605.
Magnus, T., Beck, M., Giess, R., Puls, I., Naumann, M., & Toyka, K. V. (2002). Disease
progression in amyotrophic lateral sclerosis: Predictors of survival. Muscle & Nerve,
25(5), 709–714. https://doi.org/10.1002/mus.10090
Manjaly, Z. R., Scott, K. M., Abhinav, K., Wijesekera, L., Ganesalingam, J., Goldstein, L. H., ...
& Turner, M. R. (2010). The sex ratio in amyotrophic lateral sclerosis: a population based
study. Amyotrophic Lateral Sclerosis, 11(5), 439-442.
Mara Gaudette, T. S., Makito Hirano. (2000). Current status of SOD1 mutations in familial
amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron
Disorders, 1(2), 83–89. https://doi.org/10.1080/14660820050515377

148
Masters, R. K., Link, B. G., & Phelan, J. C. (2015). Trends in education gradients of
‘preventable’ mortality: a test of fundamental cause theory. Social Science &
Medicine, 127, 19-28.
McCombe, P. A., & Henderson, R. D. (2010). Effects of gender in amyotrophic lateral sclerosis.
Gender Medicine, 7(6), 557–570. https://doi.org/10.1016/j.genm.2010.11.010
McMurray, R. J., Clarke, O. W., Barrasso, J. A., Clohan, D. B., Epps, C. H., Glasson, J., ... &
Halkola, K. A. (1991). Gender disparities in clinical decision making. JAMA, 266(4),
559-562.
Mehta, P., Kaye, W., Bryan, L., Larson, T., Copeland, T., Wu, J., ... & Horton, K. (2016).
Prevalence of amyotrophic lateral sclerosis—United States, 2012–2013. Morbidity and
Mortality Weekly Report: Surveillance Summaries, 65(8), 1-12.
Mehta, P., Kaye, W., Raymond, J., Wu, R., Larson, T., Punjani, R., ... & Horton, K. (2018).
Prevalence of amyotrophic lateral sclerosis—United States, 2014. Morbidity and
Mortality Weekly Report, 67(7), 216.
Menezes, A. R., Lavie, C. J., DeSchutter, A., & Milani, R. V. (2014). Gender, race and cardiac
rehabilitation in the United States: is there a difference in care?. The American Journal of
the Medical Sciences, 348(2), 146-152.
Ross, C. E., & Mirowsky, J. (2010). Why education is the key to socioeconomic differentials in
health. Handbook of Medical Sociology, 6, 33-51.
Mitchell, John Douglas, Pauline Callagher, Joyce Gardham, Catriona Mitchell, Mandy Dixon,
Robert Addison-Jones, Wendy Bennett, and Mary R. O'Brien. "Timelines in the
diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor
neuron disease (MND)–a 20-year review: can we do better?." Amyotrophic Lateral
Sclerosis 11, no. 6 (2010): 537-541.
Mitsumoto, H., & Bene, M. D. (2000). Improving the quality of life for people with ALS: the
challenge ahead. Amyotrophic Lateral Sclerosis and Other Motor Neuron
Disorders, 1(5), 329-336.
Mitsumoto, H., Brooks, B. R., & Silani, V. (2014). Clinical trials in amyotrophic lateral
sclerosis: Why so many negative trials and how can trials be improved? The Lancet
Neurology, 13(11), 1127–1138. https://doi.org/10.1016/S1474-4422(14)70129-2
Muddasir Qureshi, M., Hayden, D., Urbinelli, L., Ferrante, K., Newhall, K., Myers, D., ... &
Cudkowicz, M. E. (2006). Analysis of factors that modify susceptibility and rate of
progression in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis, 7(3),
173-182.
Murphy, A., Loci, L., Mitsumoto, H., Lomen-Hoerth, C., Kisanuki, Y., Andrews, J., ... & Atassi,
N. (2014). The Northeast ALS Consortium (NEALS) Upper Motor Neuron Disease
(UMND) Registry (P5. 076).

149
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004). Participation in cancer clinical trials:
race-, sex-, and age-based disparities. JAMA, 291(22), 2720-2726.
Nelson, L. M., McGuire, V., Longstreth, W. T., & Matkin, C. (2000). Population-Based CaseControl Study of Amyotrophic Lateral Sclerosis in Western Washington State. I.
Cigarette Smoking and Alcohol Consumption. American Journal of Epidemiology,
151(2), 156–163. https://doi.org/10.1093/oxfordjournals.aje.a010183
Nzwalo, H., de Abreu, D., Swash, M., Pinto, S., & de Carvalho, M. (2014). Delayed diagnosis in
ALS: the problem continues. Journal of the Neurological Sciences, 343(1-2), 173-175.
Obermann, M., & Lyon, M. (2015). Financial cost of amyotrophic lateral sclerosis: a case
study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16(1-2), 54-57.
O'Brien, M. R., Whitehead, B., Jack, B. A., & Mitchell, J. D. (2011). From symptom onset to a
diagnosis of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND):
experiences of people with ALS/MND and family carers–a qualitative
study. Amyotrophic Lateral Sclerosis, 12(2), 97-104.
Oliver, D. J., & Turner, M. R. (2010). Some difficult decisions in ALS/MND. Amyotrophic
Lateral Sclerosis, 11(4), 339-343.
Onesti, E., Schettino, I., Gori, M. C., Frasca, V., Ceccanti, M., Cambieri, C., ... & Inghilleri, M.
(2017). Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet
adaptation, and riluzole management. Frontiers in Neurology, 8, 94.
Paillisse, C., Lacomblez, L., Dib, M., Bensimon, G., Garcia‐Acosta, S., & Meininger, V. (2005).
Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with
riluzole. Amyotrophic Lateral Sclerosis, 6(1), 37–44.
https://doi.org/10.1080/14660820510027035
Pampel, F. C. (2009). The persistence of educational disparities in smoking. Social
Problems, 56(3), 526-542.
Pereira, A. (2003). “Live and Let Live: Healthcare Is a Fundamental Human Right.” Connecticut
Public Interest Law Journal 3:481.
Pescosolido, B. A. (2006). Of pride and prejudice: the role of sociology and social networks in
integrating the health sciences. Journal of Health and Social Behavior, 47(3), 189-208.
Phelan, J. C., & Link, B. G. (2013). Fundamental cause theory. In Medical Sociology on the
Move (pp. 105-125). Springer, Dordrecht.
Phelan, J. C., & Link, B. G. (2015). Is racism a fundamental cause of inequalities in
health?. Annual Review of Sociology, 41, 311-330.

150
Phelan, J. C., Link, B. G., & Tehranifar, P. (2010). Social conditions as fundamental causes of
health inequalities: theory, evidence, and policy implications. Journal of Health and
Social Behavior, 51(1_suppl), S28-S40.
Phelan, J. C., Link, B. G., Diez-Roux, A., Kawachi, I., & Levin, B. (2004). “Fundamental
causes” of social inequalities in mortality: a test of the theory. Journal of Health and
Social Behavior 45(3), 265-285.
Phillips, K. A., Mayer, M. L., & Aday, L. A. (2000). Barriers To Care Among Racial/Ethnic
Groups Under Managed Care: Ethnic minorities continue to encounter barriers to care in
the current managed care–dominated US health care system. Health Affairs, 19(4), 65-75.
Pulley, M. T., Brittain, R., Hodges, W., Frazier, C., Miller, L., Matyjasik‐Liggett, M., ... &
Berger, A. R. (2019). Multidisciplinary amyotrophic lateral sclerosis telemedicine care:
the store and forward method. Muscle & Nerve, 59(1), 34-39.
Pupillo, E., Messina, P., Giussani, G., Logroscino, G., Zoccolella, S., Chiò, A., … Beghi, E.
(2014). Physical activity and amyotrophic lateral sclerosis: A European population-based
case–control study. Annals of Neurology, 75(5), 708–716.
https://doi.org/10.1002/ana.24150
Quick Facts About ALS & The ALS Association. (2020). Retrieved from
http://www.alsa.org/news/media/quick-facts.html
Radunović, A., Mitsumoto, H., & Leigh, P. N. (2007). Clinical care of patients with amyotrophic
lateral sclerosis. The Lancet Neurology, 6(10), 913-925.
Raymond, J., Oskarsson, B., Mehta, P., & Horton, K. (2019). Clinical characteristics of a large
cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS)
Registry, 2010–2015. Amyotrophic Lateral Sclerosis and Frontotemporal
Degeneration, 20(5-6), 413-420.
Reisine, S., Mcquillan, J., & Fifield, J. (1995). Predictors of work disability in rheumatoid
arthritis patients. Arthritis & Rheumatism: Official Journal of the American College of
Rheumatology, 38(11), 1630-1637.
Ridings, J. E. (2013). The thalidomide disaster, lessons from the past. In Teratogenicity
Testing (pp. 575-586). Humana Press, Totowa, NJ.
Rodriguez, J., Chopade, P., & Chen, I. H. A. (2018). Characterization of Amyotrophic Lateral
Sclerosis (ALS) Seen in the Medical University of South Carolina ALS Multidisciplinary
Clinic (P1. 342).Roberson, N. L. (1994). Clinical trial participation: viewpoints from
racial/ethnic groups. Cancer, 74(S9), 2687-2691.
Rothstein, J. D. (2017). Edaravone: a new drug approved for ALS. Cell, 171(4), 725.

151
Rubin, M. S., Clouston, S., & Link, B. G. (2014). A fundamental cause approach to the study of
disparities in lung cancer and pancreatic cancer mortality in the United States. Social
Science & Medicine, 100, 54-61.
Saposnik, G., & Kapral, M. K. (2009). Understanding stroke in women: similar care, worse
outcomes?.
Schulz, A., Parker, E., Israel, B., & Fisher, T. (2001). Social context, stressors, and disparities in
women's health. Journal-American Medical Womens Association, 56(4), 143-150.
Shavers, V. L., Lynch, C. F., & Burmeister, L. F. (2001). Factors that influence African‐
Americans' willingness to participate in medical research studies. Cancer:
Interdisciplinary International Journal of the American Cancer Society, 91(S1), 233-236.
Shi, L., Lebrun, L. A., & Tsai, J. (2010). Access to medical care, dental care, and prescription
drugs: the roles of race/ethnicity, health insurance, and income. Southern Medical
Journal, 103(6), 509.
Shi, L., Chen, C. C., Nie, X., Zhu, J., & Hu, R. (2014). Racial and socioeconomic disparities in
access to primary care among people with chronic conditions. The Journal of the
American Board of Family Medicine, 27(2), 189-198.
Shneerson, J. M. (2011). Who will benefit from tracheostomy ventilation in motor neuron
disease?.
Slatcher, R. B. (2010). Marital Functioning and Physical Health: Implications for Social and
Personality Psychology. Social and Personality Psychology Compass, 4(7), 455–469.
https://doi.org/10.1111/j.1751-9004.2010.00273.x
Spataro, R., Volanti, P., Lo Coco, D., & La Bella, V. (2017). Marital status is a prognostic factor
in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 136(6), 624-630.
Srinivasan, J., Scala, S., Jones, H. R., Saleh, F., & Russell, J. A. (2006). Inappropriate surgeries
resulting from misdiagnosis of early amyotrophic lateral sclerosis. Muscle & Nerve:
Official Journal of the American Association of Electrodiagnostic Medicine, 34(3), 359360.
Stephens, H. E., Felgoise, S., Young, J., & Simmons, Z. (2015). Multidisciplinary ALS clinics in
the USA: A comparison of those who attend and those who do not. Amyotrophic Lateral
Sclerosis and Frontotemporal Degeneration, 16(3-4), 196-201.
Stephens, H. E., Young, J., Felgoise, S. H., & Simmons, Z. (2016). A qualitative study of
multidisciplinary ALS clinic use in the United States. Amyotrophic Lateral Sclerosis and
Frontotemporal Degeneration, 17(1-2), 55-61.
Stommel, E. W., Field, N. C., & Caller, T. A. (2013). Aerosolization of cyanobacteria as a risk
factor for amyotrophic lateral sclerosis. Medical Hypotheses, 80(2), 142–145.
https://doi.org/10.1016/j.mehy.2012.11.012

152
Straus, R. (1957). The nature and status of medical sociology. American sociological
review, 22(2), 200-204.
Sutedja, N. (2007). Risk Factors for Motor Neuron Diseases. 202.
Sutedja, N. A., Veldink, J. H., Fischer, K., Kromhout, H., Wokke, J. H. J., Huisman, M. H. B., ...
& Van den Berg, L. H. (2007). Lifetime occupation, education, smoking, and risk of
ALS. Neurology, 69(15), 1508-1514.
Suther, S., & Kiros, G. E. (2009). Barriers to the use of genetic testing: a study of racial and
ethnic disparities. Genetics in Medicine, 11(9), 655-662.
Swinnen, B., & Robberecht, W. (2014). The phenotypic variability of amyotrophic lateral
sclerosis. Nature Reviews Neurology, 10(11), 661–670.
https://doi.org/10.1038/nrneurol.2014.184
Timmermans, S., & Haas, S. (2008). Towards a sociology of disease. Sociology of Health &
Illness, 30(5), 659-676.
Timmermans, S., & Buchbinder, M. (2010). Patients-in-waiting: living between sickness and
health in the genomics era. Journal of Health and Social Behavior, 51(4), 408-423.
Turkman, Y. E., Williams, C. P., Jackson, B. E., Dionne-Odom, J. N., Taylor, R., Ejem, D., ... &
Rocque, G. B. (2019). Disparities in Hospice Utilization for Older Cancer Patients Living
in the Deep South. Journal of Pain and Symptom Management, 58(1), 86-91.
Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chiò, A., De Carvalho, M., ... &
Nicholson, G. (2013). Controversies and priorities in amyotrophic lateral sclerosis. The
Lancet Neurology, 12(3), 310-322.
Umberson, D., Thomeer, M. B., Reczek, C., & Donnelly, R. (2016). Physical illness in gay,
lesbian, and heterosexual marriages: Gendered dyadic experiences. Journal of Health and
Social Behavior, 57(4), 517-531.
van Es, M. A., Hardiman, O., Chiò, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & Van
den Berg, L. H. (2017). Amyotrophic lateral sclerosis. The Lancet, 390(10107), 20842098.
Vennila, V., Madhu, V., Rajesh, R., Ealla, K. K. R., Velidandla, S. R., & Santoshi, S. (2014).
Tetracycline-induced discoloration of deciduous teeth: case series. Journal of
International Oral Health: JIOH, 6(3), 115.
Virnig, Beth A., A. Marshall McBean, Sara Kind, and Rishi Dholakia. "Hospice use before
death: variability across cancer diagnoses." Medical Care 40, no. 1 (2002): 73-78.
Voustianiouk, A., Seidel, G., Panchal, J., Sivak, M., Czaplinski, A., Yen, A., ... & Lange, D. J.
(2008). ALSFRS and appel ALS scores: discordance with disease progression. Muscle &

153
Nerve: Official Journal of the American Association of Electrodiagnostic
Medicine, 37(5), 668-672.
Waite, L. J., & Gallagher, M. (2001). The Case for Marriage: Why Married People are Happier,
Healthier, and Better off Financially. Random House Digital, Inc..
Wang, M.-D., Little, J., Gomes, J., Cashman, N. R., & Krewski, D. (2017). Identification of risk
factors associated with onset and progression of amyotrophic lateral sclerosis using
systematic review and meta-analysis. NeuroToxicology, 61, 101–130.
https://doi.org/10.1016/j.neuro.2016.06.015
Warner, D. F., & Brown, T. H. (2011). Understanding how race/ethnicity and gender define agetrajectories of disability: An intersectionality approach. Social Science &
Medicine, 72(8), 1236-1248.
Washington, K. T., Bickel-Swenson, D., & Stephens, N. (2008). Barriers to hospice use among
African Americans: a systematic review. Health & Social Work, 33(4), 267-274.
Watanabe, H., Atsuta, N., Nakamura, R., Hirakawa, A., Watanabe, H., Ito, M., … Sobue, G.
(2015). Factors affecting longitudinal functional decline and survival in amyotrophic
lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal
Degeneration, 16(3–4), 230–236. https://doi.org/10.3109/21678421.2014.990036
Weisskopf, M. G., Cudkowicz, M. E., & Johnson, N. (2015). Military Service and Amyotrophic
Lateral Sclerosis in a Population-based Cohort. Epidemiology (Cambridge, Mass.), 26(6),
831–838. https://doi.org/10.1097/EDE.0000000000000376
Williams, D. R., & Collins, C. (2001). Racial Residential Segregation: A Fundamental Cause of
Racial Disparities in Health. Public Health Reports, 116(5), 404–416.
https://doi.org/10.1093/phr/116.5.404
Williams, D. R., & Jackson, P. B. (2005). Social sources of racial disparities in health. Health
Affairs, 24(2), 325-334.
Yokoi, D., Atsuta, N., Watanabe, H., Nakamura, R., Hirakawa, A., Ito, M., Watanabe, H.,
Katsuno, M., Izumi, Y., Morita, M., Taniguchi, A., Oda, M., Abe, K., Mizoguchi, K.,
Kano, O., Kuwabara, S., Kaji, R., Sobue, G., & JaCALS. (2016). Age of onset
differentially influences the progression of regional dysfunction in sporadic amyotrophic
lateral sclerosis. Journal of Neurology, 263(6), 1129–1136.
https://doi.org/10.1007/s00415-016-8109-0
Yu, Y., Su, F.-C., Callaghan, B. C., Goutman, S. A., Batterman, S. A., & Feldman, E. L. (2014).
Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control
Study of ALS in Michigan. PLOS ONE, 9(6), e101186.
https://doi.org/10.1371/journal.pone.0101186

154
APPENDIX A: SUPPLEMENTAL TABLES, CHAPTER ONE

Table A1.1 Model 1: Multinomial Logistic Regression Predicting the Reporting of Onset Location,
Distal Risk Factors, Relative Risk Ratios (N=9789)

Racial/Ethnic Minority
Women
Education (ref= Tech, Trade, or
Some College)
High School or Less
College or More
Constant
*p < .05, **p < .01, ***p < .001

Base Category: Limb
Bulbar
Relative
Confidence
Risk Ratio
Interval
1.18
(.89, 1.58)
1.53 ***
(1.39, 1.69)
1.23 *
1.12
.21 ***

(1.04, 1.46)
(.98, 1.27)
(.18, .24)

Relative
Risk Ratio
.90
.57 ***

Global
Confidence
Interval
(.53, 1.54)
(.47, .69)

1.10
.77 *
.11 ***

(.84, 1.45)
(.63, .95)
(.09, .13)
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Table A1.2. Model 2: Multinomial Logistic Regression Predicting the Reporting of Onset Location,
Distal Risk Factors, Veteran Status, Relative Risk Ratios (N=9789)
Base Category: Limb
Bulbar
Global
Relative Risk
Confidence
Relative Risk
Confidence
Ratio
Interval
Ratio
Interval
Racial/Ethnic Minority
1.18
(.89, 1.58)
.89
(.52, 1.53)
Women
1.52 ***
(1.36, 1.69)
.49 ***
(.40, .60)
Education (ref= Tech, Trade, or
Some College)
High School or Less
1.23 *
(1.04, 1.46)
1.09
(.82, 1.52)
College or More
1.12
(.98, 1.27)
.77 *
(.63, .96)
Civilian
1.03
(.90, 1.18)
1.70 ***
(1.36, 2.12)
Constant
.20 ***
(.18, .24)
.08 ***
(.06, .10)
*p < .05, **p < .01, ***p < .001
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Table A1.3. Model 3: Multinomial Logistic Regression Predicting the Reporting of Onset Location,
Social Position, Veteran Status, Proximate Risk Factors, Relative Risk Ratios (N=9789)
Base Category: Limb
Bulbar
Relative
Confidence
Risk Ratio
Interval
Racial/Ethnic Minority
Women
Education (ref= Tech, Trade, or
Some College)
High School or Less
College or More
Civilian
Low Occupational Risk
Ever Smoked Cigarettes (ref=Never)
Ever Drank Alcohol (ref=Never)
Constant
*p < .05, **p < .01, ***p < .001

Relative
Risk Ratio

Global
Confidence
Interval

1.19
1.51 ***

(.89, 1.59)
(1.35, 1.69)

.86
.47 ***

(.50, 1.47)
(.39, .58)

1.22 *
1.14 *
1.05
.97
1.11
.95
.20 ***

(1.03, 1.45)
(1.00, 1.30)
(.92, 1.20)
(.83, 1.13)
(1.00, 1.23)
(.83, 1.08)
(.16, .25)

1.14
.69 ***
1.64 ***
1.56 **
.89
1.10
.06 ***

(.86, 1.50)
(.55, .86)
(1.31, 2.06)
(1.18, 2.07)
(.74, 1.07)
(.86, 1.41)
(.04, .09)

